

QY 75 CRLHFKEDMGQKCPCLDCAVVRFO-KANCSATSDAICGDCLPGRYRKTKLVGFQ-D 132

Db 121 VDCVPCPGHSPGNNAQCKPWTNCTLSGKQTRHPASSLDAY-CEQ-RSLATLIL 174

QY 133 MECVPC--GDPPPEPHCASKVNLVKTASASSPRDTALAIVCSALATVLLAL 186

RESULT 2

ENTRY 512783 #type complete

TITLE OX40 antigen precursor - rat

ALTERNATE_NAMES nerve growth factor receptor homolog

ORGANISM #formal_name Rattus norvegicus #common_name Norway rat

DATE 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 20-Sep-1999

ACCESSIONS 512783; S08036

REFERENCE 512783

#authors Mallett, S.; Fossum, S.; Barclay, A.N.

#journal EMBO J. (1990) 9:1063-1068

#title Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor.

#cross-references MUID:90214614

#accession 512783

#molecule_type mRNA

#residues 1-271 #label MAL

CLASSIFICATION #cross-references EMBL:X17037; NID:957830; PID:957831

KEYWORDS #superfamily CD27 antigen; NGF receptor repeat homology growth factor receptor; transmembrane protein

FEATURE 1-19 #domain signal sequence #status predicted #label SIG

20-271 #product OX40 antigen #status predicted #label MAT

211-335 #domain transmembrane #status predicted #label TM

SUMMARY #length 271 #molecular_weight 29895 #checksum 379

Query Match 4.8%; Score 149; DB 2; Length 271;

Best Local Similarity 29.1%; Pred. No. 1,30e+08;

Matches 39; Conservative 27; Mismatches 57; Indels 11; Gaps 8;

Db 9 TAFLLG-LSLGVYKL-NCVADITPS-GHKC-CRECPQGHMVSRCQ-HTRDTVCHP 61

QY 15 TLVLVLTGLSCVTCESDQRFDRSDSGNVCNCGPQKELSKEGFGYGEDAQCVA 74

Db 62 CEPGRYNAVNTDKQCTQCNHRSSEIKONCTPTEDTV-CQAPPGIOPRODSSHKICV 120

QY 75 CRLHFKEDMGQKCPCLDCAVVRFO-KANCSATSDAICGDCLPGRYRKTKLVGFQDM 133

Db 121 DCVPC--PPGHSP 132

QY 134 ECVPCGDPPPEYEP 147

RESULT 3

ENTRY JN0006 #type complete

TITLE nerve growth factor receptor, low affinity precursor - chicken

ALTERNATE_NAMES NGF receptor

ORGANISM #formal_name Gallus gallus #common_name chicken

DATE 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 10-Sep-1999

ACCESSIONS JN0006; A60504

REFERENCE JN0006

#authors Large, T.H.; Weskamp, G.; Helder, J.C.; Radeke, M.J.; Misko, T.P.; Shooter, E.M.; Reichardt, L.F.

#journal Neuron (1989) 2:1123-1134

#title Structure and developmental expression of the nerve growth factor receptor in the chicken central nervous system.

#cross-references MUID:9016579

#accession JN0006

#molecule_type mRNA

#residues 1-416 #label IAR

REFERENCE #experimental_source embryonic chick brain

A60504

#authors Heuer, J.G.; Fatemle-Nainte, S.; Wheeler, E.F.; Bothwell, M.

#journal Dev. Biol. (1990) 137:287-304

#title Structure and developmental expression of the chicken NGF receptor.

#cross-references MUID:90152140

#accession A60504

#status preliminary; not compared with conceptual translation

#molecule_type mRNA

#residues 21-35, 'Y', 37-172, 'K', 174-275, 'S', 277-395, 'R', 397-416

COMMENT #label HEU

COMMENT This receptor is found on sensory and sympathetic neurons, on neuroblastoma cells, and on a variety of nonneuronal derivatives of the neural crest.

COMMENT The cysteine-rich region of the extracellular domain may form part or all of the NGF-binding site.

COMMENT This protein is thought to form a high-affinity receptor when it associates with the 140k tsk proto-oncogene, which contains an intracellular tyrosine kinase domain.

CLASSIFICATION #superfamily nerve growth factor receptor; NGF receptor repeat homology

KEYWORDS duplication; glycoprotein; heterodimer; monomer; phosphoprotein; receptor; transmembrane protein

FEATURE 1-20

21-416

21-239 #domain signal sequence #status predicted #label SIG

24-57 #product nerve growth factor receptor #status predicted #label MAT

59-100 #domain extracellular #status predicted #label EXT

101-139 #domain NGF receptor repeat homology #label NG1

141-181 #domain NGF receptor repeat homology #label NG2

189-237 #domain NGF receptor repeat homology #label NG3

240-261 #domain NGF receptor repeat homology #label NG4

262-416 #region serine/threonine-rich

52 #domain transmembrane #status predicted #label MEM

#domain intracellular #status predicted #label INT

#binding_site carbohydrate (Asn) (covalent) #status predicted

SUMMARY #length 416 #molecular_weight 44654 #checksum 3542

Query Match 4.7%; Score 146; DB 1; Length 416;

Best Local Similarity 30.0%; Pred. No. 4.18e+08;

Matches 54; Conservative 29; Mismatches 83; Indels 14; Gaps 13;

Db 90 PC-VESDAYRCAYGVFQDELSSCKECSICEVFGFLMFCR-D-SQDTYCECPCEGTF 146

QY 24 SCKVTCESGDDR-QOE-FRDR-SGNCVPCNCGGKELSKEGFGYGEDACVACRLHFR 80

Db 147 SDEANFVDCPLCTICEENEMVVR-ECTATSDACCRDLHPRTHTPSLAGSDSPEPTR 205

QY 81 KEDMGF-QCKKPCUDCAVVRFOKANCSATSDAICGDCLPGRYRKTKLVGFQMECVPC 138

Db 206 DPFNTGMAITLADIYTVTGMSSQPVVSRGTADNLIPYCSILAAYVGL-VAYIAF-KR 263

QY 139 GD-PPPEPHCASKVNLVKTASASSPRDTA--LAIVCSALATVLLALILCVIYCKR 195

RESULT 4

ENTRY JC4302 #type complete

TITLE tumor necrosis factor receptor p55 precursor - pig

ORGANISM #formal_name Sus scrofa domestica #common_name domestic pig

DATE 29-Nov-1995 #sequence_revision 08-Feb-1996 #text_change 23-Jul-1999

ACCESSIONS JC4302; PC4093

REFERENCE JC4302

#authors Suter, B.; Pauli, U.

#journal Gene (1995) 163:263-266

#title Cloning of the cDNA encoding the porcine p55 tumor necrosis factor receptor.

#cross-references MUID:96011645

#accession JC4302

#molecule_type mRNA

#residues 1-461 #label SUT

REFERENCE #cross-references GB:U19994; NID:g1141752; PID:MAC48499.1;

PC4093

```

#cross-references MUID:91285014
#accession S15677
##molecule_type mRNA
##residues 1-454 ##label BAR
#cross-references EMBL:X59238; NID:953578; PIDN:CAAA1922.1; PID:953579
REFERENCE
#authors Rothe, J.G.; Brockhaus, M.; Gentz, R.; Lesslauer, W.
#journal Immunogenetics (1991) 34:338-340
#title Molecular cloning and expression of the mouse Tnf receptor type b.
#cross-references MUID:92039815
#accession S19021
##molecule_type mRNA
##residues 1-454 ##label ROT
#cross-references EMBL:X57796; NID:954848; PIDN:CAAA0936.1; PID:954849
REFERENCE
#authors Bebo, B.F.
#journal Immunogenetics (1994) 39:450-451
#title Nucleotide sequence of the TNF type I receptor from a mouse endothelioma cell line.
#cross-references MUID:94245292
#accession I51532
##status translated from GB/EMBL/DBJ
##molecule_type mRNA
##residues 1-454 ##label RES
#cross-references GB:L2634; NID:943073; PIDN:AA59361.1; PID:94307333
COMMENT This protein is one of two distantly related receptors for both TNF-alpha (cachectin) and TNF-beta (lymphotoxin).
CLASSIFICATION
#superfamily tumor necrosis factor receptor type 1; NGF receptor repeat homology duplication; glycoprotein; receptor; transmembrane protein
KEYWORDS
#domain signal sequence #status predicted #label SIG\
FEATURE
#product tumor necrosis factor receptor type 1 #status predicted #label MAT\
1-29 #domain extracellular #status predicted #label EXT\
30-454 #domain NGF receptor repeat homology #label NG1\
44-82 #domain NGF receptor repeat homology #label NG2\
84-126 #domain NGF receptor repeat homology #label NG3\
127-167 #domain NGF receptor repeat homology #label NG4\
168-204 #domain transmembrane #status predicted #label MEM\
213-235 #domain intracellular #status predicted #label INT\
236-454 #binding_site carboxylate (Asn) (covalent) #status predicted
54,151,202
SUMMARY
#length 454 #molecular-weight 50129 #checksum 4839
Query Match 4.6%; Score 142; DB 1; Length 454;
Best Local Similarity 26.9%; Pred. No. 1.95e-07;
Matches 29; Conservative 16; Mismatches 58; Indels 5; Gaps 5;
Db 44 CPQKRYVSHKNNKSIQCKRKHGTYLSDCSP-GRDVRCRECEKGTFTASQNYLRQISC 102
OY 34 CRQEPFRNSNCVPCNOCGGMGLSNCEGFGYGEDAQACACRLHRRKKEWMGQK-CKPC 92
Db 103 KTKCKENSQVEISPCQADKDTVCG-CKENQFORLYSTHFQCYDCSC 149
OY 93 LDCA-VVNRFOKANCASATDAICDCLPG-FYRKTKLVGFQDMECVPC 138
RESULT 6
ENTRY 157826 #type complete
TITLE tumor necrosis factor receptor - mouse
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 23-Jul-1999
ACCESSIONS 157826
REFERENCE 157826
#authors Rothe, J.G.; Bluetmann, H.; Gentz, R.; Lesslauer, W.;
Steinmetz, M.
#journal Mol. Immunol. (1993) 30:165-176
#title Genomic organization and promoter function of the murine tumor necrosis factor receptor beta gene.
#cross-references MUID:93156721

```

```

#accession 157826 preliminary: translated from GB/EMBL/DBJ
#status
##molecule_type DNA
##residues 1-454 ##label RES
##cross-references GB:M7656; NID:g202100; PIDN:AAA0465.1; PID:g202102
GENERICs
#gene TNFR-2
#introns 13/3; 65/1; 108/1; 158/1; 184/2; 210/1; 248/1; 257/3; 353/1
CLASSIFICATION
#superfamily tumor necrosis factor receptor type I; NGF
#receptor repeat homology
#cytokine receptor
KEYWORDS
FEATURE
#domain NGF receptor repeat homology #label NGF
SUMMARY 44-82 #length 454 #molecular_weight 50030 #necksun 4267
Query Match 4.6%; Score 142; DB 2; Length 454;
Best Local Similarity 26.9%; Pred.No. 1.95e-07;
Matches 29; Conservative 16; Mismatches 58; Indels 5; Gaps 5;

Db 44 CPQGYVSHKNNISICTCHGTYLTVSDCSP-GRDTVCCECEKGTFTASQNTLRCLSC 102
OY 34 CRODEFNRSGNVCVPCNCGFMELSKEGFGYEDACVACRLHRRKEDWGFQK-CKPC 92
Db 103 KTCREMSQVEISPOADKDTVC-CKENOFQRLSTHOCYDCSPC 149
OY 93 LDCA-VVNRFPKANCATSDAICDCILPG-FYKRTKLVGEDMECVPC 138

RESULT 7
ENTRY #type complete
TITLE tumor necrosis factor receptor 1 precursor - human
ALTERNATE_NAMES P55 tumor necrosis factor receptor; TNF receptor
CONTRINS tumor necrosis factor alpha inhibitor; tumor necrosis factor
ORGANISM binding protein 1 (TNF blocking factor)
DATE #formal_name Homo sapiens #common_name man
DATE 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change
22-Jun-1999
ACCESSIONS
A38289; A34900; A36555; C36555; A38281; S12057;
J07058; A60231; A38258; A60594; A35010; J02404
A38208

REFERENCE
#authors Fuchs, P.; Strehl, S.; Dworzak, M.; Himmler, A.; Ambros, P.F
#journal Genomics (1992) 13:219-224
#title Structure of the human TNF receptor 1 (p60) gene (TNFR1) and
#localization to chromosome 12p13.
#cross-references M0ID:92250049
#accession A38208
##molecule_type DNA
##residues 1-455 ##label FUC
##cross-references GB:M7586; GB:M75866; NID:g339746;
PIDN:AAA61201.1; PID:g339750

REFERENCE
#authors Loeschner, H.; Pan, Y.C.E.; Lahm, H.W.; Gentz, R.; Brockhaus
#journal M.; Tabuchi, R.; Lesslauer, W.
#title Cell (1990) 61:351-359
#localization Molecular cloning and expression of the human 55 kd tumor
#necrosis factor receptor.
#cross-references M0ID:90235284
#accession A34899
##molecule_type mRNA
##residues 1-455 ##label LOE
##cross-references GB:M58286; GB:M3480; NID:g339753; PIDN:AAA36753.1;
PID:g339754
#experimental_source placenta
#note part of this sequence, including the amino end of the
mature protein, confirmed by protein sequencing

REFERENCE
#authors Schall, T.J.; Lewis, M.; Kolter, K.J.; Lee, A.; Rice, G.C.;
Wong, G.H.W.; Gatanaga, T.; Granger, G.A.; Lentz, R.; Raab
H.; Kohr, W.J.; Goeddel, D.V.
#journal Cell (1990) 61:361-370
#title Molecular cloning and expression of a receptor for human
tumor necrosis factor.
#cross-references M0ID:90235285

```

#accession A34900
 ##molecule-type mRNA
 ##residues 1-455 ##label SCH
 ##cross-references GB:M33294; NID:g339744; PIDN:AAA03210.1; PID:g339745
 REFERENCE
 #authors Himmler, A.; Maurer-Fogy, I.; Kiroenke, M.; Scheulich, P.; Plizemaelier, K.; Lantz, M.; Olsson, I.; Hauptmann, R.; Stratos, C.; Adolf, G.R.
 #journal DNA Cell Biol. (1990) 9:705-715
 #title Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein.
 #cross-references MIMD:91090841
 #accession A36555
 ##molecule-type mRNA
 ##residues 1-455 ##label HIM
 ##cross-references GB:M63121; NID:g339755; PIDN:AAA36754.1; PID:g339756
 #accession C36555
 ##molecule-type protein
 ##residues 50-38/41-53, 'X', 55-79, 'XX', 82-94, 'NK', 'XX', 100-104;
 ; 107-128; 162-167, 'X', 169-201 ##label H12
 #note the purified protein, called tumor necrosis factor binding protein, is a soluble derivative of the receptor
 REFERENCE
 #authors A38281
 Gray, P.W.; Barrett, K.; Chantry, D.; Turner, M.; Feldmann, M.
 #journal Proc. Natl. Acad. Sci. U.S.A. (1990) 87:7380-7384
 #title Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein.
 #cross-references MIMD:91017509
 #accession A38281
 ##molecule-type mRNA
 ##residues 1-455 ##label GRA
 ##cross-references GB:M37764
 #note the authors translated the codon TGG for residue 371 as Thr, AAG for residue 372 as Leu, and GAC for residue 427 as Asn
 REFERENCE
 #authors S12057
 Noppar, Y.; Kemper, O.; Brakebusch, C.; Engelmann, H.; Zwang, R.; Aderka, D.; Holtmann, H.; Wallach, D.
 #journal EMBO J. (1990) 9:3269-3278
 #title Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.
 #cross-references MIMD:91006021
 #accession S12057
 ##molecule-type mRNA
 ##residues 1-455 ##label NOP
 ##cross-references EMBL:X53131; NID:g37223; PIDN:CAA39021.1; PID:g37224
 #note parts of soluble TNF binding protein 1, including its amino and carboxyl ends, were confirmed by protein sequencing
 REFERENCE
 #authors JT0758
 Kemper, O.; Wallach, D.
 #journal Gene (1993) 134:209-216
 #title Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor.
 #cross-references MIMD:94085779
 #accession JT0758
 ##molecule-type DNA
 ##residues 1-13 ##label KEM
 REFERENCE
 #authors A60231
 Seelinger, P.; Vey, E.; Turcatti, G.; Wingfield, P.; Dayer, J.M.
 #journal Eur. J. Immunol. (1990) 20:1167-1174
 #title Tumor necrosis factor inhibitor: purification, NH-2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities.
 #cross-references MIMD:90292116
 #accession A60231
 ##molecule-type protein


```

##residues 41-43,'X',45-53,'X',55-57 ##label SEC
REFERENCE A38258
#authors Gatnaga, T.; Hwang, C.; Kohr, W.; Cappuccini, F.; Luccl III,
J.A.; Jeffes, E.W.B.; Lentz, R.; Tomich, J.; Yamamoto,
R.S.; Granger, G.A.
#journal Proc. Natl. Acad. Sci. U.S.A. (1990) 87:8781-8784
#title Purification and characterization of an inhibitor (soluble
tumor necrosis factor receptor) for tumor necrosis factor
and lymphotoxin obtained from the serum ultrafiltrates of
human cancer patients.
#cross-references MUID:91062364
#accession A38258
##molecule-type protein
##residues 41-60 ##label GAT
REFERENCE #experimental-source cancer patient serum
A60594
#authors Olsson, I.; Lantz, M.; Nilsson, E.; Peetre, C.; Thyse, H.;
Grubb, A.; Adolf, G.
#journal Eur. J. Haematol. (1989) 42:270-275
#title Isolation and characterization of a tumor necrosis factor
binding protein from urine.
#cross-references MUID:89171156
#accession A60594
##molecule-type protein
##residues 41-43,'X',45-53,'V',55-57,'XK',60 ##label OLS
REFERENCE #experimental-source renal failure patient urine
A35010
#authors Engelmann, H.; Novick, D.; Wallach, D.
#journal J. Biol. Chem. (1990) 265:1531-1536
#title Two tumor necrosis factor-binding proteins purified from
human urine. Evidence for immunological cross-reactivity
with cell surface tumor necrosis factor receptors.
#cross-references MUID:90110215
#accession A35010
##molecule-type protein
##residues 41-45 ##label ENG
REFERENCE #experimental-source normal urine
JC2404
#authors Kajihara, J.; Asada, A.; Kirihara, S.; Kato, K.
#journal Biosci. Biotechnol. Biochem. (1994) 58:2266-2268
#title Amino acid sequence of natural tumor necrosis factor alpha
inhibitor purified from human urine.
#cross-references MUID:95128033
#accession JC2404
##molecule-type protein
##residues 41-53,'X',55-144,'X',146-150,'X',152-186,'X',188-201
##label KAJ
#experimental-source urine
#comment This protein is one of two known receptors for both TNF-alpha
(cachectin) and TNF-beta (lymphotoxin).
GENERIC
#gene GDB:TNFR1
#cross-references GDB:125913; OMIM:191190
#map-position 12p13.2-12p13.2
#introns 13/3; 65/1; 108/1; 158/1; 184/2; 209/1; 247/1; 256/3; 353/1
#superfamily tumor necrosis factor receptor type 1; NGF
receptor repeat homology
#keywords duplication; glycoprotein; receptor; transmembrane protein
FEATURE
1-21 #domain signal sequence #status predicted #label SIG\
22-455 #product tumor necrosis factor receptor type 1 #status
predicted #label MAT\
30-211 #domain extracellular #status predicted #label EXT\
41-201 #product TNF binding protein 1 (tumor necrosis factor
alpha inhibitor) #status experimental #label TBP1\
44-82 #domain NGF receptor repeat homology #label NG1\
84-126 #domain NGF receptor repeat homology #label NG2\
127-167 #domain NGF receptor repeat homology #label NG3\
168-196 #domain NGF receptor repeat homology #label NG4\
212-234 #domain transmembrane #status predicted #label MEM\
235-455 #domain intracellular #status predicted #label INT\
54,145,151 #binding-site carboxydrate (Asn) (covalent) #status
predicted

```

```

SUMMARY #length 455 #molecular-weight 50494 #checksum 153
Query Match 4.6%; Score 143; DB 1; Length 455;
Best Local Similarity 25.2%; Pred. No. 1,33e-07;
Matches 32; Conservative 30; Mismatches 57; Indels 8; Gaps 8;
Db 11 LPI-VILELGVIGPSVIGLVPGLGDRKRSV-CPQSKYTHPONNSICCKHGYL 68
:::|||||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
1 MALKVLEQKTFE-TLV-LIGYLSCKVTCESGDCRQOEFRDRSGNCVPCNCGGMEL 58
Qy
Db 69 YNDCP-GPQDPDRCRCESGTFASENHRLCSCKCKEMQVBISSCTYDRDYCG- 126
:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Qy 59 SKECGFGYGDQACVACRLHFRKE-DWGFQCKPCLDCA-VVNRQKANCATSDAICGD 116
Db 127 CRKNQYR 133
Qy 117 CLPGFYR 133
RESULT 8
ENTRY 154182 #type complete
TITLE tumor necrosis factor receptor 2-related protein - human
ORGANISM #formal_name Homo sapiens #common_name man
DATE 24-May-1996 #sequence_revision 24-May-1996 #text_change
29-Aug-1997
ACCESSIONS 154182
REFERENCE 154182
#authors Baens, M.; Chaffanet, M.; Cassiman, J.J.; Van den Berghe, H.;
Maeynen, P.
#journal Genomics (1993) 16:214-218
#title Construction and evaluation of a hncDNA library of human 12p
transcribed sequences derived from a somatic cell hybrid.
#cross-references MUID:93252381
#accession 154182
##status preliminary; translated from GB/EMBL/DBJ
##molecule-type mRNA
##residues 1-435 ##label RES
#cross-references GB:L04270; NID:g339761; PID:g339762
GENERIC
#gene GDB:LTBR
#cross-references GDB:1230195; OMIM:600979
#map-position 12p13.3-12p13.1
SUMMARY #length 435 #molecular-weight 46709 #checksum 63
Query Match 4.4%; Score 136; DB 2; Length 435;
Best Local Similarity 26.3%; Pred. No. 1,90e-06;
Matches 26; Conservative 24; Mismatches 41; Indels 8; Gaps 8;
Db 37 ASENQCTPQDEKEYE-POHRTCCSRCPGTYSACS-RI-RDYCATCAENSYNHNN 93
:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Qy 28 TCSSGDCR-QQ-EFRDRSGNCVPCNCGGMELSKRCGFGYGDQACVACRLHFRKEDNG 85
Db 94 YLTIQCLCRPCDPVWGLEIAPCTSKRTQC-RCQPGMF 131
:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Qy 86 FQK-CRKCCLICAVVNRQK-AMCSATSDAICGCLPGFY 122
RESULT 9
ENTRY 137383 #type complete
TITLE Fas soluble protein - human
ORGANISM #formal_name Homo sapiens #common_name man
DATE 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change
02-Jul-1996
ACCESSIONS 137383
REFERENCE 137383
#authors Cascino, I.; Fluccl, G.; Papoff, G.; Rubertl, G.
#journal J. Immunol. (1995) 154:2706-2713
#title Three functional soluble forms of the human
apoptosis-inducing Fas molecule are produced by alternative
splicing
#cross-references MUID:95181785
#accession 137383
#status preliminary; translated from GB/EMBL/DBJ

```

[illegible]

SUMMARY		#length	335	#molecular-weight	37732	#checksum	4899
Query Match	4.3%;	Score	133;	DB	2;	Length	335;
Best Local Similarity	26.9%;	Pred. No.	5.85e-06;				
Matches	21;	Conservative	21;	Mismatches	30;	Indels	6;
Gaps	6;						
Db	59	CHRCPCGERKARCCTYN-GDEPDVCPCOGKRGKTYTAKHFFSSRCRCRCRLCDBGHGJEVRI	117				
Oy	49	CNO-CGFGMEISKCKCGGCGYEDGDMQVACRLHR-FKEDWGFO-KCKPCLDCAYVNRFO-KA	104				
Db	118	NCTRQNTKC-RCKPNFF	134				
Oy	105	NCSATSDAIGCDLPGFY	122				
RESULT	11						
ENTRY	GOVZML	#type complete					
TITLE	T2 protein - myxoma virus (strain Lausanne)						
ORGANISM	#formal name myxoma virus						
DATE	31-Dec-1992	#sequence-revision	31-Dec-1992	#text-change			
ACCESSIONS	A40566						
REFERENCE	Upton, C.; Macen, J.L.; Schreiber, M.; Mcfadden, G.						
#authors							
#journal	Virology (1991) 184:370-382						
#title	Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence.						
#cross-references	MUID:91335768						
#accession	A40566						
#molecule_type	DNA						
#residues	1-326	#label	UPT				
#cross-references	GB:M5181; GB:N37976; NID:9332309; PIDN:AAA4632.1;						
CLASSIFICATION	superfamily myxoma virus T2 protein; NGF receptor repeat homology						
KEYWORDS	glycoprotein						
FEATURE							
64-105	#domain NGF receptor repeat homology #label NG2\						
106-147	#domain NGF receptor repeat homology #label NG3\						
66,181,205,238	#binding site carbohydrate (Asn) (covalent) #status predicted						
SUMMARY	#length 326 #molecular-weight 35208 #checksum 9255						
Query Match	4.2%;	Score	130;	DB	1;	Length	326;
Best Local Similarity	29.5%;	Pred. No.	1.77e-05;				
Matches	28;	Conservative	16;	Mismatches	42;	Indels	9;
Gaps	8;						
Db	24	DRKCRGNDY-EKDGILC-CTSCPPGSYSRLCG-P-GSDTYCSPCKNETFTASTNHADA	78				
Oy	30	ESGCGRQEFERDRSGNCPVPCNOGCPGMEISKCKGFGYGEDGACVACRLHRFKEDWGFO-OK	88				
Db	79	CVSCGRGCTG-HLSESGSCDKTRDYRC-DCSAGN	111				
Oy	89	CKPCLD-CAYVNRFOKANKSATSDAIGCDLPGFY	122				
RESULT	12						
ENTRY	GOPRT1	#type complete					
TITLE	tumor necrosis factor receptor 1 precursor - rat						
CONTAINS	tumor necrosis factor binding protein 1 (TNF blocking factor)						
ORGANISM	#formal name Rattus norvegicus #common_name Norway rat						
DATE	30-Jun-1992	#sequence-revision	07-Oct-1994	#text-change			
ACCESSIONS	B36555						
REFERENCE	Himmler, A.; Maurer-Fogy, I.; Kroenke, M.; Scheurich, P.; Strätow, C.; Adolf, G.R.						
#authors							
#journal	DNA Cell Biol. (1990) 9:705-715						
#title	Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein.						

##cross-references MUID:91090841
#accession B36555
#molecule_type mRNA
#residues 1-461 ##label HIM
##cross-references GB:M61122; NID:9207361; PIDN:AAA42256.1; PID:9207362
COMMENT This protein is one of two known receptors for both TNF-alpha (cachectin) and TNF-beta (lymphotoxin).

CLASSIFICATION #superfamily tumor necrosis factor receptor type 1; NGF receptor repeat homology
KEYWORDS duplication; glycoprotein; receptor; transmembrane protein
FEATURE
1-29
30-461
30-211
30-201
44-82
84-126
127-167
168-204
212-234
235-461
54,151,201

SUMMARY #length 461 #molecular-weight 50969 #checksum 1617

Query Match 4.2%; Score 130; DB 1; Length 461;
Best Local Similarity 25.9%; Pred. No. 1,77e-05;
Matches 28; Conservative 16; Mismatches 59; Indels 5; Gaps 5;

Db 44 CPQGVAPHPKNNISICCTKCHKGYLVSDPSP-GEITYCEVCDCGTFTASQNHVQCISC 102
QY 34 CROGFEFDRSGNCVPCNOCGPMELSKGCGEGDQACVACRLHREKDWGF-QKCRPC 92
DB 103 KTCRKEHGVESIPCKADMVTCG-CKKNQRYLSEHFPCVQCSPC 149
QY 93 LDCA-VVNRFOKANCASATSDICDCLPG-FYRRTKLVGFQDMCVCPC 138

RESULT 13
ENTRY A46484 #type complete
TITLE apoptosis-mediating membrane-associated polypeptide Fas - mouse
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 16-Jul-1999
ACCESSION A46484
#authors Watanabe-Fukunaga, R.; Brannan, C.I.; Itoh, N.; Yonehara, S.; Copeland, N.G.; Jenkins, N.A.; Nagata, S.
#journal J. Immunol. (1992) 148:1274-1279
#title The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen.
#cross-references MUID:92148151
#accession A46484
#status Preliminary
#molecule_type mRNA
#residues 1-327 ##label WAT
##cross-references GB:M63649; NID:9193225; PID:9193226
##experimental_source BAW3 macrophage cell line
##note sequence extracted from NCBI backbone (NCBIN:81544, NCBI:81545)

REFERENCE A47254
#authors Adachi, M.; Watanabe-Fukunaga, R.; Nagata, S.
#journal Proc. Natl. Acad. Sci. U.S.A. (1993) 90:1756-1760
#title Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of 1pr mice.
#cross-references MUID:93189576
#accession A47254
#status Preliminary
#molecule_type nucleic acid

##residues 1-96 ##label ADA
##cross-references GB:S56490; NID:9298505; PID:9298506
##experimental_source MRL 1pr/1pr
##note sequence extracted from NCBI backbone (NCBIN:126850, NCBIN:126853, NCBIN:126863, NCBI:126864)
CLASSIFICATION #superfamily NGF receptor repeat homology
KEYWORDS transmembrane protein
FEATURE
44-79
81-124
SUMMARY #domain NGF receptor repeat homology #label NGF
#length 327 #molecular-weight 37417 #checksum 8479

Query Match 4.1%; Score 127; DB 2; Length 327;
Best Local Similarity 26.0%; Pred. No. 5.31e-05;
Matches 20; Conservative 18; Mismatches 34; Indels 5; Gaps 5;

Db 56 CQCPQPKKIVEDCKMN-GGTPICAPCTEGKEVMDKNHYADKRCRLCDEHLEVEETN 114
QY 49 CNOGPEMERLSKEGFGYGDQACVACRLHR-FKEDWGF-QKCRPCIDCAVNNRFO-KAN 105
DB 115 CTITQNTKC-KCKRDFY 130
QY 106 CSATSDAICDCLPGFY 122

RESULT 14
ENTRY D36858 #type complete
TITLE gene G4R protein - variola virus
ALTERNATE_NAMES B23R protein (GCP)
ORGANISM #formal_name variola virus
DATE 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 26-Aug-1999
ACCESSION D36858; S46888; S32385; S35987
REFERENCE
#authors Blinov, V.M.
#submission submitted to Genbank, November 1992
#description not shown.
#accession D36858
#status Preliminary
#molecule_type DNA
#residues 1-349 ##label BLI
##cross-references GB:X69196; NID:9456756; PID:9457087
##experimental_source strain India-1967, ssp. major, isolate Ind3
S46868
#authors Kolychalov, A.A.; Blinov, V.M.; Gytarov, V.V.; Podnyakov, S.G.; Chizhikov, V.E.; Evloy, I.V.; Totmenin, A.V.; Shchelkunov, S.N.; Sandakchiev, L.S.
#submission submitted to the EMBL Data Library, April 1992
#description Nucleotide sequence analysis of the region of variola virus XhoI F O H P Q genome fragment.
#accession S46888
#status Preliminary
#molecule_type DNA
#residues 1-349 ##label KOL
##cross-references EMBL:X67117; NID:9516428; PID:9516449
##experimental_source strain India-1967, isolate Ind3
S32385
#authors Shchelkunov, S.N.; Blinov, V.M.; Sandakchiev, L.S.
#journal PNAS Lett. (1993) 319:80-83
#title Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms.
#cross-references MUID:93202281
#accession S32385
#status Preliminary
#molecule_type DNA
#residues 31-168 ##label SHC
##cross-references EMBL:X69198
##experimental_source strain India-1967, ssp. major
GENETICS
#gene G4R
CLASSIFICATION #superfamily myxoma virus T2 protein; NGF receptor repeat homology
FEATURE
32-66 #domain NGF receptor repeat homology #label NGF\

Query Match	4.1%	Score 128;	DB 2;	Length 349;
Best Local Similarity	28.7%	Pred. No. 3.69e-05;		
Matches	27;	Conservative	21;	Mismatches 37;
				Indels 9;
				Gaps 8;
Db	29	NGKCKDIYK-RHMLC--CLSCPFGIYASRLCD-S-KITVQCTPCGSGFTTISRNNHLPAC	83	
Qy	31	SGDRQDFRDRSNCVPCNOCGPMELSECEFGYGEDACQACVACRLHFRKE-DWGFQKC	89	
Db	84	LSCNGRCS-NQVETRSCTTHNRIC-EGSPGY	115	
Qy	90	KPCLD-CAVYVRFQKANCASATSDAICGDLPGFY	122	
RESULT	15			
ENTRY		148854	#type fragment	
TITLE		gene murine tumour necrosis factor receptor 2 protein - mouse		
ORGANISM		(fragment)		
DATE		#format_name Mus musculus #common_name house mouse		
		02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change		
		23-Jul-1999		
ACCESSIONS		I48854		
REFERENCE		I48854		
#authors		Powell, E.E.; Wicker, L.S.; Peterson, L.B.; Todd, J.A.		
#journal		Mamm. Genome (1994) 5:726-727		
#title		Allelic variation of the type 2 tumor necrosis factor receptor gene.		
#cross-references		MOTID:95178484		
#accession		I48854		
#status		Preliminary; translated from GB/EMBL/DBJ		
#molecule_type		mRNA		
#residues		1-459 #label RES		
#cross-references		EMBL:X75401; NID:g433830; PIDD:CAA53981.1;		
		PID:g433831		
CLASSIFICATION		#superfamily tumor necrosis factor receptor type 2; NGF		
		receptor repeat homology		
FEATURE				
151-188		#domain NGF receptor repeat homology #label NGF		
SUMMARY		#length 459 #checksum 3156		
Query Match	4.1%	Score 126;	DB 2;	Length 459;
Best Local Similarity	25.0%	Pred. No. 7.63e-05;		
Matches	24;	Conservative	20;	Mismatches 45;
				Indels 7;
				Gaps 7;
Db	20	EPGYEQIISQEIYDKRKQ-WCAKCPGQYVHFCN-K-TSDTVACADEASNTQVWNOF	76	
Qy	30	ESG-DGR-QQEFRRSNCVPCNOCGPMELSECEFGYGEDACQACVACRLHFRKEDWG-F	86	
Db	77	RFTLSCSSSCTDQVTRACTKQONRYCA-CEAGRY	111	
Qy	87	QKCPCLDCAVYVRFQKANCASATSDAICGDLPGFY	122	

Search completed: Tue Apr 18 13:59:33 2000
Job time : 63 secs.

[illegible]

```

01 15 TLVLVLGLSKVTCESGDRCQGEFRBSRGNCVPCNCGGFMELSKRCGFGYGEDACVA 74
02
03 Db 63 CETGFYNEAVNYDTCKQCTOCNHRSSGSELKONCTPTQDTC-RCRPETOPROD-SGFKLG 120
04      ::||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
05 QY 75 CRLHFRFKEDMGFOCKCKDLCCAVVNRFO-KANCSATSDALCGDLPGFYKRTKLVGFO-D 132
06
07 Db 121 VDCVPCPGHFSPPNNQACKPWTNCTLSGKOTRRPADSLDAV-CED-RSLLATLL 174
08      ::|||::||::||::||::||::||::||::||::||::||::||::||::||::||
09 QY 133 MECVPC-GEPPPEYEPHCASKVNLVKIASTASSPBDTALAAVICALAVLALL 186
10
11 RESULT 3
12 ID US-08-097-827-7 STANDARD; PRT; 206 AA.
13 AC xxxxxx
14 XX
15 DT
16 XX
17
18 Sequence 7, Application US/08097827
19
20 Sequence 7, Application US/08097827
21 Patent No. 5457035
22 GENERAL INFORMATION:
23 APPLICANT: Baum, Peter
24 APPLICANT: Goodwin, Ray
25 APPLICANT: Fanslow, William
26 APPLICANT: Gayle, Richard
27 TITLE OF INVENTION: No. 5457035el cytokine which is a ligand for
28 TITLE OF INVENTION: OX40
29 NUMBER OF SEQUENCES: 13
30 CORRESPONDENCE ADDRESSES:
31 ADDRESSEE: Immunex Corporation
32 STREET: 51 University Street
33 City: Seattle
34 STATE: WA
35 COUNTRY: USA
36 ZIP: 98101
37
38 COMPUTER READABLE FORM:
39 MEDIUM TYPE: Floppy disk
40 COMPUTER: IBM PC compatible
41 OPERATING SYSTEM: PC-DOS/MS-DOS
42 SOFTWARE: Patentin Release #1.0, Version #1.25
43 CURRENT APPLICATION DATA:
44 APPLICATION NUMBER: US/08/097,827
45 FILING DATE:
46 CLASSIFICATION: 536
47 ATTORNEY/AGENT INFORMATION:
48 NAME: Perkins, Patricia A.
49 REGISTRATION NUMBER: 34,693
50 REFERENCE/DOCKET NUMBER: 2806
51 TELECOMMUNICATION INFORMATION:
52 TELEPHONE: 206-587-0730
53 INFORMATION FOR SEQ. ID NO: 7:
54 SEQUENCE CHARACTERISTICS:
55 LENGTH: 206 amino acids
56 TYPE: amino acid
57 TOPOLOGY: linear
58 MOLECULE TYPE: protein
59 SEQUENCE 206 AA; 22939 MM; 232405 CN;
60
61 Query Match 5.7%; Score 178; DB 1; Length 206;
62 Best local similarity 27.8%; Pred. No. 1,81e-05;
63 Matches 49; Conservative 36; Mismatches 77; Indels 14; Gaps 11;
64
65 Db 9 TALLLG-LILGVARLNLNVKHTYPS-GHKC--CRCQPGHGAVNRCD--HTRDTLCHP 62
66      |||||::||::||::||::||::||::||::||::||::||::||::||::||::||
67 QY 15 TLVLVLGLSKVTCESGDRCQGEFRBSRGNCVPCNCGGFMELSKRCGFGYGEDACVA 74
68
69 Db 63 CETGFYNEAVNYDTCKQCTOCNHRSSGSELKONCTPTQDTC-RCRPETOPROD-SGFKLG 120
70      ::||::||::||::||::||::||::||::||::||::||::||::||::||
71 QY 75 CRLHFRFKEDMGFOCKCKDLCCAVVNRFO-KANCSATSDALCGDLPGFYKRTKLVGFO-D 132
72
73 Db 121 VDCVPCPGHFSPPNNQACKPWTNCTLSGKOTRRPADSLDAV-CED-RSLLATLL 174
74      ::|||::||::||::||::||::||::||::||::||::||::||::||::||
75 QY 133 MECVPC-GEPPPEYEPHCASKVNLVKIASTASSPBDTALAAVICALAVLALL 186
76
77 Db 121 VDCVPCPGHFSPPNNQACKPWTNCTLSGKOTRRPADSLDAV-CED-RSLLATLL 174

```


DE Sequence 54, Application US/08465982
XX
CC Sequence 54, Application US/08465982
CC Patent No. 5863786
CC GENERAL INFORMATION:
CC APPLICANT: M.J.C. Turner, F.M. Brennan
CC TITLE OF INVENTION: Modified human TNFalpha (Tumor
CC TITLE OF INVENTION: Necrosis Factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robbins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/465,982
CC FILING DATE:
CC CLASSIFICATION:
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319
CC FILING DATE: 10-May-1993
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robbins, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 54:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 158 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 158 AA: 17375 MW; 124033 CN;
SQ
Query Match 4.9%; Score 151; DB 2; Length 158;
Best Local Similarity 24.6%; Pred. No. 2.27e-03;
Matches 31; Conservative 32; Mismatches 55; Indels 8; Gaps 8;
DB 11 LPL-VLELIVGIRPSGVIGLVPHLGDREKRDV-CPOGKTIHPQNNISICCTKCHKGYTL 68
QY 1 MALKVLEDEKTEFF-TLLV-LLGTLSCVTCESGDCRQDFRDRSGNVCVPCNQCSPGMEL 58
DB 69 YNDCP-GPGQDTDCRECSGSFTASENHLRHCLSCSKCKREKGOVEISSCTVDRDTVCT- 126
QY 59 SKEGCFGEFGEDACVACRLHFRKE-DWGFQKCKPCIDCA-VVNRQKANCATSATSDALICGD 116
DB 127 CHAGFF 132
QY 117 CLPGFY 122
RESULT 7
ID US-08-050-319B-54 STANDARD; PRT; 158 AA.
XX
AC xxxxxx
XX
DT
XX
DE Sequence 54, Application US/08050319B
XX
CC Sequence 54, Application US/08050319B
CC Patent No. 5633145
CC GENERAL INFORMATION:

CC APPLICANT: M.Feldmann, P.W. Gray,
CC APPLICANT: M.J.C. Turner, F.M. Brennan
CC TITLE OF INVENTION: Modified human TNFalpha (Tumor
CC TITLE OF INVENTION: Necrosis Factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robbins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319B
CC FILING DATE: 10-May-1993
CC CLASSIFICATION: 435
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robbins, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 54:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 158 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 158 AA: 17375 MW; 124033 CN;
SQ
Query Match 4.9%; Score 151; DB 1; Length 158;
Best Local Similarity 24.6%; Pred. No. 2.27e-03;
Matches 31; Conservative 32; Mismatches 55; Indels 8; Gaps 8;
DB 11 LPL-VLELIVGIRPSGVIGLVPHLGDREKRDV-CPOGKTIHPQNNISICCTKCHKGYTL 68
QY 1 MALKVLEDEKTEFF-TLLV-LLGTLSCVTCESGDCRQDFRDRSGNVCVPCNQCSPGMEL 58
DB 69 YNDCP-GPGQDTDCRECSGSFTASENHLRHCLSCSKCKREKGOVEISSCTVDRDTVCT- 126
QY 59 SKEGCFGEFGEDACVACRLHFRKE-DWGFQKCKPCIDCA-VVNRQKANCATSATSDALICGD 116
DB 127 CHAGFF 132
QY 117 CLPGFY 122
RESULT 8
ID US-08-219-237B-8 STANDARD; PRT; 139 AA.
XX
AC xxxxxx
XX
DT
XX
DE Sequence 8, Application US/08219237B
XX
CC Sequence 8, Application US/08219237B
CC Patent No. 5874546
CC GENERAL INFORMATION:
CC APPLICANT: NAGATA, Shigekazu
CC APPLICANT: ITOH, Naoto
CC APPLICANT: YONEHARA, Shin
CC TITLE OF INVENTION: DNA Coding for Human Cell Surface Antigen
CC NUMBER OF SEQUENCES: 11
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: James W. Hellwege
CC STREET: P.O. Box 226 Eads Station

CC INFORMATION FOR SEQ ID NO: 10:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 154 amino acids
CC TYPE: amino acid
CC STRANDEDNESS: not relevant
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC HYPOTHETICAL: NO
CC FRAGMENT TYPE: Internal
CC FEATURE:
CC NAME/KEY: Protein
CC LOCATION: 1..154
CC OTHER INFORMATION: /note="TNFRI, see Fig. 5"
CC SEQUENCE 154 AA; 17350 MW; 115236 CN;
SO

Query Match 4.7%; Score 147; DB 2; Length 154;
Best Local Similarity 26.1%; Pred. No. 4.58e-03;
Matches 24; Conservative 20; Mismatches 44; Indels 4; Gaps 4;

Db 2 CPQGYIHQNNISICCTCKHGTIYNDCP-GPGDPTDCDECSQSFASSENHLRHCLSC 60
QY 34 CROQEFRRSGNCVPCNOCGPGMEISKEGFGYGEDACVACRLHFKFE-DWGFQCKKPC 92
Db 61 SKCRKEMGVEISSCTVDRTVCG-CRKNQYR 91
QY 93 LDCA-VVNFQANCSATSDAICGDLPGFYR 123

RESULT 11
ID US-08-050-319B-57 STANDARD; PRT; 167 AA.
XX xxxxxx
XX

DE - Sequence 57, Application US/08050319B
XX Sequence 57, Application US/08050319B
CC Patent No. 5633145
CC GENERAL INFORMATION:
CC APPLICANT: M.Feldmann, P.W. Gray,
CC APPLICANT: M.J.C. Turner, F.M.Brennan
CC TITLE OF INVENTION: Modified human TNFalpha (Tumor
CC TITLE OF INVENTION: Necrosis Factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robbins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319B
CC FILING DATE: 10-May-1993
CC CLASSIFICATION: 435
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robbins, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 57:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 167 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear

CC MOLECULE TYPE: protein
CC SEQUENCE 167 AA; 18626 MW; 139513 CN;
SO

Query Match 4.6%; Score 143; DB 1; Length 167;
Best Local Similarity 25.2%; Pred. No. 9.20e-03;
Matches 32; Conservative 30; Mismatches 57; Indels 8; Gaps 8;

Db 11 LPL-VLELVGIIYPSGVIGLPHLDREKRDY-CPQGYIHQNNISICCTCKHGTIYL 68
QY 1 MALKVLLLEQEKTFE-TLLV-LIGYLSCKVTCESGDCRQOEFRRSGNCVPCNOCGPGMEI 58
Db 69 YNDGP-GPGDPTDCDECSQSFASSENHLRHCLSCSKCRKEMGVEISSCTVDRTVCG- 126
QY 59 SKEGFGYGEDACVACRLHFKFE-DWGFQCKPCLDCA-VVNFQANCSATSDAICGD 116
Db 127 CRKNQYR 133
QY 117 CLPGFYR 123

RESULT 12
ID US-08-465-982-2 STANDARD; PRT; 167 AA.
XX xxxxxx
XX

DE Sequence 2, Application US/08465982
XX Sequence 2, Application US/08465982
CC Patent No. 5863786
CC GENERAL INFORMATION:
CC APPLICANT: M.Feldmann, P.W. Gray,
CC APPLICANT: M.J.C. Turner, F.M.Brennan
CC TITLE OF INVENTION: Modified human TNFalpha (Tumor
CC TITLE OF INVENTION: Necrosis Factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robbins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC OPERATING SYSTEM: IBM PC compatible
CC SOFTWARE: Patentin Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/465,982
CC FILING DATE:
CC CLASSIFICATION:
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319
CC FILING DATE: 10-May-1993
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robbins, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 2:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 167 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 167 AA; 18626 MW; 139513 CN;
SO

Query Match 4.6%; Score 143; DB 2; Length 167;
Best Local Similarity 25.2%; Pred. No. 9.20e-03;


Matches	323;	Conservative	30;	Mismatches	57;	Indels	8;	Gaps	8;
Db	11	LPL-VLLELVGIPSGYIGLVPLHGDREKDSV-CFQGXIIHPQNNISICTCKCHKGYTL	68						
Oy	1	MLAKVLLEQKEKTEFF-TLLVY-LLGYLSCKVTCESGDCRQGEFRDRSGNCVPCNCGPGMEL	58						
Db	69	YNDCC-GRGQOTDCCRECSGGSFTASENTLRCLCSKCRKEMGVEYLSSCTVDRDYCG-	126						
Oy	59	SKECGEFGYGEADQACVACRLHARFE-DWGFOKRCPLDCA-VVNRFORANSAISDAICGD	116						
Db	127	CRKNQYR	133						
Oy	117	CLPGFYR	123						
RESULT	13								
ID	US-08-050-319B-2	STANDARD;	PRT;	167	AA.				
XX	xxxxxx								
XX									
DT									
XX									
XX									
DE	Sequence 2, Application US/08050319B								
XX									
CC	Sequence 2, Application US/08050319B								
CC	Patent No. 5633145								
CC	GENERAL INFORMATION:								
CC	APPLICANT: M.Feldmann, P.W. Gray,								
CC	APPLICANT: M.J.C. Turner, F.M Brennan								
CC	TITLE OF INVENTION: Modified human TNFaIpha (Tumor								
CC	TITLE OF INVENTION: Necrosis Factor alpha) Receptor								
CC	NUMBER OF SEQUENCES: 57								
CC	CORRESPONDENCE ADDRESS:								
CC	ADDRESSEE: Reed & Roblins								
CC	STREET: 635 Bryant Street								
CC	CITY: Palo Alto								
CC	STATE: California								
CC	COUNTRY: USA								
CC	ZIP: 94301								
CC	COMPUTER READABLE FORM:								
CC	MEDIUM TYPE: Floppy disk								
CC	COMPUTER: IBM PC compatible								
CC	OPERATING SYSTEM: PC-DOS/MS-DOS								
CC	SOFTWARE: Patentin Release #1.0, version #1.25								
CC	CURRENT APPLICATION DATA:								
CC	APPLICATION NUMBER: US/08/050,319B								
CC	FILING DATE: 10-May-1993								
CC	CLASSIFICATION: 435								
CC	ATTORNEY/AGENT INFORMATION:								
CC	NAME: Robblins, Roberta L.								
CC	REGISTRATION NUMBER: 33,208								
CC	REFERENCE/DOCKET NUMBER: 5150-0030								
CC	TELECOMMUNICATION INFORMATION:								
CC	TELEPHONE: (415) 617-8899								
CC	TELEFAX: (415) 327-3231								
CC	INFORMATION FOR SEQ ID NO: 2:								
CC	SEQUENCE CHARACTERISTICS:								
CC	LENGTH: 167 amino acids								
CC	TYPE: amino acid								
CC	TOPOLOGY: linear								
CC	MOLECULE TYPE: protein								
CC	SEQUENCE 167 AA; 18626 MW; 139513 CN;								
Query Match	4.6%;	Score 143;	DB 1;	Length 167;					
Best Local Similarity	25.2%;	Pred. No. 9,20e-03;							
Matches	32;	Conservative	30;	Mismatches	57;	Indels	8;		

QY	59	SKECGCGEDDPAQCVACHLHFKE-DMGFOCKCPCLDCA-VVNFQKANCATSDAICGD	116
Db	127	CRKNQYR 133	
QY	117	CLPGFYR 123	
RESULT	14		
ID	US-08-465-982-57	STANDARD;	PRT; 167 AA.
AC	xxxxxx		
DT			
DE			
XX			
XX			
CC	Sequence 57, Application US/08465982		
CC	Patent No. 5863786		
CC	GENERAL INFORMATION:		
CC	APPLICANT: M.Feldmann, P.W. Gray,		
CC	APPLICANT: M.J.C. Turner, P.M Brennan		
CC	TITLE OF INVENTION: Modified human TNFa1pha (Tumor		
CC	TITLE OF INVENTION: Necrosis Factor alpha) Receptor		
CC	NUMBER OF SEQUENCES: 57		
CC	CORRESPONDENCE ADDRESS:		
CC	ADDRESSEE: Reed & Robbins		
CC	STREET: 635 Bryant Street		
CC	CITY: Palo Alto		
CC	STATE: California		
CC	COUNTRY: USA		
CC	ZIP: 94301		
CC	COMPUTER READABLE FORM:		
CC	MEDIUM TYPE: Floppy disk		
CC	COMPUTER: IBM PC compatible		
CC	OPERATING SYSTEM: PC-DOS/MS-DOS		
CC	SOFTWARE: Patentin Release #1.0, version #1.25		
CC	CURRENT APPLICATION DATA:		
CC	APPLICATION NUMBER: US/08/465,982		
CC	FILING DATE:		
CC	CLASSIFICATION:		
CC	PRIOR APPLICATION DATA:		
CC	APPLICATION NUMBER: US/08/050,319		
CC	FILING DATE: 10-May-1993		
CC	ATTORNEY/AGENT INFORMATION:		
CC	NAME: Robbins, Roberta L.		
CC	REGISTRATION NUMBER: 33,208		
CC	REFERENCE/DOCKET NUMBER: 5150-0030		
CC	TELECOMMUNICATION INFORMATION:		
CC	TELEPHONE: (415) 617-8999		
CC	TELEFAX: (415) 327-3231		
CC	INFORMATION FOR SEQ ID NO: 57:		
CC	SEQUENCE CHARACTERISTICS:		
CC	LENGTH: 167 amino acids		
CC	TYPE: amino acid		
CC	TOPOLOGY: linear		
CC	MOLECULE TYPE: protein		
CC	SEQUENCE 167 AA; 18626 MW; 139513 CN;		
Query Match	4.6%;	Score 143;	DB 2; Length 167;
Best Local Similarity	23.2%;	Pred. No. 9,20e-03;	
Matches	32; Conservativity	30; Mismatches	57; Indels 8; Gaps 8;
Db	11	LPL-VLLELVGIVPSGVIGLVPHLGDREKRDV-CPOGKIHPONNSICTCKHKTLYL 68	
QY	1	MLAKTLVQJKEITFF-TLLV-LLGVLSCVYTCESGDCKRQERDRDSGNCVPCNCGPQMEI 58	
Db	69	YNDCP-GFGQDTPDCRECESSGFTASENHLRHQLSCSKCRKEMGVEIISCTVDRTVCG- 126	
QY	59	SKECGCGEDDPAQCVACHLHFKE-DMGFOCKCPCLDCA-VVNFQKANCATSDAICGD 116	
Db	127	CRKNQYR 133	
QY	117	CLPGFYR 123	

```

15 RESULT 15
16 ID US-08-050-319B-25 STANDARD: PRT: 455 AA.
17 XX
18 XX
19 AC xxxxxx
20 XX
21 DT
22 DE Sequence 25, Application US/08050319B
23 CC
24 CC Sequence 25, Application US/08050319B
25 CC Patent No. 5633145
26 CC GENERAL INFORMATION:
27 CC APPLICANT: M.Feldmann, P.W. Gray,
28 CC APPLICANT: M.J.C. Turner, F.M. Brennan
29 CC TITLE OF INVENTION: Modified human TNFalpha (Tumor
30 CC TITLE OF INVENTION: Necrosis factor alpha) Receptor
31 CC NUMBER OF SEQUENCES: 57
32 CC CORRESPONDENCE ADDRESS:
33 CC ADDRESSEE: Reed & Robbins
34 CC STREET: 635 Bryant Street
35 CC CITY: Palo Alto
36 CC STATE: California
37 CC COUNTRY: USA
38 CC ZIP: 94301
39 CC COMPUTER READABLE FORM:
40 CC MEDIUM TYPE: Floppy disk
41 CC COMPUTER: IBM PC compatible
42 CC OPERATING SYSTEM: PC-DOS/MS-DOS
43 CC SOFTWARE: Patent in Release #1.0, version #1.25
44 CC CURRENT APPLICATION DATA:
45 CC APPLICATION NUMBER: US/08/050,319B
46 CC FILING DATE: 10-May-1993
47 CC CLASSIFICATION: 435
48 CC ATTORNEY/AGENT INFORMATION:
49 CC NAME: Robbins, Roberta L.
50 CC REGISTRATION NUMBER: 33,208
51 CC REFERENCE/DOCKET NUMBER: 5150-0030
52 CC TELECOMMUNICATION INFORMATION:
53 CC TELEPHONE: (415) 617-8999
54 CC TELEFAX: (415) 327-3231
55 CC INFORMATION FOR SEQ ID NO: 25:
56 CC SEQUENCE CHARACTERISTICS:
57 CC LENGTH: 455 amino acids
58 CC TYPE: amino acid
59 CC TOPOLOGY: linear
60 CC MOLECULE TYPE: protein
61 CC SEQUENCE 455 AA; 50579 MW; 1048388 CN;
62 CC
63 CC
64 CC
65 CC
66 CC
67 CC
68 CC
69 CC
70 CC
71 CC
72 CC
73 CC
74 CC
75 CC
76 CC
77 CC
78 CC
79 CC
80 CC
81 CC
82 CC
83 CC
84 CC
85 CC
86 CC
87 CC
88 CC
89 CC
90 CC
91 CC
92 CC
93 CC
94 CC
95 CC
96 CC
97 CC
98 CC
99 CC
100 CC
101 CC
102 CC
103 CC
104 CC
105 CC
106 CC
107 CC
108 CC
109 CC
110 CC
111 CC
112 CC
113 CC
114 CC
115 CC
116 CC
117 CC
118 CC
119 CC
120 CC
121 CC
122 CC
123 CC
124 CC
125 CC
126 CC
127 CC
128 CC
129 CC
130 CC
131 CC
132 CC
133 CC
134 CC
135 CC
136 CC
137 CC
138 CC
139 CC
140 CC
141 CC
142 CC
143 CC
144 CC
145 CC
146 CC
147 CC
148 CC
149 CC
150 CC
151 CC
152 CC
153 CC
154 CC
155 CC
156 CC
157 CC
158 CC
159 CC
160 CC
161 CC
162 CC
163 CC
164 CC
165 CC
166 CC
167 CC
168 CC
169 CC
170 CC
171 CC
172 CC
173 CC
174 CC
175 CC
176 CC
177 CC
178 CC
179 CC
180 CC
181 CC
182 CC
183 CC
184 CC
185 CC
186 CC
187 CC
188 CC
189 CC
190 CC
191 CC
192 CC
193 CC
194 CC
195 CC
196 CC
197 CC
198 CC
199 CC
200 CC
201 CC
202 CC
203 CC
204 CC
205 CC
206 CC
207 CC
208 CC
209 CC
210 CC
211 CC
212 CC
213 CC
214 CC
215 CC
216 CC
217 CC
218 CC
219 CC
220 CC
221 CC
222 CC
223 CC
224 CC
225 CC
226 CC
227 CC
228 CC
229 CC
230 CC
231 CC
232 CC
233 CC
234 CC
235 CC
236 CC
237 CC
238 CC
239 CC
240 CC
241 CC
242 CC
243 CC
244 CC
245 CC
246 CC
247 CC
248 CC
249 CC
250 CC
251 CC
252 CC
253 CC
254 CC
255 CC
256 CC
257 CC
258 CC
259 CC
260 CC
261 CC
262 CC
263 CC
264 CC
265 CC
266 CC
267 CC
268 CC
269 CC
270 CC
271 CC
272 CC
273 CC
274 CC
275 CC
276 CC
277 CC
278 CC
279 CC
280 CC
281 CC
282 CC
283 CC
284 CC
285 CC
286 CC
287 CC
288 CC
289 CC
290 CC
291 CC
292 CC
293 CC
294 CC
295 CC
296 CC
297 CC
298 CC
299 CC
300 CC
301 CC
302 CC
303 CC
304 CC
305 CC
306 CC
307 CC
308 CC
309 CC
310 CC
311 CC
312 CC
313 CC
314 CC
315 CC
316 CC
317 CC
318 CC
319 CC
320 CC
321 CC
322 CC
323 CC
324 CC
325 CC
326 CC
327 CC
328 CC
329 CC
330 CC
331 CC
332 CC
333 CC
334 CC
335 CC
336 CC
337 CC
338 CC
339 CC
340 CC
341 CC
342 CC
343 CC
344 CC
345 CC
346 CC
347 CC
348 CC
349 CC
350 CC
351 CC
352 CC
353 CC
354 CC
355 CC
356 CC
357 CC
358 CC
359 CC
360 CC
361 CC
362 CC
363 CC
364 CC
365 CC
366 CC
367 CC
368 CC
369 CC
370 CC
371 CC
372 CC
373 CC
374 CC
375 CC
376 CC
377 CC
378 CC
379 CC
380 CC
381 CC
382 CC
383 CC
384 CC
385 CC
386 CC
387 CC
388 CC
389 CC
390 CC
391 CC
392 CC
393 CC
394 CC
395 CC
396 CC
397 CC
398 CC
399 CC
400 CC
401 CC
402 CC
403 CC
404 CC
405 CC
406 CC
407 CC
408 CC
409 CC
410 CC
411 CC
412 CC
413 CC
414 CC
415 CC
416 CC
417 CC
418 CC
419 CC
420 CC
421 CC
422 CC
423 CC
424 CC
425 CC
426 CC
427 CC
428 CC
429 CC
430 CC
431 CC
432 CC
433 CC
434 CC
435 CC
436 CC
437 CC
438 CC
439 CC
440 CC
441 CC
442 CC
443 CC
444 CC
445 CC
446 CC
447 CC
448 CC
449 CC
450 CC
451 CC
452 CC
453 CC
454 CC
455 CC
456 CC
457 CC
458 CC
459 CC
460 CC
461 CC
462 CC
463 CC
464 CC
465 CC
466 CC
467 CC
468 CC
469 CC
470 CC
471 CC
472 CC
473 CC
474 CC
475 CC
476 CC
477 CC
478 CC
479 CC
480 CC
481 CC
482 CC
483 CC
484 CC
485 CC
486 CC
487 CC
488 CC
489 CC
490 CC
491 CC
492 CC
493 CC
494 CC
495 CC
496 CC
497 CC
498 CC
499 CC
500 CC
501 CC
502 CC
503 CC
504 CC
505 CC
506 CC
507 CC
508 CC
509 CC
510 CC
511 CC
512 CC
513 CC
514 CC
515 CC
516 CC
517 CC
518 CC
519 CC
520 CC
521 CC
522 CC
523 CC
524 CC
525 CC
526 CC
527 CC
528 CC
529 CC
530 CC
531 CC
532 CC
533 CC
534 CC
535 CC
536 CC
537 CC
538 CC
539 CC
540 CC
541 CC
542 CC
543 CC
544 CC
545 CC
546 CC
547 CC
548 CC
549 CC
550 CC
551 CC
552 CC
553 CC
554 CC
555 CC
556 CC
557 CC
558 CC
559 CC
560 CC
561 CC
562 CC
563 CC
564 CC
565 CC
566 CC
567 CC
568 CC
569 CC
570 CC
571 CC
572 CC
573 CC
574 CC
575 CC
576 CC
577 CC
578 CC
579 CC
580 CC
581 CC
582 CC
583 CC
584 CC
585 CC
586 CC
587 CC
588 CC
589 CC
590 CC
591 CC
592 CC
593 CC
594 CC
595 CC
596 CC
597 CC
598 CC
599 CC
600 CC
601 CC
602 CC
603 CC
604 CC
605 CC
606 CC
607 CC
608 CC
609 CC
610 CC
611 CC
612 CC
613 CC
614 CC
615 CC
616 CC
617 CC
618 CC
619 CC
620 CC
621 CC
622 CC
623 CC
624 CC
625 CC
626 CC
627 CC
628 CC
629 CC
630 CC
631 CC
632 CC
633 CC
634 CC
635 CC
636 CC
637 CC
638 CC
639 CC
640 CC
641 CC
642 CC
643 CC
644 CC
645 CC
646 CC
647 CC
648 CC
649 CC
650 CC
651 CC
652 CC
653 CC
654 CC
655 CC
656 CC
657 CC
658 CC
659 CC
660 CC
661 CC
662 CC
663 CC
664 CC
665 CC
666 CC
667 CC
668 CC
669 CC
670 CC
671 CC
672 CC
673 CC
674 CC
675 CC
676 CC
677 CC
678 CC
679 CC
680 CC
681 CC
682 CC
683 CC
684 CC
685 CC
686 CC
687 CC
688 CC
689 CC
690 CC
691 CC
692 CC
693 CC
694 CC
695 CC
696 CC
697 CC
698 CC
699 CC
700 CC
701 CC
702 CC
703 CC
704 CC
705 CC
706 CC
707 CC
708 CC
709 CC
710 CC
711 CC
712 CC
713 CC
714 CC
715 CC
716 CC
717 CC
718 CC
719 CC
720 CC
721 CC
722 CC
723 CC
724 CC
725 CC
726 CC
727 CC
728 CC
729 CC
730 CC
731 CC
732 CC
733 CC
734 CC
735 CC
736 CC
737 CC
738 CC
739 CC
740 CC
741 CC
742 CC
743 CC
744 CC
745 CC
746 CC
747 CC
748 CC
749 CC
750 CC
751 CC
752 CC
753 CC
754 CC
755 CC
756 CC
757 CC
758 CC
759 CC
760 CC
761 CC
762 CC
763 CC
764 CC
765 CC
766 CC
76
```

Search completed: Tue Apr 18 14:02:57 2000
Job time : 10 secs.


 ***** (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
 Copyright (c) 1993-1998 University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

Mparch_pp protein - protein database search, using Smith-Waterman algorithm
 Run on: Tue Apr 18 13:57:47 2000; Maspar time 22.57 Seconds
 Tabular output not generated. 443.989 Million cell updates/sec

Title: >US-09-490-187-2
 Description: (1-423) from US09490187.pep
 Perfect Score: 3111
 Sequence: 1 MALKVLEQKTEFTLVLL.....AVHPATQTSIQVRQLGSL 423

Scoring table: PAM 150
 Gap 11

Searched: 188963 seqs, 23666106 residues

Post-processing: Minimum Match 0%
 Listing first 45 summaries

Database: a-geneseq36
 1:geneseqp

Statistics: Mean 34.781; Variance 154.568; scale 0.225

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	3111	100.0	423	1 W93581	Human hAPO4-alpha prot	1.36e-283
2	3066	98.6	423	1 W70387	Amino acid sequence of	3.07e-279
3	3040	97.7	417	1 W98146	Human TRAIN-R.	1.01e-276
4	3007	96.7	417	1 W70386	Amino acid sequence of	1.57e-273
5	2177	70.0	416	1 W93579	Mouse hAPO4-alpha (lon	2.24e-193
6	1368	44.0	214	1 W98145	Mouse TRAIN-R (Long fo	1.08e-115
7	1368	44.0	214	1 W93580	Mouse hAPO4-alpha (sho	1.08e-115
8	1193	38.3	150	1 W98148	TRAIN-R short, soluble	5.39e-99
9	1008	32.4	150	1 W93583	Mouse hAPO4 gamma prot	2.06e-81
10	1008	32.4	150	1 W98144	Mouse TRAIN-R (short f	2.06e-81
11	328	10.5	109	1 W93582	Rat hAPO4-alpha protei	2.92e-18
12	248	8.0	30	1 W98147	TRAIN-R secreted form	2.92e-11
13	187	6.0	186	1 R62655	COMPOX virus Pst I/Cla	4.09e-06
14	178	5.7	206	1 W48977	Mouse OX40 extracellul	2.23e-05
15	178	5.7	206	1 R81881	Mouse type-II membrane	2.23e-05
16	178	5.7	206	1 R81882	Plasmid pOC406/OX40/Fc	2.23e-05
17	178	5.7	438	1 W48976	OX40/Fc mutleth.	2.23e-05
18	172	5.5	1	1 W93584	Mouse hAPO4-beta prote	6.86e-05
19	159	5.1	176	1 W80254	Amino acid sequence of	7.60e-04
20	151	4.9	159	1 R24083	Truncated TNF-alpha 55	3.27e-03
21	150	4.8	181	1 W26708	Human apoptosis protei	3.92e-03
22	148	4.8	355	1 R85073	COMPOX virus T2-equiva	5.63e-03
23	150	4.8	417	1 W95538	Death domain containin	3.92e-03

24	150	4.8	417	1 W26709	Human apoptosis protei	3.92e-03
25	150	4.8	417	1 W31517	Death domain containin	3.92e-03
26	150	4.8	417	1 W57045	Human apoptosis induci	3.92e-03
27	150	4.8	428	1 W95537	Death domain containin	3.92e-03
28	150	4.8	428	1 W31516	Death domain containin	3.92e-03
29	150	4.8	833	1 W64486	Human DR3 protein.	3.92e-03
30	143	4.6	168	1 R24084	Truncated TNF-alpha 55	1.38e-02
31	143	4.6	199	1 R24080	Truncated TNF-alpha 55	1.38e-02
32	143	4.6	211	1 W89225	Tumour necrosis factor	1.38e-02
33	143	4.6	311	1 W89229	Tumour necrosis factor	1.38e-02
34	143	4.6	366	1 W89228	Tumour necrosis factor	1.38e-02
35	143	4.6	371	1 R07449	Tumour necrosis factor	1.38e-02
36	143	4.6	397	1 W89227	Tumour necrosis factor	1.38e-02
37	143	4.6	417	1 W89226	Tumour necrosis factor	1.38e-02
38	143	4.6	420	1 W89224	Tumour necrosis factor	1.38e-02
39	143	4.6	443	1 R51033	Mutant p55 tumour necr	1.38e-02
40	143	4.6	455	1 R1082	Human 55KD TNF-binding	1.38e-02
41	143	4.6	455	1 R42059	Lambda derived TNF-R.	1.38e-02
42	143	4.6	455	1 R51034	Mutant p55 tumour necr	1.38e-02
43	143	4.6	455	1 R10986	30KD TNF inhibitor pre	1.38e-02
44	143	4.6	455	1 R42197	p55 Tumour necrosis fa	1.38e-02
45	143	4.6	455	1 R24000	TNF-alpha 55KD recepto	1.38e-02

ALIGNMENTS

RESULT	ID	Score	Query Match	Length	Description
1	W93581	100.0%	Score 3111	DB 1	Length 423
AC	W93581	100.0%	Score 3111	DB 1	Length 423
DT	18-JUN-1999				(first entry)
DE	Human hAPO4-alpha protein.				
KW	Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;				
KW	developmental abnormality; gestational abnormality; prostate cancer;				
KW	AP06; AP08; AP09; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease;				
KW	cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;				
OS	apoptosis; human; APO4-alpha.				
PN	Homo sapiens.				
PD	WO9911791-A2.				
PE	11-MAR-1999.				
PF	04-SEP-1998; U:8393.				
PR	05-SEP-1997; US-924634.				
PA	(UNIV) UNIV WASHINGTON.				
PI	Chauchary PM;				
DR	WPI; 99-205191/17.				
DR	N-PSDB; X23415.				
PT	New Tumor Necrosis Factor family receptor polypeptides and ligands -				
PT	useful for diagnosis and treatment of prostate cancer and				
PT	developmental or gestational abnormalities				
PS	Claim 1; Fig 7C; 156pp; English.				
CC	This invention describes isolated Tumor Necrosis Factor (TNF) family				
CC	receptor polypeptides: APO4, APO6, APO8 and APO9 or their active				
CC	fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or				
CC	their active fragments. APO4 is useful for diagnosing prostate cancer				
CC	by determining levels of APO4 in an individual. Prostate cancer can also				
CC	be treated using APO4 selective binding agents linked to a therapeutic				
CC	molety. APO4 polypeptides are also useful for identifying selective				
CC	binding agents. useful in diagnosis/treatment of disease by binding of				
CC	agents to the polypeptide/active fragment which is extracellular, or				
CC	expressed on the cell surface. The binding is preferably performed in				
CC	vivo. APO4 polypeptides/active fragments are also useful for screening				
CC	for agonists and antagonists by binding and observing the change in APO4				
CC	activity. Effective pharmacological agents useful in diagnosis or				
CC	treatment of disease are also identified using APO4 polypeptides/active				
CC	fragments and APO4 signal transducer molecules that specifically interact				
CC	with a cytoplasmic domain of APO4 and detecting a change in level of APO4				
CC	activity. The method is performed in vivo or in vitro. APO polypeptides				
CC	are all useful as immunogens for preparing antibodies. APO4 is also				
CC	useful for diagnosis/treatment of developmental or gestational				
CC	abnormalities. APO8 was transfected to human breast carcinoma cell line				
CC	KMF-7, and induced apoptosis.				
SQ	Sequence 423 AA;				

Best Local Similarity 100.0%; Pred. No. 1,366-283;
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 MALVLEQETFTLLVLLGLYSCKVTCEGSDCRQGEFDRSGNVCPCNCGPGLSK 60
QY 1 MALVLEQETFTLLVLLGLYSCKVTCEGSDCRQGEFDRSGNVCPCNCGPGLSK 60
61 ECGGYGEDACVACRLHREKEDMGFOCKRPLCDCAVYNNRQKANCATSATSDALICDCLPG 120
QY 61 ECGGYGEDACVACRLHREKEDMGFOCKRPLCDCAVYNNRQKANCATSATSDALICDCLPG 120
121 FYRRTKLVGFDMECVPCGDPPEPEPHCASKVNLVKTASTASSPRDLAAVICSALAT 180
QY 121 FYRRTKLVGFDMECVPCGDPPEPEPHCASKVNLVKTASTASSPRDLAAVICSALAT 180
181 VLLALLILCVIYCKRQMEKRPMSLSRSDIQYNMETELSCFDRPOLHEVYHRRACQCRD 240
QY 181 VLLALLILCVIYCKRQMEKRPMSLSRSDIQYNMETELSCFDRPOLHEVYHRRACQCRD 240
241 SVQTCGVRLLPMSKCEACSPNPATLGCYVHSAASLQANAGPAGEMVPTFFGSLTQSI 300
QY 241 SVQTCGVRLLPMSKCEACSPNPATLGCYVHSAASLQANAGPAGEMVPTFFGSLTQSI 300
301 CGEFSDAWPLMOPMGDNISFCDSYPELTGEDIHSLNPELESSTLSDNSODLVGAV 360
QY 301 CGEFSDAWPLMOPMGDNISFCDSYPELTGEDIHSLNPELESSTLSDNSODLVGAV 360
361 PVQSHSENFATDLISRYNNTLVESASTODALITMRSQLDSEGAIVHPATQTSIQVRQL 420
QY 361 PVQSHSENFATDLISRYNNTLVESASTODALITMRSQLDSEGAIVHPATQTSIQVRQL 420
Db 421 GSL 423
QY 421 GSL 423

RESULT 2

ID W70387 standard; Protein; 423 AA.
AC W70387;
DE 02-DEC-1998 (first entry)
KW Human; beta-OAF065; stroma cell; antibody; inflammatory;
KW cytokine-mediated disease; rheumatism; ulcerative colitis.
OS Homo sapiens.
FH Key Location/Qualifiers
FT MISC_difference 223
FT /note- "encoded by AGA"
FT MISC_difference 224
FT /note- "encoded by CCT"
FN W09838304-A1.
PD 03-SEP-1998.
PF 26-FEB-1998; J00799.
PR 27-FEB-1997; JP-043143.
PA (ONOX) ONO PHARM CO LTD.
PI Fukushima D. Konishi M. Tada H;
DR WPI; 98-481205/41.
DR N-PSDB; V33362.
PT Membrane polypeptide expressed by human stroma cells, and antibodies
PT recognising it - for treatment of inflammatory and other
PT cytokine-mediated diseases.
PS Disclosure; Pages 37-49; 54pp; Japanese.
CC This is the amino acid sequence of the human beta-OAF065, used in
CC the method of the invention. The process involves the use of peptides
CC expressed by stroma cells, and its antibodies are used for in the
CC prevention and treatment of inflammatory and other cytokine-mediated
CC diseases such as rheumatism, ulcerative colitis.
SQ Sequence 423 AA;

Query Match 98.6%; Score 3066; DB 1; Length 423;
Best Local Similarity 98.1%; Pred. No. 3,076-279;
Matches 415; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Db 1 MALVLEQETFTLLVLLGLYSCKVTCEGSDCRQGEFDRSGNVCPCNCGPGLSK 60

QY 1 MALVLEQETFTLLVLLGLYSCKVTCEGSDCRQGEFDRSGNVCPCNCGPGLSK 60
Db 61 ECGGYGEDACVACRLHREKEDMGFOCKRPLCDCAVYNNRQKANCATSATSDALICDCLPG 120
QY 61 ECGGYGEDACVACRLHREKEDMGFOCKRPLCDCAVYNNRQKANCATSATSDALICDCLPG 120
121 FYRRTKLVGFDMECVPCGDPPEPEPHCASKVNLVKTASTASSPRDLAAVICSALAT 180
QY 121 FYRRTKLVGFDMECVPCGDPPEPEPHCASKVNLVKTASTASSPRDLAAVICSALAT 180
181 VLLALLILCVIYCKRQMEKRPMSLSRSDIQYNMETELSCFDRPOLHEVYHRRACQCRD 240
QY 181 VLLALLILCVIYCKRQMEKRPMSLSRSDIQYNMETELSCFDRPOLHEVYHRRACQCRD 240
241 SVQTCGVRLLPMSKCEACSPNPATLGCYVHSAASLQANAGPAGEMVPTFFGSLTQSI 300
QY 241 SVQTCGVRLLPMSKCEACSPNPATLGCYVHSAASLQANAGPAGEMVPTFFGSLTQSI 300
301 CGEFSDAWPLMOPMGDNISFCDSYPELTGEDIHSLNPELESSTLSDNSODLVGAV 360
QY 301 CGEFSDAWPLMOPMGDNISFCDSYPELTGEDIHSLNPELESSTLSDNSODLVGAV 360
361 PVQSHSENFATDLISRYNNTLVESASTODALITMRSQLDSEGAIVHPATQTSIQVRQL 420
QY 361 PVQSHSENFATDLISRYNNTLVESASTODALITMRSQLDSEGAIVHPATQTSIQVRQL 420
Db 421 GSL 423
QY 421 GSL 423

RESULT 3

ID W98146 standard; Protein; 417 AA.
AC W98146;
DE 05-JUL-1999 (first entry)
DE Human TRAIN-R.
KW TRAIN-R; receptor; human; tumour necrosis factor receptor;
KW agonist; antagonist; cancer; immunological disease; therapy;
KW cytostatic.
OS Homo sapiens.
FH Key Location/Qualifiers
FT Peptide 1..21
FT /note- "signal peptide"
FT Protein 22..417
FT /note- "mature protein"
FT Domain 25..173
FT /note- "extracellular domain"
FT Domain 174..190
FT /note- "transmembrane domain"
FT Domain 191..417
FT /note- "cytoplasmic domain"
FN W09913078-A1.
PD 18-MAR-1999.
PF 11-SEP-1998; U19030.
PR 06-MAY-1998; US-084422.
PR 12-SEP-1997; US-058631.
PA (BIOG) BIOGEN INC.
PI Hession C. Tschopp J;
DR WPI; 99-229238/19.
DR N-PSDB; X24978.
PT New cysteine-rich tumor necrosis factor receptor
PS Claim 2; Page 26; 30pp; English.
CC The present sequence is a novel human cysteine-rich tumor
CC necrosis factor receptor family member termed TRAIN-R that is
CC expressed at low levels in every tissue and cell line tested thus
CC far, with higher expression detected in heart, prostate, ovary,
CC testis, peripheral blood lymphocytes, thyroid and adrenal gland.
CC Cell death can be induced by administering an agent capable of
CC inhibiting the binding of TRAIN-R to its ligand. A claimed method
CC of treating, or reducing, the advancement, severity or effects of
CC an immunological disease in a mammal comprises administering a
CC pharmaceutical composition which comprises a TRAIN-R blocking agent,

CC e.g. soluble TRAI-N-R. TRAI-N-R can be fused to an immunoglobulin to
 CC produce a fusion protein which may be targeted to various sites.
 CC It can be used in binding assays, and to identify antagonists and
 CC agonists. Anti-TRAI-N-R antibodies can be used to reduce the
 CC severity of an immune response or to treat cancer. TRAI-N-R
 CC blocking agents can also be used to reduce the severity or effects
 CC of an immunological disease (all claimed).

Sequence 417 AA:

Query Match 97.7%; Score 3040; DB 1; Length 417;

Best Local Similarity 99.3%; Pred. No. 1,01e-276;

Matches 412; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 1 MALVLLLEOEKFTFTLLVLLGYLSCKVTCESGDCRQRFDRSGNCVPCNCGFMELSK 60
 1 MALVLLLEOEKFTFTLLVLLGYLSCKVTCESGDCRQRFDRSGNCVPCNCGFMELSK 60
 QY 61 ECGGYEDACVACRLHREKEDMGFKPCPLDCAVNNFORANKSATSDAICGDCPLG 120
 61 ECGGYEDACVACRLHREKEDMGFKPCPLDCAVNNFORANKSATSDAICGDCPLG 120
 QY 121 FYRRTKLVGFDMEVCVCGDPPPEPHCASKVNLVYIASTASSPRDTALAIVCSALAT 180
 121 FYRRTKLVGFDMEVCVCGDPPPEPHCASKVNLVYIASTASSPRDTALAIVCSALAT 180
 QY 121 FYRRTKLVGFDMEVCVCGDPPPEPHCASKVNLVYIASTASSPRDTALAIVCSALAT 180
 121 FYRRTKLVGFDMEVCVCGDPPPEPHCASKVNLVYIASTASSPRDTALAIVCSALAT 180
 QY 181 VLLALLILCVIYCKRQMEKPPSWLSLSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 181 VLLALLILCVIYCKRQMEKPPSWLSLSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 QY 181 VLLALLILCVIYCKRQMEKPPSWLSLSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 181 VLLALLILCVIYCKRQMEKPPSWLSLSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 Db 241 SVOTCGFVRILPSCMCEACSPNATIGCGVHSAASLOARNAGAGMVPFFESLTQSI 300
 241 SVOTCGFVRILPSCMCEACSPNATIGCGVHSAASLOARNAGAGMVPFFESLTQSI 300
 QY 241 SVOTCGFVRILPSCMCEACSPNATIGCGVHSAASLOARNAGAGMVPFFESLTQSI 300
 241 SVOTCGFVRILPSCMCEACSPNATIGCGVHSAASLOARNAGAGMVPFFESLTQSI 300
 Db 301 CGEESDAMPILMONGMDNISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 301 CGEESDAMPILMONGMDNISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 QY 301 CGEESDAMPILMONGMDNISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 301 CGEESDAMPILMONGMDNISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 Db 361 PVQSHSENFATDLSRYNNTLVESASTQDALTMRSQDQESGAVIHATQTSIQ 415
 361 PVQSHSENFATDLSRYNNTLVESASTQDALTMRSQDQESGAVIHATQTSIQ 415
 QY 361 PVQSHSENFATDLSRYNNTLVESASTQDALTMRSQDQESGAVIHATQTSIQ 415

RESULT 4
 ID W0386 standard; Protein; 417 AA.
 AC W0386;
 DT 02-DEC-1998 (first entry)
 DE Amino acid sequence of human alpha-OAF065.
 KW Human; alpha-OAF065; stroma cell; antibody; inflammatory;
 KW cytokine-mediated disease; rheumatism; ulcerative colitis.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT MISC_difference 223
 FT MISC_difference 224 /note- "encoded by AGA"
 FT MISC_difference 224 /note- "encoded by CCT"
 FT W09836304-A1.
 PN W09836304-A1.
 PD 03-SEP-1998.
 PF 26-FEB-1998; J00799.
 PR 27-FEB-1997; JP-043143.
 PA (ONOR) ONO PHARM CO LTD.
 PA Fukushima D, Konishi M, Tada H;
 DR N-PSDB: V33361.
 DR WPI: 98-481205/41.
 PT Membrane polypeptide expressed by human stroma cells, and antibodies
 PT recognising it - for treatment of inflammatory and other
 PT cytokine-mediated diseases.
 PS Claim 1; Pages 28-30; 54p; Japanese.
 CC This is the amino acid sequence of the human alpha-OAF065, used in
 CC the method of the invention. The process involves the use of peptides
 CC expressed by stroma cells, and its antibodies are used for in the
 CC prevention and treatment of inflammatory and other cytokine-mediated
 CC diseases such as rheumatism, ulcerative colitis.
 SQ Sequence 417 AA;

Query Match 96.7%; Score 3007; DB 1; Length 417;
 Best Local Similarity 98.1%; Pred. No. 1.57e-273;
 Matches 407; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Db 1 MALVLLLEOEKFTFTLLVLLGYLSCKVTCESGDCRQRFDRSGNCVPCNCGFMELSK 60
 1 MALVLLLEOEKFTFTLLVLLGYLSCKVTCESGDCRQRFDRSGNCVPCNCGFMELSK 60
 QY 61 ECGGYEDACVACRLHREKEDMGFKPCPLDCAVNNFORANKSATSDAICGDCPLG 120
 61 ECGGYEDACVACRLHREKEDMGFKPCPLDCAVNNFORANKSATSDAICGDCPLG 120
 QY 121 FYRRTKLVGFDMEVCVCGDPPPEPHCASKVNLVYIASTASSPRDTALAIVCSALAT 180
 121 FYRRTKLVGFDMEVCVCGDPPPEPHCASKVNLVYIASTASSPRDTALAIVCSALAT 180
 QY 121 FYRRTKLVGFDMEVCVCGDPPPEPHCASKVNLVYIASTASSPRDTALAIVCSALAT 180
 121 FYRRTKLVGFDMEVCVCGDPPPEPHCASKVNLVYIASTASSPRDTALAIVCSALAT 180
 QY 181 VLLALLILCVIYCKRQMEKPPSWLSLSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 181 VLLALLILCVIYCKRQMEKPPSWLSLSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 Db 241 SVOTCGFVRILPSCMCEACSPNATIGCGVHSAASLOARNAGAGMVPFFESLTQSI 300
 241 SVOTCGFVRILPSCMCEACSPNATIGCGVHSAASLOARNAGAGMVPFFESLTQSI 300
 QY 241 SVOTCGFVRILPSCMCEACSPNATIGCGVHSAASLOARNAGAGMVPFFESLTQSI 300
 241 SVOTCGFVRILPSCMCEACSPNATIGCGVHSAASLOARNAGAGMVPFFESLTQSI 300
 Db 301 CGEESDAMPILMONGMDNISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 301 CGEESDAMPILMONGMDNISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 QY 301 CGEESDAMPILMONGMDNISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 301 CGEESDAMPILMONGMDNISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 Db 361 PVQSHSENFATDLSRYNNTLVESASTQDALTMRSQDQESGAVIHATQTSIQ 415
 361 PVQSHSENFATDLSRYNNTLVESASTQDALTMRSQDQESGAVIHATQTSIQ 415
 QY 361 PVQSHSENFATDLSRYNNTLVESASTQDALTMRSQDQESGAVIHATQTSIQ 415

RESULT 5
 ID W93579 standard; Protein; 416 AA.
 AC W93579;
 DT 18-JUN-1999 (first entry)
 DE Mouse APO4-alpha (long) protein.
 KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;
 KW developmental abnormality; gestational abnormality; prostate cancer;
 KW APO6; APO8; APO9; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease;
 KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
 KW apoptosis; mouse; APO4-alpha.
 OS Mus sp.
 PN W09911791-A2.
 PD 11-MAR-1999.
 PF 04-SEP-1998; U18393.
 PR 05-SEP-1997; US-924634.
 PA (UNIW) UNIV WASHINGTON.
 PA Chaudhary PM;
 DR WPI: 99-205191/17.
 DR N-PSDB: X23413.
 PT New Tumor Necrosis Factor family receptor polypeptides and ligands -
 PT useful for diagnosis and treatment of prostate cancer and
 PT developmental or gestational abnormalities
 PS Claim 1; Fig 7A; 156p; English.
 CC This invention describes isolated Tumor Necrosis Factor (TNF) family
 CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active
 CC fragments, and isolated TNF related ligands 1 and 3 (TNFR1 and TNFR3) or
 CC their active fragments. APO4 is useful for diagnosing prostate cancer
 CC by determining levels of APO4 in an individual. Prostate cancer can also
 CC be treated using APO4 selective binding agents linked to a therapeutic
 CC moiety. APO4 polypeptides are also useful for identifying selective
 CC binding agents, useful in diagnosis/treatment of disease by binding of
 CC agents to the polypeptide/active fragment which is extracellular, or
 CC expressed on the cell surface. The binding is preferably performed *in*
 CC vivo. APO4 polypeptides/active fragments are also useful for screening
 CC for agonists and antagonists by binding and observing the change in APO4
 CC activity. Effective pharmacological agents useful in diagnosis or
 CC treatment of disease are also identified using APO4 polypeptides/active
 CC fragments and APO4 signal transducer molecules that specifically interact
 CC with a cytoplasmic domain of APO4 and detecting a change in level of APO4

CC activity. The method is performed in vivo or in vitro. APO polypeptides are all useful as immunogens for preparing antibodies. APO4 is also useful for diagnosis/treatment of developmental or gestational abnormalities. APO8 was transfected to human breast carcinoma cell line MCF-7, and induced apoptosis.

Query Match 70.0%; Score 2177; DB 1; Length 416;
Best Local Similarity 70.5%; Pred. No. 2,246-193;
Matches 294; Conservative 63; Mismatches 55; Indels 5; Gaps 5;

DB 1 MALKVLPLHRTVFAALFLHLACKVSCETGDCRQGFDRSGNCVLCRQCGPMELSK 60
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 1 MALKVLLEQETFTFLVLGLYLSCKVTCESGDCRQGFDRSGNCVPCNCGPMELSK 60
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 61 ECGFGYEDACVACRHLRFKEDMGFOCKRCPDCAVYVNFQKANCSTSDALCGDCLPG 120
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 61 ECGFGYEDACVACRHLRFKEDMGFOCKRCPDCAVYVNFQKANCSTSDALCGDCLPG 120
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 121 FYRRTKLVGFQDMCEVCGPDPPEPHCSKVLVYSSVSSFRDTALAAYICSLAT 180
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 121 FYRRTKLVGFQDMCEVCGPDPPEPHCSKVLVYSSVSSFRDTALAAYICSLAT 180
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 181 VLALLILCVYICKRQFMKKPSMSLRSDIQYNGSELSCFDPRLRHCARACQYHRD 240
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 181 VLALLILCVYICKRQFMKKPSMSLRSDIQYNGSELSCFDPRLRHCARACQYHRD 240
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 241 SAPMTGPHVLPISLCEBARSSARAVLGCGRSPPTLQERNPASYGNTMPAFFGSRSKI 300
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 241 SVQCGGPRVRLPMSMCEACSPNPATLCGVHSAASLQARANAGVEVPPFFGSLTQSI 300
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 301 CAEFSADANPLWQNPVGGS-SLQDSYPRLTGEDTNSLNPENESTASLDSSGGQDLAATA- 358
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 301 CGEFSADANPLWQNPVGGS-SLQDSYPRLTGEDTNSLNPENESTASLDSSGGQDLAATA- 360
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 359 ALES-SGNVSTSDPSRHGDGTWEOITLADQARTPSQGGMEDENILAMPRAFQ 414
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 361 EVQSHSENFATDLSRIYNT-LV-ESASTQALTRMSQLOEGAVIHPATQTSLOQ 415
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
RESULT 6
ID W98145 standard; protein; 214 AA.
AC W98145; 1999 (first entry)
DT 03-JUL-1999
DE Mouse TRAIIN-R (long form).
KW Mouse TRAIIN-R; receptor; mouse; tumour necrosis factor receptor;
KW agonist; antagonist; cancer; immunological disease; therapy;
KW cytosolic.
OS Mus musculus.
PN W09913078-A1.
PD 18-MAR-1999.
PF 11-SEP-1998; U19030.
PR 06-MAY-1998; US-084422.
PR 12-SEP-1997; US-058631.
PI (BIOI) BIOGEN INC.
PI Hession C, Ischopp J;
PI WPI; 99-229238/19.
DR N-PSDB; X24977.
PT New cysteine-rich tumor necrosis factor receptor
PS Claim 2; Page 26; 30pp; English.
CC The present sequence is a novel murine cysteine-rich tumour
CC necrosis factor receptor family member termed TRAIIN-R (long form).
CC TRAIIN-R is expressed at high levels in murine brain and lung, and
CC at lower levels in liver, skeletal muscle and kidney. Cell death
CC can be induced by administering an agent capable of inhibiting the
CC binding of TRAIIN-R to its ligand. A claimed method of treating, or
CC reducing, the advancement, severity or effects of an immunological
CC disease in a mammal comprises administering a pharmaceutical
CC composition which comprises a TRAIIN-R blocking agent, e.g. soluble
CC TRAIIN-R (see W98144). TRAIIN-R can be fused to an immunoglobulin
CC molecule to produce a fusion protein which may be targeted to
CC various sites. It can be used in binding assays, and to identify
CC antagonists and agonists. Anti-TRAIIN receptor antibodies can be

CC used to reduce the severity of an immune response or to treat cancer.
CC TRAIIN-R blocking agents can be used to reduce the severity or effects
CC of an immunological disease (all claimed).

Query Match 44.0%; Score 1368; DB 1; Length 214;
Best Local Similarity 85.2%; Pred. No. 1,086-115;
Matches 173; Conservative 17; Mismatches 13; Indels 0; Gaps 0;

DB 1 MALKVLPLHRTVFAALFLHLACKVSCETGDCRQGFDRSGNCVLCRQCGPMELSK 60
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 1 MALKVLLEQETFTFLVLGLYLSCKVTCESGDCRQGFDRSGNCVPCNCGPMELSK 60
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 61 ECGFGYEDACVACRHLRFKEDMGFOCKRCPDCAVYVNFQKANCSTSDALCGDCLPG 120
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 61 ECGFGYEDACVACRHLRFKEDMGFOCKRCPDCAVYVNFQKANCSTSDALCGDCLPG 120
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 121 FYRRTKLVGFQDMCEVCGPDPPEPHCSKVLVYSSVSSFRDTALAAYICSLAT 180
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 121 FYRRTKLVGFQDMCEVCGPDPPEPHCSKVLVYSSVSSFRDTALAAYICSLAT 180
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
DB 181 VLALLILCVYICKRQFMKKPS 203
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
QY 181 VLALLILCVYICKRQFMKKPS 203
| | | | | : : : : : | | | | | : : : : : | | | | | : : : : : | | | | | : : : : :
RESULT 7
ID W93580 standard; protein; 214 AA.
AC W93580;
DT 18-JUN-1999 (first entry)
DE Mouse MAP04-alpha (short) protein.
KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;
KW developmental abnormality; gestational abnormality; prostate cancer;
KW APO6; APO8; APC9; TNRL-1; TNRL-3; diagnosis; treatment; therapy; disease;
KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
KW apoptosis; mouse; MAP04-alpha.
OS Mus sp.
PN W09911791-A2.
PD 11-MAR-1999.
PF 04-SEP-1998; U18393.
PR 05-SEP-1997; US-924634.
PI (UNIV) UNIV WASHINGTON.
PI Chaudhary PW;
PI WPI; 99-205191/17.
DR N-PSDB; X23414.
PT New Tumor Necrosis Factor family receptor polypeptides and ligands -
PT useful for diagnosis and treatment of prostate cancer and
PT developmental or gestational abnormalities
PS Claim 1; Fig 7B; 156pp; English.
CC This invention describes isolated Tumor Necrosis Factor (TNF) family
CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active
CC fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
CC their active fragments. APO4 is useful for diagnosing prostate cancer
CC by determining levels of APO4 in an individual. Prostate cancer can also
CC be treated using APO4 selective binding agents linked to a therapeutic
CC moiety. APO4 polypeptides are also useful for identifying selective
CC binding agents; useful in diagnosis/treatment of disease by binding of
CC agents to the polypeptide/active fragment which is extracellular, or
CC expressed on the cell surface. The binding is preferably performed in
CC vivo. APO4 polypeptides/active fragments are also useful for screening
CC for agonists and antagonists by binding and observing the change in APO4
CC activity. Effective pharmacological agents useful in diagnosis or
CC treatment of disease are also identified using APO4 polypeptides/active
CC fragments and APO4 signal transducer molecules that specifically interact
CC with a cytoplasmic domain of APO4 and detecting a change in level of APO4
CC activity. The method is performed in vivo or in vitro. APO polypeptides
CC are all useful as immunogens for preparing antibodies. APO4 is also
CC useful for diagnosis/treatment of developmental or gestational
CC abnormalities. APO8 was transfected to human breast carcinoma cell line
CC MCF-7, and induced apoptosis.

Query Match 44.0%; Score 1368; DB 1; Length 214;

[illegible]

RESULT	8
ID	W98148 standard; Peptide; 150 AA.

AC W98148; (AC 05-JUL-1999 (first entry)
DT TRAlN-R short, soluble form.
DE TRAlN-R: receptor; human: tumour necrosis factor receptor;
KW agonist; antagonist; cancer; immunological disease; therapy;
KW cytostatic.
OS Homo sapiens.
PN W09913078-A1.
PN 18-MAR-1999.
PE 11-SEP-1998; U19030.
PR 06-MAY-1998; US-0844432.
PR 12-SEP-1997; US-0586311.
PA (BIOJ) BIOGEN INC.
PI Hession C, Tschopp J;
PT WPI; 99-229238/19.
PS New cysteine-rich tumor necrosis factor receptor
PS disclosure: Page 28; 30pp; English.
CC The present sequence comprises the putative short, secreted soluble
CC form of a novel human cysteine-rich tumor necrosis factor receptor
CC family member termed TRAlN-R. The sequence was produced from a
CC 30-amino acid peptide (see W98147) encoded by a cloned exon
CC sequence (see X24979) and by comparison to the murine TRAlN-R
CC short form (see W98144). The human soluble TRAlN-R protein is
CC expected to inhibit signalling by full-length human TRAlN-R (see
CC W98146). Human TRAlN-R is expressed at low levels in every tissue
CC and cell line tested thus far, with higher expression detected in
CC heart, prostate, ovary, testis, peripheral blood lymphocytes,
CC thyroid and adrenal gland. Cell death can be induced by
CC administering an agent capable of inhibiting the binding of TRAlN-R
CC to its ligand. A claimed method of treating, or reducing, the
CC advancement, severity or effects of an immunological disease in a
CC mammal comprises administering a pharmaceutical composition which
CC comprises a TRAlN-R blocking agent, e.g. soluble TRAlN-R. TRAlN-R
CC can be fused to an immunoglobulin to produce a fusion protein which
CC may be targeted to various sites. It can be used in binding assays
CC and to identify antagonists and agonists. Anti-TRAlN-R antibodies
CC can be used to reduce the severity of an immune response or to treat
CC cancer. TRAlN-R blocking agents can also be used to reduce the
CC severity or effects of an immunological disease (all claimed).
SQ Sequence 150 AA;

Query Match	38.38;	Score 1193;	DB 1;	Length 150;
Best Local Similarity	99.38;	Pred. No. 5.39e-99;		
Matches	148; Conservative	1;	Mismatches 0;	Indels 0; Gaps 0;

Db 1 MALKVLROEKTEFFLLVLILVGLSKVWCEGGDDCRQGEFRDRSNCVPCNCGGGMELSK 60
Qy 1 MALKVLROEKTEFFLLVLILVGLSKVWCEGGDDCRQGEFRDRSNCVPCNCGGGMELSK 60
Db 61 ECGFGYGGDACVVCRLRFRFKEDMGFOKRCGLDCAVNNRQKANGSATSPATGGDCLPG 120
|||||:|||||

Qy	61	ECGGYGEEDNQCACRLHREFKEDMGFKCKRCPLCDCAVYNNRQKANCATSIDALCGDCLPG	120
D6	121	FYRKTLVGFQDMECVPCGDDPPPEYEPHC	149
Qy	121	FYRKTLVGFQDMECVPCGDDPPPEYEPHC	149

RESULT	9
ID	W93583 standard; Protein; 150 AA.

AC W93583.1 (first entry)
DT 18-JUN-1999
DE Mouse APO4-gamma protein.
KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;
KW developmental abnormality; gestational abnormality; prostate cancer;
KW APO6; APO8; APO9; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease;
KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
KW apoptosis; mouse; APO4-gamma.
OS Mus sp.
PN W09911791.A2.
PD 11-MAR-1999.
PF 04-SEP-1998; U18393.
PR 05-SEP-1997; U5-924634.
PA (UNIT) UNIV WASHINGTON.
PI Chaudhary PM;
DR WPI: 99-205191/17.
DR N-PSDS: X23417.
PT New Tumor Necrosis Factor family receptor polypeptides and ligands -
PT useful for diagnosis and treatment of prostate cancer and
PT developmental or gestational abnormalities
PS Disclosure: Fig 7E: 156bp; English.
CC This invention describes isolated Tumor Necrosis Factor (TNF) family
CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active
CC fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
CC their active fragments. APO4 is useful for diagnosing prostate cancer
CC by determining levels of APO4 in an individual. Prostate cancer can also
CC be treated using APO4 selective binding agents linked to a therapeutic
CC moiety. APO4 polypeptides are also useful for identifying selective
CC binding agents useful in diagnosis/treatment of disease by binding of
CC agents to the polypeptide/active fragment which is extracellular, or
CC expressed on the cell surface. The binding is preferably performed *in*
CC vivo. APO4 polypeptides/active fragments are also useful for screening
CC for agonists and antagonists by binding and observing the change in APO4
CC activity. Effective pharmacological agents useful in diagnosis or
CC treatment of disease are also identified using APO4 polypeptides/active
CC fragments and APO4 signal transducer molecules that specifically interact
CC with a cytoplasmic domain of APO4 and detecting a change in level of APO4
CC activity. The method is performed *in vivo* or *in vitro*. APO polypeptides
CC are all useful as immunogens for preparing antibodies. APO4 is also
CC useful for diagnosis/treatment of developmental or gestational
CC abnormalities. APO8 was transfected to human breast carcinoma cell line
CC MCF-7, and induced apoptosis.
SQ Sequence 150 AA;

Query Match	32.48;	Score 1008;	DB 1;	length 150;
Best Local Similarity	81.98;	Pred. No. 2.06e-81;		
Matches 122;	Conservative	15;	Mismatches 12;	Indels 0;
			Gaps	0

```

Db 1 MAKVYLPJHRFVTLAAATLEFLHLACKYSCFEGDROOEFDRDSNGVLCCKOQGPHELSK 60
      ||| : : : : ||| : : : : ||| : : : : ||| : : : : ||| : : : : |||
QY 1 MALAKVLEIQEKTFFTLVLVGLYLSCKYTCESGGDROOEFDRDSNGVCPKQOQGPHELSK 60
      ||| : : : : ||| : : : : ||| : : : : ||| : : : : ||| : : : : |||

Db 61 ECGFEGYGDACVCPORPHREKEDMGFOCKRCACADALVNNFORANGSHTSDAYCGDCLPG 120
      ||| : : : : ||| : : : : ||| : : : : ||| : : : : ||| : : : : |||
QY 61 ECGFEGYGDACVCAQLRREKEDMGFOCKRCCLDCAVANNFORANGSATSDAICGDCLPG 120
      ||| : : : : ||| : : : : ||| : : : : ||| : : : : ||| : : : : |||

Db 121 FYRKRTLVGPODMECVPCGDDPPPYEPBHC 149
      ||| : : : : ||| : : : : ||| : : : : ||| : : : : ||| : : : : |||
QY 121 FYRKRTLVGPODMECVPCGDDPPPYEPBHC 149
      ||| : : : : ||| : : : : ||| : : : : ||| : : : : ||| : : : : |||

```

RESULT	10
ID	W98144 standard; Protein; 150 AA.
AC	W98144;

CC thyroid and adrenal gland. Cell death can be induced by
CC administering an agent capable of inhibiting the binding of TRAI-R
CC to its ligand. A claimed method of treating, or reducing, the
CC advancement, severity or effects of an immunological disease in a
CC mammal comprises administering a pharmaceutical composition which
CC can be fused to a TRAI-R blocking agent, e.g. soluble TRAI-R. TRAI-R
CC can be used to an immunoglobulin to produce a fusion protein which
CC may be targeted to various sites. It can be used in binding assays,
CC and to identify antagonists and agonists. Anti-TRAI-R antibodies
CC can be used to reduce the severity of an immune response or to treat
CC cancer. TRAI-R blocking agents can also be used to reduce the
CC severity or effects of an immunological disease (all claimed).
CC Sequence 30 AA;

Sequence 30 AA;

Query Match	8.0%;	Score 248;	DB 1;	Length 30;
Best Local Similarity	100.0%;	Pred. No. 2.94e-11;		
Matches	29;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;

```
Db      1 FYRKTCLVGFDMECVPCGGDDPPPYEPHC 29
        |||||
Oy     121 FYRKTCLVGFDMECVPCGGDDPPPYEPHC 149
```

RESULT 13
ID R62655 standard; Protein; 186 AA.
AC R62655;
DT 30-JUN-1995 (first entry)
DE Compx virus Pst I/Cla I fragment viral protein .
KW Compx virus fragment Pst I/Cla I; cytokine antagonist;
KM tumour necrosis factor; immune response regulation.
OS Compx virus.
PN US3359039-A.
PD 25-OCT-1994.
PE 09-JUL-1993; 089458.
PR 09-JUL-1993; US-089458.
PA (TMV) IMMUNEX CORP.
PI Goodwin RG, Smith CA;
DR WPI: 94-341063/42.
DR N-PSDB: Q72995.
PT Isolated viral proteins capable of binding TNF - therefore
claim 1; Columns 21-22; 13pp: English.
PS Q72995 encodes R62655 a viral protein from the Pst I/Cla I
fragment of the compx virus, which binds cytokines and tumour
necrosis factor (TNF). The viral protein can be used to regulate
immune response as part of a therapeutic composition. It can also
be used as an antagonist of TNF.
SQ Sequence 186 AA;

Query Match	6.0%;	Score 187;	DB 1;	Length 186;
Best Local Similarity	30.0%;	Pred. No. 4.09e-06;		
Matches	33;	Mismatches 40;	Indels 9;	Gaps 9

Db 34 NGSCDDDEYLDTKHN--CCNCRPPG--EFKIKICS--G--SDNKCRCRCPHHYTVTPVNSG 89
 0y 31 SGDCRQGEFDRBSGNCVPCNCGSGPGEISKE--CGHGYEDAQVACALHFKEDMEGQR-- 88
 Db 90 CHQCRKPT--GSPDYKCYGIGLQNSKCS--CLPWFCAITSSSTEDRCRCIP 137
 0y 89 CKPLDCAVYNNRCKSCSTSDAICGDLPEFYKRTILVGFQD--MCCVP 137

RESULT	14
ID	W48977 standard; Protein; 206 AA.
AC	W48977;
DT	25-SEP-1998 (first entry)
DE	Mouse OX40 extracellular domain.
KW	OX40: cytokine; T cell antigen; TH-2 immune response; OX40-L.
RY	OX40/FC.
OS	Mus_sp.
PN	U53783665-A.
PD	21-JUL-1998.
PF	22-JUN-1995; 494574.

PR 23-JUL-1993; US-097827.
 PR 22-JUN-1995; US-494574.
 PA (IMV) IMMUNEX CORP.
 FI Baum PR, Fanslow WC, Gayle RB, Goodwin RG;
 DR WPI: 98-427099/36.
 DR N-P850.
 PT Purified polypeptide OX-40 ligands - for co-stimulation of T-cell
 PT production and binding assays for OX-40 and homologues
 PT Example 1: Col 33-34: 26pp: English.
 CC The present sequence represents the mouse OX40 extracellular domain
 CC The extracellular domain of OX40 is its ligand binding domain. The
 CC cDNA (V32640) encoding OX40 extracellular domain was used in the
 CC construction of the chimeric OX40/Fc cDNA (V32640). The invention
 CC claims for a murine OX40-L cytokine (W48975) that binds to the OX40
 CC murine T cell antigen. The OX40-L protein is claimed to be useful
 CC for co-stimulation of T-cell production and in binding assays for
 CC detecting OX40 or its homologues. The OX40-L protein is also claimed
 CC to generate a "TH-2 immune response.
 SQ Sequence 206 AA;

Query Match	5.7%;	Score 178;	DB 1;	Length 206;
Best Local Similarity	27.8%;	Pred. No. 2.23e-05;		
Matches	49;	Conservative	36;	Mismatches 77;
				Indels 14;
				Gaps 11;

[illegible]

ID	RESULT	15
AC	R81881; standard; Protein; 206 AA.	
DT	08-JUL-1996 (first entry)	
DE	Mouse type-II membrane polypeptide OX40 extracellular domain.	
KW	OX40; OX40-L; cytokine; cell surface molecule;	
OS	mus musculus.	
PN	US5457035-A.	
PD	10-OCT-1993.	
PF	23-JUL-1993; 097827.	
PR	23-JUL-1993; US-097827.	
PA	(IMMUNEX) IMMUNEX CORP.	
PI	Baum PR, Fanslow WC, Gayle RB, Goodwin RG;	
DR	WPI: 95-357992/46.	
DR	N-PDBE; T00826.	
PT	New isolated DNA encoding the OX40 ligand polypeptide - also vectors	
PT	and host cells. used to produce recombinant ligand used in e.g.	
PT	prim. T cell culture, to modulate immune response etc.	
PS	Example 1; Column 33-34; 26pp; English.	
CC	This sequence encodes the extracellular domain of OX40, a membrane	
CC	glycoprotein present on the CD4 positive subset of activated T	
CC	cells.	
CC	Sequence 206 AA;	

	Query Match	5.7%	Score 178;	DB 1:	Length 206;
	Best Local Similarity	27.8%;	Pred. No. 2,23e-05;		
	Matches	49;	Conservative	36;	Mismatches 77; Indels 14; Gaps 11.
Db	9	TALLLG-LTGVARLRNCVKHTYPS-GHRC--CREQPGHGAVNRCD--HTRDTLCHP	62		
		: : : : : : : : : :	:		
Oy	15	TLLVLGLSKVTCESDCKQDEFDRBSGNCVPCNCGPEMELSKCEGYGDACVA	74		
		: : : : : : : : : :	:		
Db	63	CETGEYNVANVDICOKCOTOCNHRSGSELKNCPPTDYDV--RCRPSTQPNRD--SGKLG	120		
	: : :	: : : : : : : : : :	:		
Oy	75	CRHAFFKEDMGFOCKRPLDCAVANRRD-KANCATSALTGDLDPGFYRTKLTVGFQ-D	132		
	: : :	: : : : : : : : : :	:		

[illegible]

Db 121 VDCVPCPGHFSPGNQACKPTNCTLSGKOTRHPASDSIDAY-CPD-RSLLATIL 174
QY 133 MECVPC--GDPPPEPPECASKYNLVKIASTASSPRDTALAAYTCSALATVILLAL 186

Search completed: Tue Apr 18 13:58:13 2000
Job time : 26 secs.

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 23, 2000, 01:27:45 ; Search time 463.49 Seconds

(without alignments)
12129.633 Million cell updates/sec

Title: US-09-490-187-1

Perfect score: 1489
Sequence: 1 ggaactgcagcctcccaagt.....gtattttttaaaaaacttt 1489

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4538634 seqs, 1887831982 residues

Total number of hits satisfying chosen parameters: 9077268

Minimum DB seq length: 0
Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : EST:*

1:	em_est1:*
2:	em_est2:*
3:	em_est3:*
4:	em_est4:*
5:	em_est5:*
6:	em_est6:*
7:	em_est7:*
8:	em_est8:*
9:	em_est9:*
10:	em_est10:*
11:	em_est11:*
12:	em_est12:*
13:	em_est13:*
14:	em_est14:*
15:	em_est15:*
16:	em_est16:*
17:	em_est17:*
18:	em_est18:*
19:	em_est19:*
20:	gb_est1:*
21:	gb_est2:*
22:	gb_est3:*
23:	gb_est4:*
24:	gb_est5:*
25:	gb_est6:*
26:	gb_est7:*
27:	gb_est8:*
28:	gb_est9:*
29:	gb_est10:*
30:	gb_est11:*
31:	gb_est12:*
32:	gb_est13:*
33:	gb_est14:*
34:	gb_est15:*
35:	gb_est16:*
36:	gb_est17:*
37:	gb_est18:*
38:	gb_est19:*
39:	gb_est20:*
40:	gb_est21:*
41:	gb_est22:*
42:	gb_est23:*
43:	gb_est24:*
44:	gb_est25:*

45:	gb_est26:*
46:	gb_est27:*
47:	gb_est28:*
48:	gb_est29:*
49:	gb_est30:*
50:	gb_est31:*
51:	gb_est32:*
52:	em_est20:*
53:	em_est21:*
54:	em_est22:*
55:	em_est23:*
56:	em_est24:*
57:	em_est25:*
58:	em_est26:*
59:	gb_est33:*
60:	gb_est34:*
61:	gb_est35:*
62:	gb_est36:*
63:	gb_est37:*
64:	gb_est38:*
65:	em_est27:*
66:	em_est28:*
67:	em_est29:*
68:	em_est30:*
69:	gb_est39:*
70:	gb_est40:*
71:	gb_est41:*
72:	gb_est42:*
73:	gb_est43:*
74:	gb_est44:*
75:	em_est31:*
76:	em_est32:*
77:	em_est33:*
78:	em_est34:*
79:	gb_est45:*
80:	gb_est46:*
81:	gb_est47:*
82:	gb_est48:*
83:	em_est35:*
84:	em_est36:*
85:	em_est37:*
86:	em_est38:*
87:	gb_est49:*
88:	gb_est50:*
89:	gb_est51:*
90:	gb_est52:*
91:	gb_est53:*
92:	em_est39:*
93:	em_est40:*
94:	em_est41:*
95:	em_est42:*
96:	em_est43:*
97:	em_est44:*
98:	em_est45:*
99:	gb_est54:*
100:	gb_est55:*
101:	em_est46:*
102:	gb_est56:*
103:	gb_est57:*
104:	gb_est58:*
105:	gb_est59:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	454	30.5	454	26	W56629
2	272.2	18.3	282	61	AL036000 DKP2p564K

ACCESSION DKF2564K1022 5', mRNA sequence.
 VERSION AL036000
 KEYWORDS AL036000.1 GI:5405629
 SOURCE EST.
 ORGANISM human.
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 REFERENCE 1 (bases 1 to 282)
 AUTHORS Wambutt, R., Heubner, D., Mewes, H.W., Gassenhuber, J. and Wiemann, S.
 TITLE EST (Wambutt, et al.)
 JOURNAL Unpublished (1999)
 COMMENT On Jun 22, 1998 this sequence version replaced gi:3246658.
 Contact: Wambutt R
 MIPs
 Am Kioferspitz 18a D-82152 Martinsried, Germany
 This is the 5' sequence of the clone insert
 clone from S. Wiemann, Molecular Genome Analysis, German Cancer
 Research Center (DKFZ), Email: s.wiemann@dkfz-heidelberg.de;
 sequenced by AGOMA within the cDNA sequencing consortium of the
 German Genome Project.
 s1 sequence also available.
 This clone is available at the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059
 Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de.

FEATURES
 source
 1..282
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="DKF2564K1022"
 /clone_1lb="564 (synonym: hibr2)"
 /tissue_type="fetal"
 /dev_stage="fetal"
 /lab_host="X1-2blue"
 /note="Vector: PAMPL; Site_1: NotI; Site_2: SalI"

BASE COUNT 57 a 85 c 75 g 63 t 2 others

ORIGIN

Query Match 18.3%; Score 272.2; DB 61; Length 282;
 Best Local Similarity 98.2%; Pred. No. 2.4e-61;
 Matches 274; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 429 atagaagaacgaacatgtcggcttcaagaacatgagatgtgtcctgttgaagaccctc 488
 |||||||
 DB 3 ATAGAAGACGAACCTGTGCGCTTTCAAGACATGAGATGTGCGCTTGTGAGACCCCTC 62
 |||||||

QY 489 ctctctcttcaagacgcgaactgtgtccagcaagtcacacctgtgaagatcgcgctccacg 548
 |||||||
 DB 63 CTCCTCTTACGAACCGACACTGTCCAGCAAGTCAACCTCTGTGAAGATCCGTCACAG 122
 |||||||

QY 549 cctcagaaccccgagggaacgcgctgtgcttctatctgaagcgctctgacccgcttc 608
 |||||||
 DB 123 CCTCAGGCCACGGGACACGGCGCTGCTGCGTATGTGACAGCTGTGCGCACCGCTCC 182
 |||||||

QY 609 tgcgtgcctgtcattcctctgtgtcattctatcttgaagaacagtttaagaaaaaac 668
 |||||||
 DB 183 TGCtGGCCCTCTCATCTCTGTGTCACTATTTGAAGACAGATTATGAGAAAGAAC 242
 |||||||

QY 669 ccagctgtgtctgtcgtgtcacagacattcagtaacag 707
 |||||||
 DB 243 CCAAGCTGCTCTGTGCGGTGCGACAGACATTCAGTACTACG 281
 |||||||

RESULT 3
 AA003356 401 bp mRNA EST 19-JUL-1996
 LOCUS
 DEFINITION mg449401.1 Soares mouse embryo NDMEL3.5 14.5 Mus musculus cDNA
 clone IMAGE:427152 5', mRNA sequence.
 ACCESSION AA003356
 VERSION AA003356.1 GI:1446796
 KEYWORDS EST.
 SOURCE house mouse.

ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 (bases 1 to 401)
 AUTHORS Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T.,
 Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M.,
 Schellenberg, K., Stepoe, M., Tan, F., Underwood, K., Moore, B.,
 Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and
 Waterston, R.
 TITLE The WashU-HMI Mouse EST Project
 JOURNAL Unpublished (1996)
 COMMENT On May 8, 1995 this sequence version replaced gi:799469.
 Contact: Marra M/Mouse EST Project
 WashU-HMI Mouse EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314.286.1800
 Fax: 314.286.1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 MGI:261704
 Seq primer: EMPriemer
 High quality sequence stop: 345.

FEATURES
 source
 1..401
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="IMAGE:427152"
 /clone_1lb="Soares mouse embryo NDMEL3.5 14.5"
 /sex="unknown"
 /tissue_type="embryo"
 /dev_stage="13.5-14.5dpc total fetus"
 /lab_host="DH10B"
 /note="vector: pT73D-Pac (Pharmacia) with a modified
 polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
 was primed with a Not I - oligo(dT) primer [5',
 TGTATCCAACTCGAAGTGGAGCGCGCGGAAATTTTGTGTTTTTTTTTTT
 T 3']; on equal amounts of mRNA from 2 13.5dpc and 2
 14.5dpc embryos [total RNA provided by Minoru Ko, Wayne
 State Univ., from 2]; double-stranded cDNA was ligated to
 Eco RI adaptors (Pharmacia), digested with Not I and
 cloned into the Not I and Eco RI sites of the modified
 pT73 vector. Library went through one round of
 normalization, and was constructed by Bento Soares and
 M.Fatima Bonaldo."

BASE COUNT 92 a 96 c 128 g 85 t

ORIGIN

Query Match 14.4%; Score 214; DB 27; Length 401;
 Best Local Similarity 77.5%; Pred. No. 5.8e-46;
 Matches 259; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 38 caacaataatatacttgataagaagaatgcttaagaatgctactagaacaagaanaa 97
 |||||||
 DB 68 CAGGAATTAACACTTTGGTGGAGAGCCATGCAATCAAGTCTCACTCTACACAGAGACG 127
 |||||||

QY 98 acgttttcacctctttagtattactagctatttgcattgtaagaatgtaagtcata 157
 |||||||
 DB 128 GTGCTCTTCGCTGCACATTCCTCTCTCACTCACTCACTGACAGTAAGAGATGCGAAGC 187
 |||||||

QY 158 ggaagctgttagacagcaagaattcagagatcggtctggaactgtgtccctgtacaacag 217
 |||||||
 DB 188 GGAAGATTGACAGGACGAGGAATTTCAAGATCGATCTGAAACTGTGCTCTGCAACAG 247
 |||||||

QY 218 tcttgagccagcatgagatgtgtctaaagaatgtgcttcggtctatgagggagatgacag 277
 |||||||
 DB 248 TCGCGACCTGACAGATGAGTGTCCAAAGAGATGTGCTTCGGCTATGGGAGAGATGACAGC 307
 |||||||

QY 278 tctgtgagcgtagcggtcagcaaggttcaaggaagacttggggtctccagaatgagacc 337
 |||||||

DB	308	TCGTGTCCTCGCAGGCGCCGACCGCTTCACGAGAACTGGGGTTTCACGAGTGAAGCA	367
07	338	tgctgcgaactgcgcagtgatgtaacgccttcaga	371
Db	368	TCGTGCGGACTGTGCTGCTGGTGAACCTCCTTCACA	401
RESULT	4		
LOCUS	AA036247	358 bp	EST
DEFINITION	m174a03.r1 Soares mouse p33NMf19.5 Mus musculus cDNA clone		26-AUG-1996
ACCESSION	AA036247		
VERSION	AA036247.1	GI:1509376	
KEYWORDS	EST.		
SOURCE	house mouse.		
ORGANISM	Mus musculus		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
AUTHORS	1 (bases 1 to 358) Marra,M., Hillel,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T., Gelsel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M., Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B., Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and Waterston,R.		
TITLE	The WashU-HHMI Mouse EST Project		
JOURNAL	Unpublished (1996)		
COMMENT	On Apr 14, 1993 this sequence version replaced gi:716824. Contact: Marra M/Mouse EST Project WashU-HHMI Mouse EST Project Washington University School of Medicine 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108 Tel: 314 286 1800 Fax: 314 286 1810 Email: mouseest@wustl.wustl.edu This clone is available royalty-free through INLNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information. MGI:2893044 Seq primer: -28M13 rev2 from Amersham High quality sequence stop: 347. Location/Qualifiers 1. 358 /organism="Mus musculus" /db_xref="taxon:10090" /clone IMAGE:472300" /clone_lib="Soares mouse p33NMf19.5" /dev_stage="19.5 dpc total fetus" /lab_host="DH10B (ampicillin resistant)" /note="vector: pRT73D (Pharmacia) with a modified polylinker; Site.1: Not I; Site.2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5'] TGTATCAATCATCTGAGTGGAGCGCGCCGATATTTTATTTTATTTT 3', double-stranded cDNA was size selected, ligated to Eco RI adapters (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pRT73 vector (Pharmacia). Library went through one round of normalization to a Cot = 5. Library constructed by Bento Soares and M.Fatima Bonaldo. RNA was kindly provided by Dr. Minoru Ko (Wayne State University)."		
BASE COUNT	81 a 98 c 110 g 69 t		
ORIGIN			
Query Match	12.4%;	Score 185;	DB 27; Length 358;
Best Local Similarity	77.5%;	Pred. No. 2.5e-38;	
Matches	224;	Conservative 0;	Mismatches 65; Indels 0; Gaps 0;
07	42	ataaatacattgtataagaagatggtcttaaaagtctactagaacaagaanaacgt	101
Db	69	AATAAACAACGTTTGGTGAGCCATGAGCAGTCAAGTCTCTACACAGAGGCTGC	128
07	102	ttttacccttttagtattactagagctatttgcattgtaaaagtgcattgtaatacagag	161

Db	129	TCCTGGCGACGACATCTCTCTTCCTCCACCCACACCTGGCATGTAACTGAGTTCCGAACCCGGAG	188
OY	162	actgtagacagcaagaattcaggatcgggtctgtgaactctgtccctcgaacacagtg	221
Db	189	ATTGCAGGACAGGAGAAATTCAGATGCATCTCGAAACAGTCTCCTCAACACAGTCGG	248
OY	222	ggccaggatgagcttgcctctgaagatcgtgcttgcgtatggggagaggtgacagctg	281
Db	249	GACCTGGCATGAGTGTTCACAGGATGTCGCTTGGCTATGGGAGGATGCACAGTGTG	308
OY	282	tggtgtcgcggctgtcacaggtcacaaggaaggaagctgggtctccacaagaat	330
Db	309	TGCCCTGCAGGCGCCACCGGTTCAAGGAAGATGGGGTTTCCAGAAAGTG	357
RESULT	5		
A0563354	643 bp	DNA	GSS
LOCUS	HS.5355_B2_B03_T7A	RPCT-11 Human Male BAC library Homo sapiens	29-MAY-1999
DEFINITION	genomic clone Plate=911 Col=6 Row=D, genomic survey sequence.		
ACCESSION	A0563354		
VERSION	A0563354.1	GI:4922825	
KEYWORDS	GSS.		
SOURCE	human.		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.		
AUTHORS	1 (bases 1 to 643) Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T., Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and Hood,L.		
TITLE	Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome		
JOURNAL	Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)		
MEDLINE	99380589		
COMMENT	Contact: Mahairas GG, Wallace JC, Hood L High Throughput Sequencing Center University of Washington 401 Queen Anne Avenue North, Seattle, WA 98109, USA Tel: (206) 616-3618 Fax: (206) 616-3887 Email: jwallace@u.washington.edu Clones are derived from the human BAC library RPCT-11. For BAC library availability, please contact Pieter de Jong (pieterdejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (http://BACPAC.med.buffalo.edu/ordering.bac.htm) or from Resear h Genetics (info@resgen.com). BAC end Web Server: http://www.htsc.washington.edu Plate: 911 Row: D Column: 6 Seq primer: T7 Class: BAC ends High quality sequence stop: 643.		
FEATURES	Location/Qualifiers		
source	1..643 /organism="Homo sapiens" /db_xref="taxon:9606" /clone="plate=911 Col=6 Row=D" /clone_lib="RPCT-11 Human Male BAC library" /sex="male" /note="Vector: pBAC3.6; Genomic sequence of BAC ends"		
BASE COUNT	151 a 154 c 158 g 167 t 13 others		
ORIGIN			
Query Match	10.3%; Score 153.4; DB 104; Length 643;		
Best Local Similarity	85.4%; Pred. No. 6.3e-30;		
Matches 169; Conservative	0; Mismatches 29; Indels 0; Gaps 0;		
OY	509	tgttcacagcaagtcgaacctgtgaagatcggtcgtcacagcgtccacgccaagggagacg	568
Db	315	TGTGTCACAGCAAGTCGAACCTCTGTAAGATCCGCTTCAAGCGCCTCAAGCCACAGGACACG	374
OY	569	gcgcgtgctgcgttatctcagcgcgtctctgccaacgctctgctgctgacctgctacctc	628

Db 375 GGGCTGTGCTGGCGTATCTGCGACCGCTCTGGCCACCGCTCTGCTGCTCATCCCTC 434
 Qy 629 tctgtcatctatgttaagagacagttatgtgaaagaaacacagctgctctgcytca 688
 Db 435 TGTGTCACTCTATTGTAGAGACAGTATGTAGAGAAACCCAGCTGTAGCTTTCAGCT 494
 Qy 689 cagacatctagtaaac 706
 Db 495 CATACATCTTATCACC 512

RESULT 6

AV111112 275 bp mRNA EST 29-JUN-1999
 LOCUS AV111112 Mus musculus C57BL/6J 10-day embryo Mus musculus cDNA
 DEFINITION clone 2600016N17, mRNA sequence.
 ACCESSION AV111112
 VERSION AV111112.1 GI:5265192
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus

REFERENCE Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 275)
 AUTHORS Caranfil, P., Shibata, K., Ozawa, Y., Konno, H., Itoh, M., Aizawa, K., Akahira, S., Akiyama, J., Fukuda, S., Fukunishi, Y., Funayama, T., Hara, A., Hayatsu, N., Hori, F., Ishikawa, T., Itoh, M., Izawa, M., Kawai, J., Kikuchi, N., Kojima, Y., Matsuyama, T., Nitsuna, H., Oda, H., Owa, C., Sato, K., Shibata, Y., Shigemoto, Y., Shiraki, T., Sogabe, Y., Sugihara, Y., Suzuki, H., Suzuki, H., Talem, M., Tomaru, Y., Tomioka, N., Watanabe, S., Yagame, M., Yamamura, T., Yokota, T., Yoshino, M., Muramatsu, M., Okazaki, Y. and Hayashizaki, Y.

TITLE RIKEN Mouse ESTs
 JOURNAL Unpublished (1999)
 COMMENT On Jun 5, 1998 this sequence version replaced gi:3187126.
 CONTACT: Chile Owa
 Genome Science Laboratory
 RIKEN

3-1-1 Koyada, Tsukuba, Ibaraki 305-0074, Japan
 Tel: 81-298-36-9145
 Fax: 81-298-36-9098
 Email: genome-resetc.riken.go.jp
 Thermostabilization and thermocyclization of thermostable enzymes by trehalose and its application for the synthesis of full length cDNA (Proc. Natl. Acad. Sci. U.S.A. 95(2):520-524 (1998))
 Transcriptional sequencing: A method for DNA sequencing using RNA polymerase (Proc. Natl. Acad. Sci. U.S.A. 95(7):3455-3460 (1998))
 Please visit our web site (<http://genome-rtc.riken.go.jp>) for further details.

FEATURES

source Location/Qualifiers
 1..275
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="2600016N17"
 /clone_1lb="Mus musculus C57BL/6J 10-day embryo"
 /sex="mixed"
 /dev_stage="10-day embryo"
 /dev_stage="10-day embryo"

BASE COUNT 77 a 86 c 55 g 37 t
 ORIGIN

Query Match 8.4%; Score 124.4; DB 59; Length 275;
 Best Local Similarity 71.3%; Pred. No. 2.3e-22;
 Matches 164; Conservative 0; Mismatches 66; Indels 0; Gaps 0;

Qy 309 aggaactggggcttcgaagaatgcagccctgtgtgactgagcagtggtgaacgcttc 368
 Db 43 AGAAGTGTGTTCCAGAGTAAGACCATTCGCCAGACTGCCCTGTAGAACCCGATC 102
 Qy 369 agaaagcaaatgttcagccagcagtgatgcatctgtggggagctcttccaggatttc 428

Db 103 TGAGAGCCATTGCTCACACACCACTGATGACTGTGGCGGGAGTGCCTGCCAGATTTT 162
 Qy 429 ataggaagacgaagaactgttcgacttcgaagaatgagtggtgtgcttgtagagaccctc 488
 Db 163 ACCAGAGACCAACTGTGTGTTTCAAGACATGAGAGTGTGCCCTGGAGACCCAGC 222
 Qy 489 cctcctccttgcgaacgcagctgttgcgaagaagtgtaacctgtgaagatc 538
 Db 223 CTCCTCCCTACGACACACAGTGTGATGTGCCAAGTGCGCAGCAGACC 272

RESULT 7

A0544065 646 bp DNA GSS 19-MAY-1999
 LOCUS RPCI-11-315F10.TV RPCI-11 Homo sapiens genomic clone
 DEFINITION RPCI-11-315F10, genomic survey sequence.
 ACCESSION A0544065
 VERSION A0544065.1 GI:4869459
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens

REFERENCE Eutheria; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 1 (bases 1 to 646)
 AUTHORS Zhao, S., Adams, M.D., Nierman, W., Malek, J., de Jong, P. and Venter, J.C.
 TITLE Use of BAC End Sequences from Library RPCI-11 for Sequence-Ready Map Building
 JOURNAL Unpublished (1997)
 COMMENT On Mar 23, 1999 this sequence version replaced gi:3324949.
 Other GSS: RPCI-11-315F10.TJ
 Contact: Shaying Zhao, William Nierman, Mark Adams
 Department of Eukaryotic Genomics
 The Institute for Genomic Research
 9712 Medical Center Dr., Rockville, MD 20850
 Tel: 301 838 0200
 Fax: 301 838 0208
 Email: hbe@tigr.org

Clones are derived from the human BAC library RPCI-11. For BAC library availability, please contact Pieter de Jong (pieter@dejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/ordering>) or from Research Genet. cs (info@resgen.com). BAC end search page: http://www.tigr.org/tdb/hunguen/bac_end_search/bac_end_search.html.
 Seq primer: 17
 Class: BAC ends.

FEATURES

source Location/Qualifiers
 1..646
 /organism="Homo sapiens"
 /db_xref="GDB:7620705"
 /db_xref="taxon:9606"
 /clone="RPCI-11-315F10"
 /clone_1lb="RPCI-11"
 /sex="Male"
 /cell_type="Lymphocytes"
 /note="Vector: pBAC3.6; Site.1: EcoRI; Site.2: EcoRI; RPCI11 Human Male BAC library"

BASE COUNT 175 a 135 c 145 g 191 t
 ORIGIN

Query Match 8.2%; Score 122.6; DB 104; Length 646;
 Best Local Similarity 93.4%; Pred. No. 8.4e-22;
 Matches 128; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 675 ggtctctggtgtcagcagcattcagttacaagagactgagctgtcttcttgaagac 734
 Db 263 GGTCTCTGCTGTCAAGAGCATTCATCAACGCGCTGTGAGTGTGTGAGAGC 322
 Qy 735 ctacagtcacgaatbtggccacagagctgtctgtccagtcgcccgttgactgaatgcaga 794
 Db 323 CTCAGCTCCAGATATGCGCACAGAGCGCTGTGCCAGTGCGCGCTGACTCAGTCCAGA 382

OY 128 tattttgcagttaagtgacttctgaaacagagagactctagaacagaagaattccaggat 187
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 327 TATAGTCATGATAAAGGACTTGTGAAACGGAGAGCTGTAGACAGCAAAATTTCCAGGGAT 268

OY 188 cggctcgtgaacctgtgtccctcgacaacagctgtgggcagagcatgagttgtctaagaa 247
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 267 CGGCTCTGAAAATGTGTTCCCTGCACCAGTGtGGGCCAGCGATGAGCTGTCTTAAGGA 208

OY 248 tgttg 252
| | |
Db 207 TATTG 203

RESULT 10			
AI551729			
LOCUS	AI551729	381 bp	mRNA
DEFINITION	vll1602.y1 Knowles Solter mouse blastocyst B3 Mus musculus CDNA clone IMAGE:835418 5', mRNA sequence.	EST	23-MAR-1999

VERSION	AI551729.1	GI:4484092
KEYWORDS	EST.	
SOURCE	house mouse.	
ORGANISM	Mus musculus	

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia
Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 381)

Marras, M., Hillier, L., Kucaba, T., Martin, J., Beck, C., Wylie, J.

Underwood, K., Steptoe, M., Thalsing, B., Allen, M., Bowers, Y., Peterson, B., Swaller, T., Glibbons, M., Pape, D., Harvey, N., Schurr, R., Ritter, E., Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann, R., Waterston, R. and Wilson, R.
The WashU-NCI Mouse Est Project 1999
Unpublished (1999)
On March 10, 1999 this document was first posted at 2004050

COMMENTS
On Feb. 10, 1998, this sequence version replaced g1:2548559.
Contact: Maira M/washu-NCI Mouse EST Project 1999
Washington University School of Medicine
444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: mousest@watson.wustl.edu
This clone is available royalty-free through LINT; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MG1:495634

This read is a RESEQUENCE of a previously sequenced mouse clone
This read has been verified (found to hit its original self in the
correct orientation)
Seq primer: -40RP.

FEATURES	Location/Qualifiers
source	1. .381

```

/organism="Mus musculus"
/strain="B6D2 F1/J"
/db_xref="taxon:10090"
/clone_image:833418
/clone_id="Knowles Solter mouse blastocyst B3"
/tissue_type="blastocyst"
/dev_stage="embryo (pre-implantation)"
/lab_host="DH10B"
/note="Organ: embryo; Vector: pSPORT; Site_1: NotI;
Site_2: SalI; Cloned unidirectionally from mRNA prepared
from 800 blastocysts. Primer: SalI(dT)
5'-GGGTGACCGTCGACCGCTTTTCTTTT-3'. cDNAs were
cloned into the NotI/SalI sites of a pSPORT vector (Life
Technologies). Two different size selections: B1 (larger
inserts) and B3."

```

Query Match	5.3%	Score 78.6;	DB 48;	Length 381;
Best Local Similarity	55.8%;	Pred. NO. 3e-10;		
Matches 150;	Conservative 0;	Mismatches 119;	Indels 0;	Gaps 0;

QY 1042 tccgaactcaccggagaagacatctatctccaaatccgaacttgaagctaaagtc 1101
Db 1 TCCGAACTCAGCTGGAGAAAGATACCAATTCCCTCAATCCGAAAAGAAAGCGCAGCATC 60
QY 1102 ttgagatcnaatagcaagtcgaagatttgatcggtggcgctgtccagtcagctcattcc 1161
Db 61 TCTGATTTCAAGTGGCGGCGCAGGATCTGGCTGGGACAGCTGCTTAGATCTTCTGGGAA 120
QY 1162 tgaaaacttcaagcagcagctatctatctatgatataaacacaacacgcytagaatcgc 1221
Db 121 TGTTCAGAAATCTACTACTACCTTGACAAATGGTGCACATGTTAAAGTCGTGGAGACAGC 180
QY 1222 atcaacacagatagcactaaacta tgaagaagccagctaga tcaagagatgycgctgcat 1281
Db 181 GCTAGCTCAGAGATGCTCAAAAGACATCCAAAGCCAAAGGAGGCTGGGAAGACGGAAAACT 240
QY 1282 ccaccacagcacttcagagctgcctccagg 1310
Db 241 GAATCTAGCCATGCGCCACACCTCTTCAGG 269

RESULT 11	
AL120773	
LOCUS	
AL120773	
485 bp	
mRNA	
EST	
27-SEP-1998	

DEFINITION	DKEF2762C192.t1 762 (synonym: hmel2) Homo sapiens cDNA clone
ACCESSION	DKEF2762C192.5', mRNA sequence.
VERSION	AL120773.1
GI	5926774

KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia
Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 485)

AUTHORS Koerner, K., Beyer, A., Mewes, H.W., Gassenhuber, J. and Wiemann, S.
 TITLE EST (Koerner, et al.)
 JOURNAL Unpublished (1999)
 COMMENT On Mar 16, 1998 this sequence version replaced gi:2961733.

Contact: Koehler K
 MIPs
 Am Klopfersplitz 18a D-82152 Martinsried, Germany
 This is the 5' sequence of the clone insert
 clone from S. Wiemann, Molecular Genome Analysis, German Cancer
 Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de;
 sequenced by BKFZ within the DNA sequencing consortium of the
 German genome project.
 No sl sequence available.
 This clone is available at the RZPD in Berlin.
 Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14055
 Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de.

```

FEATURES
source      Location/Qualifiers
1. .485

```

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_id="DKFp762C192"
/clone_lib="762 (synonym: hme12)"
/tissue_type="melanoma (Memo cell line)"
/dev_stage="adult"
/lab_host="PH10B"
/notes="vector: pSport1; Site_1: NotI; Site_2: SalI"

```

Query Match	4.2%	Score 61.8	DB 64	Length 485
Best Local Similarity	90.4%	Pred. No. 8.7e-06		
Matches 66	Conservative 0	Mismatches 7	Indels 0	Gaps 0

Oy 15 ccaggtgctgcgggaagaacacctccacaataatacatttgatagaagaagtgccttaa 74
| | | | |
Db 413 CTAGTGTCTGACGCGAACCCTCCACCAATAATTAATTGATTAAGAAGAAAGATGCTTAA 472

Oy 75 aagtcgtacttaga 87

```

Db      473 AAGTCTACTTGA 485

RESULT 12
LOCUS   AQ173919/c
DEFINITION
HE_3204_A2_C10_MR CIT Approved Human Genomic Sperm Library D Homo
sapientis genomic clone Plate=3204 Col=20 Row=E, genomic survey
sequence.
ACCESSION
AQ173919.1 GI:3571286
VERSION
AQ173919.1
KEYWORDS
GSS.
SOURCE
human.
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 405)
Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T.,
Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and
Hood,L.
Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)
99380589
COMMENT
Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Sequence Tagged Connector
Plate: 3204 row: E column: 20
Class: BAC ends
High quality sequence stop: 405.
FEATURES
source
1..405
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_plate="3204 Col=20 Row=E"
/clone_lib="CIT Approved Human Genomic Sperm Library D"
/sex="male"
/note="Organ: sperm; Vector: pBelobAC11; BAC Clones in
E-Coli DH10B"
BASE COUNT      109 a      98 c      112 g      85 t      1 others
ORIGIN
Query Match      4.0%; Score 59; DB 99; Length 405;
Best Local Similarity 92.5%; Pred. No. 4.6e-05;
Matches 62; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 454 tcaagacatgagtgctgtgagagccctccctcctctacgaacgcacgtgc 513
|||||
Db 405 TCAAGACATGAGTGCTGTGAGAGCCCTCTCTCTCTTACGAACGCACGTGA 346

QY 514 cagcaag 520
|||
Db 345 GTGAACG 339

RESULT 13
LOCUS   CNS00LPM/c
DEFINITION
CNS00LPM 1101 bp DNA GSS 03-JUN-1999
Drosophila melanogaster genome survey sequence TET3 end of BAC:
BACR32J01 of RPCR-98 library from Drosophila melanogaster (fruit
fly), genomic survey sequence.
ACCESSION
AL068516
VERSION
AL068516.1 GI:4958747
KEYWORDS
GSS.
SOURCE
fruit fly.
ORGANISM
Drosophila melanogaster

```

```

REFERENCE
AUTHORS
1 (bases 1 to 1101)
Genoscope.
TITLE
Direct Submission
JOURNAL
Submitted (02-JUN-1999) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT
Determination of this BAC-end sequence was carried out as part of a
collaboration with the Berkeley Drosophila Genome Project (BDGP).
The BDGP is constructing a physical map of the Drosophila
melanogaster genome using these BACs. For further information
please see http://www.fruitfly.org The BDGP Drosophila
melanogaster BAC library was prepared by Kazutoyo Osoegawa and
Aaron Mamoser in Pieter de Jong's laboratory in the Department of
Cancer Genetics at the Roswell Park Cancer Institute in Buffalo,
NY. The library is named RPCR-98 and was constructed by partial
EcoRI digestion of Drosophila DNA provided by the BDGP from the
isogenic strain Y2; cn bw sp, the same strain used for the BDGP's
P1 and EST libraries. A more detailed description of the library
and how to order individual BAC clones, the entire library, or
filters for hybridization from the BACPAC Resource Center can be
found at http://bacpac.med.buffalo.edu/drosophila_bac.htm.
FEATURES
source
1..1101
Location/Qualifiers
/organism="Drosophila melanogaster"
/db_xref="taxon:7227"
/clone_lib="RPCR-98"
/clone_plate="BACR32J01"
/note="end : TET3"
BASE COUNT      350 a      161 c      165 g      254 t      171 others
ORIGIN
Query Match      2.9%; Score 43.4; DB 79; Length 1101;
Best Local Similarity 61.4%; Pred. No. 0.74;
Matches 51; Conservative 10; Mismatches 22; Indels 0; Gaps 0;

QY 1407 tttttttcaccttaataattcttatgtgtagatgttttaataaatatt 1466
|||||
Db 327 TTTTITTTGMMTTTTTTATBATTTATKATTTCTTTTACASCHTTTTTACTGBAIAWIC 268

QY 1467 caagattttttaaaacttt 1489
|||
Db 267 TTTACTAATKTAATGATAATTTT 245

RESULT 14
LOCUS   AA759377/c
DEFINITION
AA759377 443 bp mRNA EST 29-DEC-1998
ah54a10.s1 Soares_testis_NHT Homo sapiens cDNA clone 1309434 3',
rna sequence.
ACCESSION
AA759377
VERSION
AA759377.1 GI:2804852
KEYWORDS
EST.
SOURCE
human.
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 443)
NCI-CCGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
On Jan 19, 1998 this sequence version replaced gi:2151262.
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert_Strausberg@nih.gov
cDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima
Bonaldo, Ph.D.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center

```


The BDGP is constructing a physical map of the *Drosophila melanogaster* genome using these BACs. For further information please see <http://www.fruitfly.org> The BDGP *Drosophila melanogaster* BAC library was prepared by Kazuhiro Oosogawa and Aaron Mammeter in Pleier de Jong's laboratory in the Department of Cancer Genetics at the Roswell Park Cancer Institute in Buffalo, NY. The library is named RRC1-98 and was constructed by partial EcoRI digestion of *Drosophila* DNA provided by the BDGP from the

```
Search completed: April 23, 2000, 01:49:00
Job time: 1275 sec
```

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 23, 2000, 09:40:26 ; Search time 28.62 Seconds

(without alignments)
6228.783 Million cell updates/sec

Title: US-09-490-187-1

Perfect score: 1489

Sequence: 1 ggaaccgcagccctccaggt.....gtatttttaaaacttt 1489

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 214294 seqs, 59861574 residues

Total number of hits satisfying chosen parameters: 428588

Minimum DB seq length: 0
Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : Issued Patents NA:*

- 1: /cgn2_6/ptodata/1/lna/5A.COMB.seq:*
- 2: /cgn2_6/ptodata/1/lna/5B.COMB.seq:*
- 3: /cgn2_6/ptodata/1/lna/5C.COMB.seq:*
- 4: /cgn2_6/ptodata/1/lna/5D.COMB.seq:*
- 5: /cgn2_6/ptodata/1/lna/6.COMB.seq:*
- 6: /cgn2_6/ptodata/1/lna/PCRTUS9.COMB.seq:*
- 7: /cgn2_6/ptodata/1/lna/backfilest1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	39.6	2.7	4673	1 US-07-638-431-1	Sequence 1, Appl
2	39.6	2.7	4673	6 PCT-US92-00018-1	Sequence 1, Appl
3	36.6	2.5	761	2 US-08-477-877B-83	Sequence 83, Appl
4	36.6	2.5	761	2 US-08-472-281A-83	Sequence 83, Appl
5	36.6	2.5	761	4 US-08-477-989B-83	Sequence 83, Appl
6	36.6	2.5	807	2 US-08-477-877B-90	Sequence 90, Appl
7	36.6	2.5	807	2 US-08-472-281A-90	Sequence 90, Appl
8	36.6	2.5	807	4 US-08-477-989B-90	Sequence 90, Appl
9	36.6	2.4	1601	2 US-08-722-001-7	Sequence 7, Appl
10	36.6	2.4	1987	2 US-08-722-001-26	Sequence 26, Appl
11	36.6	2.4	1997	2 US-08-722-001-27	Sequence 27, Appl
12	36.6	2.4	2004	2 US-08-722-001-11	Sequence 11, Appl
13	36.6	2.4	2485	2 US-08-424-424B-1	Sequence 11, Appl
14	36.6	2.4	2486	6 PCT-US94-05363A-1	Sequence 1, Appl
15	35.4	2.4	1183	4 US-08-705-937-10	Sequence 10, Appl
16	34.8	2.3	1639	1 US-08-334-698-5	Sequence 5, Appl
17	34.8	2.3	1639	1 US-08-228-932-5	Sequence 5, Appl
18	34.8	2.3	1639	3 US-08-468-939-5	Sequence 5, Appl
19	34.8	2.3	1639	2 US-08-406-855A-5	Sequence 5, Appl
20	34.8	2.3	1639	4 US-08-722-190-5	Sequence 5, Appl
21	34.8	2.3	1639	6 PCT-US95-04203-5	Sequence 5, Appl
22	34.6	2.3	1542	4 US-09-122-230-8	Sequence 8, Appl
23	34.6	2.3	1909	4 US-09-122-230-6	Sequence 8, Appl
24	34.6	2.3	7218	1 US-08-232-463-14	Sequence 14, Appl
25	34.2	2.3	19124	4 US-08-487-825B-13	Sequence 13, Appl
26	33.8	2.3	568	2 US-08-582-237-20	Sequence 20, Appl
27	33.8	2.3	568	3 US-08-582-298-20	Sequence 20, Appl

C 28	33.8	2.3	1493	1 US-08-340-820-24	Sequence 24, Appl
C 29	33.8	2.3	1493	1 US-08-593-535-24	Sequence 24, Appl
C 30	33.8	2.3	1740	2 US-08-362-512A-3	Sequence 3, Appl
C 31	33.8	2.3	2861	1 US-08-299-953-1	Sequence 1, Appl
C 32	33.8	2.3	2861	2 US-08-459-415-1	Sequence 1, Appl
C 33	33.8	2.3	2861	6 PCT-US95-11231-1	Sequence 1, Appl
C 34	33.8	2.3	3881	1 US-08-299-953-2	Sequence 2, Appl
C 35	33.8	2.3	3881	2 US-08-459-415-2	Sequence 2, Appl
C 36	33.8	2.3	3881	6 PCT-US95-11231-2	Sequence 2, Appl
C 37	33.4	2.2	2762	3 US-08-198-446B-12	Sequence 12, Appl
C 38	33.4	2.2	2762	3 US-08-870-693-12	Sequence 12, Appl
C 39	33.2	2.2	1593	1 US-08-307-489-50	Sequence 50, Appl
C 40	33.2	2.2	8174	1 US-07-914-281-5	Sequence 5, Appl
C 41	33.2	2.2	8174	1 US-08-393-246-5	Sequence 5, Appl
C 42	33.2	2.2	8174	2 US-08-525-058A-5	Sequence 5, Appl
C 43	33.2	2.2	8174	4 US-08-696-731-5	Sequence 3, Appl
C 44	33.2	2.2	8174	6 PCT-US91-00899-3	Sequence 1, Appl
C 45	33.2	2.2	14176	1 US-08-307-489-1	Sequence 1, Appl

ALIGNMENTS

RESULT 1
US-07-638-431-1
; Sequence 1, Application US/07638431
; Patent No. 5198535
; GENERAL INFORMATION:
; APPLICANT: Hoffman, Stephen L.
; APPLICANT: Charenylt, Iudin
; APPLICANT: Hedstrom, Richard
; APPLICANT: Khushf, Srisin
; APPLICANT: Rogers IV, William O.
; TITLE OF INVENTION: Protective malaria sporozoite surface protein
; TITLE OF INVENTION: Immunogen and gene
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: A. David Spevack
; STREET: NMRDC Building 1 T-12 National Naval
; STREET: Medical Center
; CITY: Bethesda
; STATE: MD
; COUNTRY: USA
; ZIP: 20814-5044
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/638,431
; FILING DATE: 19910110
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Spevack, Avrom D.
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (301) 295-6759
; TELEFAX: (301) 295-4033
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 4673 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: N
; ANTI-SENSE: N
; ORIGINAL SOURCE:
; ORGANISM: Plasmodium yoelii
; STRAIN: 17X(NL)
; DEVELOPMENTAL STAGE: erythrocytic stage
; TISSUE TYPE: Blood
; CELL TYPE: erythrocytic stage

Query Match	2.58;	Score 36.6;	DB 2;	Length 761;
Best Local Similarity	54.0%;	Pred. NO. 0.21;		
Matches 75; Conservative	0;	Mismatches 64;	Indels 0;	Gaps 0;

```

oy 1348 acttacagtagatcagaacctctgtlccacagataagaattgggggaacctgatgattt 1407
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 410 AATTATATAGATCAGAACAAAGTTATGTGCAAAATTTGCAACCAAACTTTTGGAATTAC 351

```

```
Oy      1408 ttttttcgcatttaacatcttctaatacgttgtagagtatgctttaaaacaatttc 1467
          ||||| | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      350 TTTTGTACTCATTTCTGTGAGATCCGGTGTTTGTGATTTTTAAAAAATATACC 291
```

```

Qy 1468 aagtatatttttaaaaaaac 1486
    ||| ||||| | |||||
Db 290 AAATGCTTTTCACAAAC 272

```

RESULT 4
US-08-472-281A-83/c
; Sequence 83, Application US/08472281A

```

:
:
: APPLICANT: Bazin, Hervé
: APPLICANT: Latime, Dominique
: TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Activation
:

```

ADDRESSEE: Carella, Byrne, Bain, Gilfillan
ADDRESSEE: Cecchi, Stewart & Olstein
STREET: 6 Becker Farm Road
City: Bethesda

CITY: Roseland
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07068

```

; MEDIUM: 5.25 INCH DISKETTE
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1

```

REGISTRATION NUMBER: 06/06/2012, 2012
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/119,032
FILING DATE: 09-SEP-1993
APPLICATION NUMBER: 08/027,008

NAME: Olstein, Elliot M.
REGISTRATION NUMBER: 24,025
REFERENCE/DOCKET NUMBER: 617500

```

; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 83:
; SEQUENCE CHARACTERISTICS:
;

```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
; NAME:

```

NAME/KEY: Nucleotide sequence encoding LO-CD2a VL chain.
US-08-472-281A-83

Query Match	2.58;	Score 36.6;	DB 2;	Length 761;
Best Local Similarity	54.08;	Pred. No. 0.21;		
Matches 75; Conservative	0;	Mismatches 64;	Indels 0;	Gaps 0

QY 1348 acctacagtagatcagaactctgttcccaagcataagaatttgggaaacctgtagtatt 1407

Db 410 aattatattagatcgaacaaagtattgtcgaataattgcaaccaaactttgtgaattac 351

OY 1408 ttttttgcaccttaataatttcctatagtgttagagtaagttaaataattc 1467
 ||||| ||| ||| ||| ||||| |||
 Db 350 tttttgtactcattcccttgagatccgggtgtttgtgatattttaaataatattacc 291

Qy	1468	aag	tattt	tttaaaaa	aac	148
Db	290	AAATGCTTTT	TCACAAAAC			272

RESULT 5
US-08-477-989B-83/c.

```

; GENERAL INFORMATION:
; APPLICANT: Bazin, Herv
; APPLICANT: Latlone, Dominique

```

APPLICANT: Postema, Christina E.
APPLICANT: White-Scharf, Mary
TITLE OF INVENTION: LO-CD2a Antibody and Uses

```

; ;
; TITLE OF INVENTION: Proliferation
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
;

```

ADDRESS: Care
ADDRESSEE: Ceccc
STREET: 6 Becke
CITY: Roseland

```

; COUNTRY: U.S.A.
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
;

```

```

;
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,989B

```

/ CONSOLIDATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/407,009
 ; FILING DATE: 29-MAR-1995

FILED DATE: 05-MAR-1993
APPLICATION NUMBER: 08/027,008
FILING DATE: 05-MAR-1993
ATTORNEY/AGENT INFORMATION:

REFERENCE/DOCKET NUMBER: 61750-147
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-994-1700

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 761 bases
; TYPE: nucleic acid
;

```

```

;
; CHAINEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
;

```

NAME/KEY: VL chain.
US-08-477-989B-83

[illegible]

OY 1368 acttcagctgatagaactcgttcccgatgaagtattggggaaccctygaaatttt 1407
 ||| | | | | | | | | | | | | | | |
Db 417 AATTATATAGATAAGAACAAAGTTATGTGCAAAATTGCAACCAACTTGGTAATTAC 358

OY 1408 ttttttgacaccttaataattcttatatgtagtagatgtttaaatatttc 1467
 |||| | | | | | | | | | | | | | | | |
Db 357 TTTTTTGTTACGATCTTCCTGTGCAGATCCCGSTGTGTTTGATTTTAAAAAATATACC 298

OY 1468 aaagtattttttaaaaac 1486
 || | | | | | | | | | | | | | | | |
Db 297 AAATGCTTTTCACAACAAAC 279

RESULT 7

US-08-472-281A-90/c
Sequence 90, Application US/08472281A
Patent No. 5817311
GENERAL INFORMATION:
APPLICANT: Bazin, Hervé
APPLICANT: Latine, Dominique
TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Act
NUMBER OF SEQUENCES: 96
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carrelia, Byrne, Bain, Gilfillan,
ADDRESSEE: Cecchi, Stewart & Olstein
STREET: 6 Becker Farm Road
CITY: Roseland
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07068

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch diskette
COMPILER: IBM PS/2
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,281A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/407,009
FILING DATE: 29-MAR-1995
APPLICATION NUMBER: 08/119,032
FILING DATE: 09-SEP-1993
APPLICATION NUMBER: 08/027,008
FILING DATE: 03-MAR-1993

ATTORNEY/AGENT INFORMATION:
NAME: Olstein, Elliot M.
REGISTRATION NUMBER: 24,025
REFERENCE/DOCKET NUMBER: 61750-142
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-994-1700
TELEFAX: 201-994-1744

INFORMATION FOR SEO ID NO: 90:
SEQUENCE CHARACTERISTICS:
LENGTH: 807 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: polynucleotide

FEATURE:
NAME/KEY: Nucleotide sequence encoding humanized LO-CD2a light chain variable

US-08-472-281A-90 .*

Query Match * ? 2.5%; Score 36.6; DB 2; Length 807;
Best Local Similarity 54.0%; Pred. No. 0.22;
Matches 75; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

OY 1348 acttacagtgatcacgaactcttgtcccagcatagaatttggygggaacctgtagattt 1407
 | | | | | | | | | | | | | | | | | | | | | |
Db 417 AATTATATATGATGACGAAGAAGTTATGTGCAAAATTGCAACCAACTTGGTAATTAC 358


```

COMPUTER: IBM PS/2
OPERATING SYSTEM: MS-DOS
SOFTWARE: WORD PERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05363A
FILING DATE: SUBMITTED HEREMITH
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: FERRARO, GREGORY D.
REGISTRATION NUMBER: 36,134
REFERENCE/DOCKET NUMBER: 325800-118
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-994-1700
TELEFAX: 201-994-1744
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2486 BASE PAIRS
TYPE: NUCLEIC ACID
STRANDEDNESS: SINGLE
TOPOLOGY: LINEAR
MOLECULE TYPE: CDNA
PCT-US94-05363A-1

```

```

Query Match      2.4%; Score 36.2; DB 6; Length 2486;
Best Local Similarity 56.2%; Pred. No. 0.59;
Matches 68; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

```

```

QY 517 caaggtcaacctcgtgaagatcgctccagcgccctccagccacggagcagcgctgac 576
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 2024 CAGCATCATCCAGCTGCGGGGTCACGCCCCGCGCTACAGCGCTGAGTCAAGAGAGAGC 2083
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 577 tgccgttctcgcagcgctcgcgcacgcgtctcgtgacctcgtcctcctctgtgtac 636
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 2084 TGCCGAGCGCTACTGATTTTCCCACTGCGCCCTACGCGCTGATCCTGATCACCCTCATCT 2143
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 637 c 637
DB 2144 C 2144

```

```

RESULT 15
US-08-705-937-10/c
Sequence 10, Application us/08705937
Patent No. 5981841
GENERAL INFORMATION:
APPLICANT: Santino, Colleen G.
APPLICANT: Conner, Timothy W.
TITLE OF INVENTION: EARLY SEED 5' REGULATORY SEQUENCE
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carmen Rodriguez, Paralegal, Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/705,937
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Nicolas G. Barzoukas,
REGISTRATION NUMBER: 38,823
REFERENCE/DOCKET NUMBER: MOBT:018 (38-2(10694)A

```

```

NAME: Janelle D. Wack
REGISTRATION NUMBER: 36,300
REFERENCE/DOCKET NUMBER: MOBT:018 (38-2(10694)A
NAME: Barbara S. Kitchell
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: MOBT:018 (38-2(10694)A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713) 787-1400
TELEFAX: (713) 789-2679
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 1183 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-705-937-10

```

```

Query Match      2.4%; Score 35.4; DB 4; Length 1183;
Best Local Similarity 52.6%; Pred. No. 0.64;
Matches 72; Conservative 0; Mismatches 65; Indels 0; Gaps 0;

```

```

QY 1352 acagtagatcagaactcgttccagcagataagatttgggggaacctgagtgattttt 1411
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 426 AAGAAATATATTAANNANATGTTAAATAATATTTTAACCTCCCTGTTCAATTTTTP 367
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1412 tttagcctcttaataattcttatatgtgtagatgttttaataataattcaagt 1471
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 366 TTATGATGCTAANAGTGTATATTATGTTTCAGATGTCCTTAATAATATTTCTTT 307
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1472 attttttaaaaactt 1488
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 306 TTGATGATATACTATT 290

```

```

Search completed: April 23, 2000, 02:01:41
Job time: 1275 sec

```

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 23, 2000, 01:41:21 ; Search time 42.52 Seconds

(without alignments)
8761.430 Million cell updates/sec

Title: US-09-490-187-1

Perfect score: 1489

Sequence: 1 ggacctgcagctccaggt.....gtatttttaaaaaacttt 1489

Scoring table: IDENTITY-NUC
Gapop 10.0 , Gapext 1.0

Searched: 311585 seqs, 125096042 residues

Total number of hits satisfying chosen parameters: 623170

Minimum DB seq length: 0

Maximum DB seq length: 1000000

Post-processing: Minimum Match 08
Listing first 45 summaries

Database : N_Geneseq_36.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1489	100.0	1489	1	Human hAPO4-alpha
2	1421.4	95.5	1496	1	Nucleotide sequence
3	1300.8	87.4	2185	1	Human TRAIN-R CDNA
4	1268.4	85.2	1704	1	Nucleotide sequence
5	733	49.2	1678	1	Mouse mAPO4-alpha
6	457.6	30.7	886	1	Mouse mAPO4-alpha
7	457.6	30.7	942	1	Mouse TRAIN-R (lon
8	360	24.2	371	1	Human secreted pro
9	325	21.8	591	1	Mouse mAPO4-gamma
10	325	21.8	599	1	Mouse TRAIN-R (sho
11	120.2	8.1	133	1	Rat hAPO4-alpha DN
12	90.4	6.1	791	1	Clone G1156 encodi
13	87.4	5.9	181	1	Human secreted pro
14	87.4	5.9	201	1	EST clone AX92. Ne
15	80.4	5.4	396	1	Mouse mAPO4-beta D
16	39.6	2.7	4673	1	P. yoelii SSP2 ant
17	38.6	2.6	1558	1	Survival motor neu
18	38.6	2.6	1560	1	Human survival mot
19	38.6	2.6	1582	1	Human survival mot
20	38.6	2.6	1582	1	Survival motor neu
21	38.4	2.6	326	1	Fragment 41-3 of t
22	38.2	2.6	4315	1	Kidney injury asso
23	37.4	2.5	5805	1	Borrelia burgdorfe
24	36.8	2.5	1453	1	Malice 33c BamHI fr
25	36.6	2.5	761	1	LO-CD2a light chai
26	36.6	2.5	761	1	LO-CD2a antibody V
27	36.6	2.5	807	1	Humanised LO-CD2a
28	36.4	2.4	1602	1	Human adrenenergic r
29	36.4	2.4	1978	1	truncated human al
30	36.4	2.4	1987	1	Human truncated al
31	36.4	2.4	1997	1	Human alpha-1C adr
32	36.4	2.4	1998	1	Human alpha-1C adr
33	36.4	2.4	2004	1	Human alpha-1C adr
34	36.4	2.4	2005	1	Human alpha-1C adr

35	36.2	2.4	2486	1	T09866	Human neurotransmi
36	36	2.4	1193	1	V74563	Staphylococcus aur
37	36	2.4	2067	1	V99092	DNA methyltransfer
38	36	2.4	19440	1	V99129	DNA methyltransfer
39	35.6	2.4	761	1	071876	LO-CD2a VL coding
40	35.4	2.4	1183	1	V29221	Nucleotide sequenc
41	35	2.4	403	1	T23006	Parietaria allerger
42	35	2.4	845	1	003998	Sequence complemen
43	34.8	2.3	1639	1	063182	Alpha 1c adrenergi
44	34.8	2.3	1639	1	062818	Genomic sequence e
45	34.8	2.3	1639	1	T03129	Alpha-1C adrenergi

ALIGNMENTS

RESULT	1	
X23415		
ID	X23415 standard; DNA; 1489 BP.	
AC	X23415;	
DT	18-JUN-1999 (first entry)	
DE	Human hAPO4-alpha DNA.	
KW	Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;	
KW	developmental abnormality; gestational abnormality; prostate cancer;	
KW	AP06; APO8; APO9; TNRL-1; TNRL-3; diagnosis; treatment; therapy; disease;	
KW	cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;	
KW	apoptosis; human; APO4-alpha; ss.	
OS	Homo sapiens.	
FS	Key	Location/Qualifiers
FT	CDS	65..1336
FT		/tag="a
FT		/product="hAPO4-alpha"
PN	W09911791-A2.	
PD	11-MAR-1999.	
PF	04-SEP-1998; U8393.	
PA	05-SEP-1997; US-924634.	
PI	(UNITV) UNIT WASHINGTON.	
PI	Chaudhary PM;	
DR	WPI; 99-205191/17.	
DR	P-PSDB; W93581.	
PT	New Tumor Necrosis Factor family receptor polypeptides and ligands -	
PT	useful for diagnosis and treatment of prostate cancer and	
PT	developmental or gestational abnormalities	
PS	Example IV; Flt 7C; 156p; English.	
CC	This invention describes isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or	
CC	receptor polypeptides: APO4, APO6, APO8 and APO9 or their active	
CC	fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or	
CC	their active fragments. APO4 is useful for diagnosing prostate cancer	
CC	by determining levels of APO4 in an individual. Prostate cancer can also	
CC	be treated using APO4 selective binding agents linked to a therapeutic	
CC	molety. APO4 polypeptides are also useful for identifying selective	
CC	binding agents. useful in diagnosis/treatment of disease by binding of	
CC	agents to the polypeptide/active fragment which is extracellular. or	
CC	expressed on the cell surface. The binding is preferably performed in	
CC	vivo. APO4 polypeptides/ active fragments are also useful for screening	
CC	for agonists and antagonists by binding and observing the changer in APO4	
CC	activity. Effective pharmacological agents useful in diagnosis or	
CC	treatment of disease are also identified using APO4 polypeptides/active	
CC	fragments and APO4 signal transducer molecules that specifically interact	
CC	with a cytoplasmic domain of APO4 and detecting a change in level of APO4	
CC	activity. The method is performed in vivo or in vitro. APO polypeptides	
CC	are all useful as immunogens for preparing antibodies. APO4 is also	
CC	useful for diagnosis/treatment of developmental or gestational	
CC	abnormalities. APO8 was transfected to human breast carcinoma cell line	
CC	MCF-7, and induced apoptosis.	
SQ	Sequence 1489 BP; 361 A; 366 C; 380 G; 382 T;	

Query Match 100.0%; Score 1489; DB 1; Length 1489;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1489; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	87	aacaaagagaaaaagtttllttaccccttltatgtatltactagcgctatttgcagtataaagtga	146
Db	67	AACAAGAGAAAAGCTTTTCTACTCTTTTGGTATCTAGCGCTATTGTCAAGTAAAGTGA	126
QY	147	ctgttgatacaggaagactgtagacagcaagaattcaaggatcgtgctbgaacggttttc	206
Db	127	CTTGTAACAGAGAGACTGTAGACACAAAGAAATTCAGGAGATGGGCTGTGAAACTGTGTC	186
QY	207	ccctgcaaccagctgtbgygcccagatbgaagtltgltcaagaagatbgtcttcgctatbgyg	266
Db	187	CCTGCACACAGTGTGGGCGCAGCATGAGAGTGTCTAAGAAATGTGGCTTGGCTATGGGG	246
QY	267	agagatgcacagtgatgtbgyggttccgygctgcacaagttcaagaagagactggygcttcaga	326
Db	247	AGGATGACAGGTGTGTACCTGCGGCTCCACAGGTTCAAGAGAGCACTGGGGCTTCAGA	306
QY	327	aagtcaagacccctgtccbgaatctgcagatbgygtbgaacccgtttcagaaggcaaatggttcag	386
Db	307	AATGCAAGCCCTGTCTGAGCTGCCAGTGTGAACCGCTTTAGAGAGCAATGTGTTGAG	366
QY	387	ccacagatgtagtgcacatctgcgyggaatgtctgcagaatttataatgagaacgaaacttg	446
Db	367	CCACAGAGATGCCATCTGGGGGAGCTGCTGCGAGAGATTTATAGAAAGCAAACTGTG	426
QY	447	tcgagcttcaagacatbgaagtgtgtbcttbtgtagaaccctctctctctcctaagaaccgc	506
Db	427	TGGGCTTTCAAGACATAGAGATGTGTGCTGTGTGTGAGAACCCCTCTCTCTTACAAACGCG	486
QY	507	actbtgcagcaaggttaacctgttgaagatbgytccaagggcctccagggcccaaggggaca	566
Db	487	ACTGTGCACAGAAAGTCAACCTGTGAAGATCGCGTCCAGGCTTCACGCCACAGGGGACA	546
QY	567	cgagcgctgagctgcggttatctcagagcgctctbgyccaacgtctctgttggccctgcatacc	626
Db	547	CGGGCGTGGCTGGCGTTATGTGAGAGGCTCTGGCACCCCTCTGCTGGCCCTGCTCAATCC	606
QY	627	tcgtgtcattctatltgtaagagacaglttatbgaanaagaaacccagctggtctctbgyt	686
Db	607	TCTGTGATCATATTGTAAAGAGACAGTTTATGAGAAAGAAACCCAGCTGCTCTGCGGCT	666
QY	687	caagagacattcagtaaaagaaacagtgagctgtgcgttlttgaacagacttaagctccag	746
Db	667	CACAGGACATTCATTAACAAGCGCTGTGAGCTGTGCTTACAGACACTCAAGCTCCACG	726
QY	747	aatbgtccacagagcgctgtctgcacaatbgyccgctgtactcagttgaaagctbgyccgg	806
Db	727	AATATGCCACAGAGCTGCTGCTGCCAGTGCCGCCGCTACTCACTGACAGACTGTGCCCCGG	786
QY	807	tcgagcttgcctccatccaatgtgtctbgtbgaagagcgctgcagccccaacccgagactcttg	866
Db	787	TGGCGTTGCTCCATCCATGATGGCTGTGAGAGGCGTGCAGGCCCAACCGGGAGACTGTG	846
QY	867	gttgtgtggtgtagtcttcgcaagccaagttcagaagaaagcagggccagccggygaga	926
Db	847	GTTGTGGGTGTCATTGTGCAGCCAGTCTTCAGCCAAGAAACCCAGGCCAGCGCGGGGAGA	906
QY	927	tgtgtgcagacttttttgatccotcaagcagatgcacatctgtbgygaagtlttaagtct	986
Db	907	TGTGTCCGACTTTTGTGGATCCCTCCACGAGTCCATCTGTGGCAGGTTTTCAGTGTGCT	966
QY	987	gagcctbgaatgcagaatcccaatggtgtgtgaacaacatccttttbtgtactcttaactg	1046
Db	967	GCGCTGTGATGCABAATCCCATGGGTGTGACAAACTCTTTTGTGACTTATCTGTG	1026
QY	1047	aactcactbgygaagacatcattctctcaatccagaaactbgaagctcaagcttcagcttbtg	1106
Db	1027	AACCTACTGAGAGACATTCATCTCTCAATCAAACTTAAAGCTCAACGCTTTGTGG	1086
QY	1107	attcaaatagacagtcagaatttgtgtgtgtbgygcttccagtcagaatctcaattctgaa	1166
Db	1087	ATTCAAAATGCAAGTCAAGATTGTGTGTGTGGGCTGTTCAGTCAAGTCTCAATTCCTTGAA	1146

Oy	1167	acttaacagcagctacgatttttccttagatatacacaaacctgtgagatcatgatcaa	1228
Oy	1167		
Dd	1147	actttaccag-nagctacgatttattctagaatatcaaacacactggtagatgacatcaa	1206
Oy	1227	ctcagatgcacctaaccatgatagaagccagctagatcaaggagtggcgctgccaccoc	1286
Dd	1207	cttcagagang-nacttacnratrtagaaagcagctaatatcagcagagactggccgtatcaccac	1266
Oy	1287	cagccactacaagctccctcccgaagtgaaagcagcagactgggtccctgtgacacagcact	1346
Dd	1267	cagccactacaagctccctccagtagagcagcagcagctgggtccctgtgacacagcact	1326
Oy	1347	gacttaccagtgatcacaaactcgttccccagataagatttgggggaacctgtgagagt	1400
Dd	1327	gactttacagtgaaacaaacctctgttccccagctaaagatttgggggaacctt-ATGAGT	1384
Oy	1407	ttttttttgactcttaacttaattctctatatgtttagagtatgttttaanaataatt	1466
Dd	1385	TTTTTTTGGACTCTTTTAATAATTTCCTGTATGTGTAGAGRATRTTTAAATAAATT	1444
Oy	1467	caagtatattttttaaaaaact 1487	
Dd	1445	CAAGTATTTTAAAAAAct 1465	
RESULT	3		
ID	X24978	standard; cDNA; 2185 BP.	
AC	X24978:		
DT	05-JUL-1999	(first entry)	
DE	Human TRAIIN-R cDNA.		
KW	TRAIIN-R; receptor; human; tumour necrosis factor receptor;		
KM	agonist; antagonist; cancer; immunological disease; therapy;		
KW	cytosolic; ss.		
OS	Homo sapiens..		
PFH	Key	Location/Qualifiers	
FT	CDS	179..1432	
FT	sig_peptide	/**tag--a	
FT		179..253	
FT		/**tag--b	
FT	mat_peptide	254..1429	
FT		/**tag--c	
PN	WO9113078-A1.		
PD	18-MAR-1999.		
PF	11-SEP-1998; UI9030.		
PR	06-MAY-1998; US-084422.		
PR	12-SEP-1997; US-058631.		
PA	(BIOJ) BIOGEN INC.		
PI	Heslson C, Tschopp J;		
DR	WPI; 99-229238/19.		
DR	P-PDB; W9146.		
PT	New cysteine-rich tumor necrosis factor receptor		
PS	Claim 1; Page 27; 30pp; English.		
CC	The present sequence encodes a novel human cysteine-rich tumour		
CC	necrosis factor receptor family member termed TRAIIN-R (see W9146).		
CC	It is a composite of 2 overlapping lambda gt10 clones (G159 and		
CC	G158) from a Clontech human adult lung cDNA library. Human		
CC	TRAIIN-R was also cloned from a second sequence subclone of a		
CC	lambda gt10 cDNA (G156, see X24978). Human TRAIIN-R is expressed		
CC	at low levels in every tissue and cell line tested thus far, with		
CC	higher expression detected in heart, prostate, ovary, testis,		
CC	peripheral blood lymphocytes, thyroid and adrenal gland.		
CC	Cell death can be induced by administering an agent capable of		
CC	inhibiting the binding of TRAIIN-R to its ligand. A claimed method		
CC	of treating, or reducing, the advancement, severity or effects of		
CC	an immunological disease in a mammal comprises administering a		
CC	pharmaceutical composition which comprises a TRAIIN-R blocking agent,		
CC	e.g. soluble TRAIIN-R. TRAIIN-R can be fused to an immunoglobulin to		
CC	produce a fusion protein which may be targeted to various sites.		
CC	It can be used in binding assays, and to identify antagonists and		
CC	agonists. Anti-TRAIIN-R antibodies can be used to reduce the		
CC	severity of an immune response or to treat cancer. TRAIIN-R		
CC	blocking agents can also be used to reduce the severity or effects		

CC of an immunological disease (all claimed). 550 G; 538 T;
SQ sequence 2185 BP; 546 A; 551 C;

CC of an immunological disease (all claimed). 550 G; 538 T;
SQ sequence 2185 BP; 546 A; 551 C;

Query Match	87.4%	Score 1300.8;	DB 1;	Length 2185;
Best Local Similarity	99.5%;	Pred. No. 0;		
Matches 1305;	Conservative	0;	Mismatches 7;	Indels 0;
				Gaps 0;

QY	1	ggacctcaagcctcccaagctgagctcggaagaacctcccaacaataatcatcttgaag	60
Db	115	ggacctcgacgctcccaagctgagctcggaagaacctcccaacaataatcatcttgaag	174
QY	61	aagaatggtcttaaaatgctactagaaacaagaanaaagcttttcactctttagtatt	120
Db	175	aaatagcttttaaaatgctactagaaacaagaanaaagcttttcactctttagtatt	234
QY	121	actggtatttgcacgttaaggaattgtgatatgaaggaactgtgacacgaagaatt	180
Db	235	actggtatttgcacgttaaggaattgtgatatgaaggaactgtgacacgaagaatt	294
QY	181	caaggaatcgctctgaacactgtgtccctgaacacaaagtgtggccaaagatgtgttc	240
Db	295	caaggaatcgctctgaacactgtgtccctgaacacaaagtgtggccaaagatgtgttc	354
QY	241	taaggaatgtgtcttcggtctatgtggagaatgtcacagtgtgtgcgtgcgtgcacag	300
Db	355	taaggaatgtgtcttcggtctatgtggagaatgtcacagtgtgtgcgtgcgtgcacag	414
QY	301	gttcaagaagaacatcggtggtctccagaatgtcaagccctgtctgaactgtgcaagtgtga	360
Db	415	gttcaagaagaacatcggtggtctccagaatgtcaagccctgtctgaactgtgcaagtgtga	474
QY	361	ccgcttccagaaggaacaaattgttccagccacaagtgtacatctcggggaactgtgtcc	420
Db	475	ccgcttccagaaggaacaaattgttccagccacaagtgtacatctcggggaactgtgtcc	534
QY	421	aggaatttataagaagaacgaactgttcggtcttcaagacatgagtggtgtgtcctgtg	480
Db	535	aggaatttataagaagaacgaactgttcggtcttcaagacatgagtggtgtgtcctgtg	594
QY	481	agaccctccctccctcttaagaacccgaactgtgcacgaagtgaacctgtgaagtgtgc	540
Db	595	agaccctccctccctcttaagaacccgaactgtgcacgaagtgaacctgtgaagtgtgc	654
QY	541	gtccagcgctcccaagcccaaggaacaagaagcgctgtcgcgttatctcagcgctgtgc	600
Db	655	gtccagcgctcccaagcccaaggaacaagaagcgctgtcgcgttatctcagcgctgtgc	714
QY	601	caccgctccgtcgtccctgtctcatctctgtgtcatctatgttaagaacagtttatga	660
Db	715	caccgctccgtcgtccctgtctcatctctgtgtcatctatgttaagaacagtttatga	774
QY	661	aaagaaccccaagcgtggtctctgtgctcaagaagcattcaagaagaagcgtgaagtgtgc	720
Db	775	aaagaaccccaagcgtggtctctgtgctcaagaagcattcaagaagaagcgtgaagtgtgc	834
QY	721	gtgttttgaagaactcaagcttccacgaatatgtccacagaagcctgtctgcacgtgcg	780
Db	835	gtgttttgaagaactcaagcttccacgaatatgtccacagaagcctgtctgcacgtgcg	894
QY	781	tgaactagtcaagactgtgcggtgcggtgtgcgtgtcttccatcatgtctgtgaagagtc	840
Db	895	tgaactagtcaagactgtgcggtgcggtgtgcgtgtcttccatcatgtctgtgaagagtc	954
QY	841	cttgaagcccaaaccccgcgacgtcttggtgtgggtgtgaattctggcgcaagcttcaagc	900
Db	955	cttgaagcccaaaccccgcgacgtcttggtgtgggtgtgaattctggcgcaagcttcaagc	1014
QY	901	aaagaacgaagcccaagccgaaggaatgtgtgcgaattcttcgtgaatccatcaagcgtgc	960
Db	1015	aaagaacgaagcccaagccgaaggaatgtgtgcgaattcttcgtgaatccatcaagcgtgc	1074
QY	961	catctgtgcgaagtttccagatgcctgtgcctctgtatgcagaatcccaatgggtgtgtgaca	1020

D _b	1075	CATCTGTGGCGGAGTTTTCACATGCTCGTGCCCTCTGATGCAGAAATCCCATGGGTGGACAAA	113340
O _y	1021	cactcttcttttgyagactcttatccctgaactcactgtagaagaacatctctcaatcc	1080
D _b	1135	CATCTCTTTTGTGACTCTATCCTGAACACTGAGAGAAGCAATCATCTCTCAATCC	1194
O _y	1081	agaacttgaaagctccaacgcctcttgattccaatagcagtcacaagtgtgtgtggggc	1140
D _b	1195	AGAACTTGAAGGCTCAACGCTTTTGATTCAAATACCACTCAAGATTGGTGGTGGGGC	1254
O _y	1141	tgttcacagtcacgtcatcattctgaaaacttaagaagcactactgattctatagatacaa	1200
D _b	1255	TGTTCCAGTCCAGTCACTCATCTCTAATAAACCTTACAGCAGCTACTGATTATCTAGATATA	1314
O _y	1201	caacacacgttgttagaatcacagcatcaaacctaagaatgacctactaactatgatagaagccagctaga	1260
D _b	1315	CAACACACTGTTGAATACACATCAACAATCAGATGACACTAATTAAGAGAACCACTAGAA	1374
O _y	1261	tcagaagaagctgagcgctctgtatccaccacagcaactagaagctccctccaggtta	1312
D _b	1375	TCAAGGAAGTGGCGCTGTATCCACCACAGCACTCAGAGTCCCTCCAGGAA	1426

	RESULT	4	:	:	:
ID	V33361	standard; cDNA to mRNA.	1704 BP.		
AC	V33361;				
DE	02-DEC-1998	(first entry)			
Nucleotide sequence of human alpha-OARF065.					
KW	Human: alpha-OARF065; stroma cell; antibody: inflammatory;				
KM	Cytokine-mediated disease; rheumatism; ulcerative colitis; SS.				
OS	Homo sapiens.				
FH	Key	Location/Qualifiers			
FT	CDS	: 45..1298			
FT		/tag= a			
FT	sig_peptide	/product= "human alpha-OARF065 protein"			
FT		: 45..119			
FT		/tag= b			
FT	mat_peptide	: 120..1295			
FT		/tag= c			
FT		/transl_except= (pos:711..713, aa= Pro)			
FT		/transl_except= (pos:714..716, aa= Arg)			
PN	M09838304-A1.				
PD	03-SEP-1998.				
PE	26-FEB-1998; J00799.				
PR	27-FEB-1997; JP-043143.				
PA	(ONOY) ONO PHARM CO LTD.				
PI	Fukushima D. Konishi M, Tada H;				
PJ	WPI; 98-481205/41.				
DR	P-PSDS; W70386.				
PT	Membrane polypeptide expressed by human stroma cells, and antibodies				
PT	recognising it - for treatment of inflammatory and other				
PT	c cytokine-mediated diseases.				
PS	Claim 5; Pages 31-32; 54pp; Japanese.				
CC	This is the nucleotide sequence of the human alpha-OARF065, used in				
CC	the method of the invention. The process involves the use of peptides				
CC	expressed by stroma cells, and its antibodies are used for in the				
CC	prevention and treatment of inflammatory and other cytokine-mediated				
CC	diseases such as rheumatism, ulcerative colitis.				
SO	Sequence 1704 BP; 429 A; 426 C; 430 G; 419 T;				
Query Match	85.2%; Score 1268.4; DB 1; Length 1704;				
Best Local Similarity	99.1%; Pred. No. 0;				
Matches 1275; Conservative	0; Mismatches 11; Indels 0; Gaps				
QY	27 gaagaactctcaacaataatatacattgtaagaagaagatgctttaaaagtgtctactag	86			
DY	7 GTAGAGCTCCTCAACAATAATTAACATTGTGGATGAAGAAGAAATGCGTTTAAAGTCCTACTAG	66			
	aacaagagaaaacgltttcaacctttagtatattactaggcatttgcatgttaaagtga	146			

```

Db 67 AACAAAGAAAAGCTTTTTCACCTTTTACTATTACTAGGCTATTGTCATGTAAGTGA 126
QY 147 cttgtgaatcaggaagactgttagaagaagaattcagggaatcgtctcgaactgtctc 206
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 127 CTGTGTAAACAGGAGACTGTATGACAGCAAGAAATTACAGGAAATCGGTCGTGAAACGTGTTC 186
QY 207 ccgtgaaccaggtgtgtggccaggacatgtgtcttaaggaattgtgcttcggtatgtgg 266
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 187 CCGCAACACAGTGTGGCCAGGACATGAGTGTCTAAGAAATGTGGCTTCGGCTATGGGG 246
QY 267 aggaatgacagtggtgtgctgtgacggttcacaggttcagaagaagatgtggcttcaga 326
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 247 AGGATGACAGTGTGTATGACGTCCGCTGACACAGCTTCAGAGAGACTGGGCTTCCAGA 306
QY 327 aatgcaaacctgtctgtgactgtgcagtggtgaaccgcttcacaagaagcaaatgttcag 386
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 307 AATGCAAGCCCTGTCTGTGAGTGGCAGATGTGAACCCGCTTCAGAAAGCAATTTGTTGAG 366
QY 387 ccacagtgatgcatactgtcgggagactgtctgcagaatttataggagaagaagaacttg 446
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 367 CCACCAATGATGCCATCTGCGGGGACTGCTGCCAGATTTTATAGGAAGACGAACCTTG 426
QY 447 tggagcttcaagacatgagtggtgtgcttgtgtgagaaacctccctcccttaagaacgc 506
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 427 TCGGCTTTCAAGACATGAGTGTGTGCTGTGTGAGAACCTTCCTCTTACGAACCGC 486
QY 507 actgtgcagcaaggtcaacctcgttgaagatcgcttcacagggcttcagccacagggaga 566
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 487 ACTGTGCAAGCAAGTCACTCTGTGAAGATCGGCTCCAGCGCTCCAGCCCAAGGGAGCA 546
QY 567 cggagctgtgtgcgttatctgtcagcgctctgcgaaccgtctcgtgacctgtctacc 626
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 547 CCGGCTGTGGCGCGCTTATCTGACGAGCTGTGGCCACGCTCTGCTGCTGCTGCTCATCC 606
QY 627 tctgtgcatctatgttagaagaagaagtttatggaaagaaccagctgtgtctctgtg 686
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 607 TCTGTGATCTATTGTATGAGAGACAGTTTATGAGAAACCAAGCTGTGTGTGGGT 666
QY 687 cacaagacatcattacaagaagaactgagctgtgtgttttgacagacactagctcagc 746
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 667 CACAGGACATTCATACACGCGCTCTGAGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 726
QY 747 aatatgccacaagagcctgtgtcagtgccgctgtgactcagtgacagctgtgcggcg 806
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 727 AATATGCCACAGAGCCTGTGCTGACGTGCGCCGCTGACTCAGTCAAGACTGCGGGCCG 786
QY 807 tggcctgtcccccacatcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 866
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 787 TGGCTGTGCTCCATCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 846
QY 867 gttgtgggtgtcattctgtcagccagctcttcaggaagaagaagccagccagccagggaga 926
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 847 GTTGTGGGGTGCATTTCTGCAGCCAGTCTTCAGGCAAGAAAGCCAGGCCCGGGAGGA 906
QY 927 tgggtgcgaacttctcgtgacccctcagcagcagctcagctgtgtgtgtgtgtgtgtgt 986
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 907 TGGGCGAGACTTCTGTGGATCCCTCAAGCAGTCCATCTGTGGGAGTTTCAGATGCTT 966
QY 987 ggcctcgtgagcaaatcccatcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 1046
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 967 GGCTCTGATGCAAAATCCATGGGTGTGTGCAACATCTTTTGTGACATCTATCTCTG 1026
QY 1047 aactcattgagaagaacatcattctctcattcagagaactggaagctcaacgctcttgg 1106
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1027 AACTCATGTGGAAGACATTTATTTCTCTCAATCCAGAACTTGAAGCTCAACGCTTTTGG 1086
QY 1107 attcaaatagcagtcagatttgggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 1166
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1087 ATTCAATAAGCAGTCAAGATTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1146
QY 1167 actttaaagcagcgtactgattatctatgatatataacacacacgtgttagaatcagatcaa 1226
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1147 ACTTTACAGCAGCTACGTATTTATCTGTATATACACACACTGTGTGAATCAGCATCAA 1206

```

```

QY 1227 ctcagatgtactaactatagaaagccagctagatcaggaagtggtgcgtcacc 1286
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1207 CTCAGATGCACTATCATATGAAAGCCAGCTAGATCAGAGAGTGGCGCTATATATCACC 1266
QY 1287 cagccactcngaagtcctccaggtta 1312
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1267 CAGCCACTCAGACGTCCTCCACAGGA 1292
RESULT 5
X23413
ID X23413 standard; DNA; 1678 BP.
AC X23413;
DT 18-JUN-1999 (first entry)
DE Mouse MAP04-alpha (long) DNA.
KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;
    developmental abnormality; gestational abnormality; prostate cancer;
    APO6; APO8; APO9; TNRL-1; TNRL-3; diagnosis; treatment; therapy; disease;
    cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
    apoptosis; mouse; MAP04-alpha; ss.
OS Mus sp.
FH key
FT Location/Qualifiers
FT CDS
FT /tag= a
FT /product= "MAP04-alpha"
PN WO9111791-A2.
PD 11-MAR-1999.
PF 04-SEP-1998; U18393.
PR 05-SEP-1997; U3-924634.
PI (UNIV ) UNIV WASHINGTON.
PI Chaudhary PM.
PI WPI: 99-205191/17.
DR P-PSDB; W93579.
PT New Tumor Necrosis Factor family receptor polypeptides and ligands -
    useful for diagnosis and treatment of prostate cancer and
    developmental or gestational abnormalities
PT Example IV; Fig 7A; 156pp; English.
PS CC This invention describes isolated Tumor Necrosis Factor (TNF) family
    receptor polypeptides: APO4, APO6, APO8 and APO9 or their active
    fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
    their active fragments. APO4 is useful for diagnosing prostate cancer
    by determining levels of APO4 in an individual. Prostate cancer can also
    be treated using APO4 selective binding agents linked to a therapeutic
    moiety. APO4 polypeptides are also useful for identifying selective
    binding agents. APO4 polypeptides are also useful for identifying selective
    agents to the polypeptide/active fragment which is extracellular, or
    expressed on the cell surface. The binding is preferably performed in
    vivo. APO4 polypeptides/ active fragments are also useful for screening
    CC for agonists and antagonists by binding and observing the change in APO4
    activity. Effective pharmacological agents useful in diagnosis or
    treatment of disease are also identified using APO4 polypeptides/active
    fragments and APO4 signal transducer molecules that specifically interact
    with a cytoplasmic domain of APO4 and detecting a change in level of APO4
    activity. The method is performed in vivo or in vitro. APO polypeptides
    are all useful as immunogens for preparing antibodies. APO4 is also
    CC useful for diagnosis/treatment of developmental or gestational
    abnormalities. APO8 was transfected to human breast carcinoma cell line
    CC MCF-7, and induced apoptosis.
SQ Sequence 1678 BP; 371 A; 467 C; 466 G; 374 T;
Query Match 49.2%; Score 733; DB 1; Length 1678;
Best Local Similarity 74.2%; Pred. NO. 1.3e-199;
Matches 941; Conservative 0; Mismatches 325; Indels 3; Gaps 1;
QY 42 aataaatacatttataaagaagaatgtcttaagaagctactgaagaagaagaacgt 101
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 49 AATAAACAATTTGTGTAGAGCCATGCGACTCAAGGCTCTACACAGAGCGGTGC 108
QY 102 ttctactccttttagttactaggtcatttgcataatgaagtgtgtgtgtgtgtgtgtgt 161
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 109 TCTTCGCTGCAATCTCTCTACTCAACCTGCATGTAAAGTGAAGTTGGAAACCGGAG 168

```


QY 162 acgtgtgacagcaagaattcaaggatcgtgtcgtgaactgtgttccctgcaaccagtgtg 221
 DB 169 ATTCGAGGCGACGAGGATTCAGATCGATCGAACTGTCTCTCTGCAACAGTGGCG 228
 QY 222 ggcacagcagtgagtgcttcaaggaatgtgtctggtcgttcaaggagagcagtg 281
 DB 229 GACCTGGCATGAGTTGTCCAGGAATGTGCTTCGGCTATGGGAGATGACACAGTGTG 288
 QY 282 tggcgtgtccgctgtcagcaagttcaaggaagcgtgtgtctccagaatgtcaagccctgtc 341
 DB 289 TGCCCGACGAGCGCGACACCGCTTCAGGAACACGCGGCTTCAGAACTGTAAACCACTGTG 348
 QY 342 tggactgtcagtggtgtgaacgcgtcttcaagaagcaaatgttcaagcaccagtgtgtcca 401
 DB 349 CGACACTGTGGCTGTGTGAACCGCTTCAGAGGCGCAACTCTCACACACAGTGTCTGTG 408
 QY 402 tctcggggagcgtctgtccagagtttataggaagcgaactgtgtcgtgttcaagaca 461
 DB 409 TCTCGGGGAGCTGCTGCGACGATTTTACCGGAGACCAACTGTTGATTTCAGACACA 468
 QY 462 tggagtgtgtcctgtgtgaggaacctctcctcttcaagaccgcaactgtgtcagcaag 521
 DB 469 TGGAGTGTGTGCTGCGGAGACCACTCTCTCTACGAGACCACTGTATACAGCAAG 528
 QY 522 tcaacctcgtgaagatcgtgtccagcgctccagcccaagcagcagcgctgtgtgtcgtg 581
 DB 529 TGAACCTTTGTGAAGATCTCTCCACCGCTCTCCAGCCCTCGGAGACAGCGCGCTGTGCTG 588
 QY 582 ttatctgcagcgtctgtgagcagcgtctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 641
 DB 589 TCACTGTGCACTGTGTGCGACGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 648
 QY 642 gtaagagacagtttatgaaagaaacccagcgtgtgtctgtcgtgtac 689
 DB 649 GCAAGAGGCGAGTTCATGAGAGAAACCCAGCTGTAAAGCTCCATCC 696

RESULT 7

X24977 standard; cDNA: 942 BP.
 ID X24977:
 AC X24977:
 DT 05-JUL-1999 (first entry)
 DE Mouse TRAIN-R (long form) cDNA.
 KW TRAIN-R receptor; mouse; tumor necrosis factor receptor;
 KM agonist; antagonist; cancer; immunological disease; therapy;
 OS Mus musculus.
 FT Key Location/Qualifiers
 FT CDS 101..745
 FT /tag- a
 PD 18-MAR-1999.
 PF 11-SEP-1998; U19030.
 PR 06-MAY-1998; U5-084422.
 PR 12-SEP-1997; U5-058631.
 PA (BIO) BIOGEN INC.
 PI Hession C, Tschopp J;
 DR WPI: 99-229238/19.
 DR P-PSDB; W98145.
 PT New cysteine-rich tumor necrosis factor receptor
 PS Claim 1, Page 26-27; 30pp; English.
 CC The present sequence encodes a novel murine cysteine-rich tumour
 CC necrosis factor receptor family member termed TRAIN-R (long form)
 CC (see W98145). Murine TRAIN-R is expressed at high levels in brain
 CC and lung, and at lower levels in liver, skeletal muscle and kidney.
 CC Cell death can be induced by administering an agent capable of
 CC inhibiting the binding of TRAIN-R to its ligand. A claimed method
 CC of treating, or reducing, the advancement, severity or effects of
 CC an immunological disease in a mammal comprises administering a
 CC pharmaceutical composition which comprises a TRAIN-R blocking agent,
 CC e.g. soluble TRAIN-R (see also W98144). TRAIN-R can be fused to an
 CC immunoglobulin molecule to produce a fusion protein which may be
 CC targeted to various sites. It can be used in binding assays, and

CC to identify antagonists and agonists. Anti-TRAIN receptor
 CC antibodies can be used to reduce the severity of an immune response
 CC or to treat cancer. TRAIN-R blocking agents can be used to reduce
 CC the severity or effects of an immunological disease (all claimed).
 SQ Sequence 942 BP; 219 A; 264 C; 258 G; 200 T;

Query Match 30.7%; Score 457.6; DB 1; Length 942;
 Best Local Similarity 81.6%; Pred. No. 4,7e-121;
 Matches 529; Conservative 0; Mismatches 119; Indels 0; Gaps 0;

QY 42 aataaataatttgataaagaatgtcttaaaagtgtcctagataaagaagaacgt 101
 DB 78 AATAAACAATTTGTGTGAGAGCCATGACACTCAAGTCTCACTCAACAGACGCTGC 137
 QY 102 tttaactctttatagattactatagctattgtcattgataaagacttgtgtatcggag 161
 DB 138 TCTTGCTGTCATTCCT 197
 QY 162 actgtagacagcaagaattcaaggatcgtgtcgtgaactgtgtccctgcaaccagtgtg 221
 DB 198 ATTCGAGGCGACGAGGATTCAGATCGATCGATCGAACTGTCTCTGCAACAGTGGC 257
 QY 222 ggcacagcagtgagtgcttcaaggaatgtgtctgtgtgtgtgtgtgtgtgtgtgtgtgt 281
 DB 258 GACCTGGCATGAGTGTGTCCAAAGATGTGGCTTCGGCTATGGGAGAGATGACAGTGTG 317
 QY 282 tggcgtgtcgtgtgtcagcaagttcaaggagactgtgtgtgtgtgtgtgtgtgtgtgtgtgt 341
 DB 318 TGCCCTGCAAGCGCGACCGGTTTCAAGGAAGACTGGGTTTCCAGAGTGTAAACCATGTG 377
 QY 342 tggactgtcagtggtgtgaacccgcttccagaagcaattgtgtcagccacagtgatgtcca 401
 DB 378 CGGACTGTGCTGTGTGAACCGCTTTCAGAGGCGCAACTGTCTACACACAGTGTGTG 437
 QY 402 tctcggggagcgtctgtcaggaatttataagaagaagcaactgtgtgtgtgtgtgtgtgtgt 461
 DB 438 TCTGCGGGGAGCTGCTGCGACGATTTTACCGGAGAACCAACTGTGTGTGTGTGTGTGTGT 497
 QY 462 tggagtgtgtgtcctgtgtgagaccctcctcctcttaagcaagcagcactgtgtcagcaag 521
 DB 498 TGGAGTGTGTGCTGCGGAGACCACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 557
 QY 522 tcaacctcgtgaagatcgtgtccagcgctccagcccaagcagcagcgctgtgtgtcgtcgt 581
 DB 558 TGAACCTTTGTGAAGATCTCTCTCCACCGCTCTCCAGCCCTGTGGACAGCGCTGTGCTG 617
 QY 582 ttatctgcagcgtctgtgagccagcgtctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 641
 DB 618 TCACTGTGCACTGTGTGCGACGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 677
 QY 642 gtaagagacagtttatgaaagaaacccagcgtgtgtctgtcgtgtac 689
 DB 678 GCAAGAGGCGAGTTCATGAGAGAAACCCAGCTGTAAAGCTCCATCC 725

RESULT 8

V11422 standard; cDNA: 371 BP.
 ID V11422:
 AC V11422:
 DT 23-JUL-1998 (first entry)
 DE Human secreted protein clone AX92.3 cDNA 5'-end.
 KW Secreted protein; prevention; treatment; gene therapy; ds.
 OS Homo sapiens.
 PN W09801554-A2.
 PD 15-JAN-1998.
 PF 07-JUL-1997; U11876.
 PR 09-JUL-1996; U5-677231.
 PA (GEN) GENETICS INST INC.
 PI Bowman M, Evans C, Jacobs K, Lavallie ER, McCoy JM,
 PI Merberg D, Racie LA, Spaulding V, Treacy M;
 DR WPI: 98-110230/10.
 DR P-PSDB; W58844.

PT Secreted proteins and polynucleotides encoding them - useful to prevent, treat and ameliorate medical conditions
PS Claim 15; Page 57; 93pp. English.
CC V1142-V1142 encode fragments of a novel secreted protein derived from clone AX923 which was isolated from a human adult testes cDNA library.
CC The protein can be used to prevent, treat or ameliorate a medical condition, while the polynucleotides can be used for gene therapy.
SQ Sequence 371 BP; 83 A; 96 C; 107 G; 82 T;

Query Match	24.2%	Score 360;	DB 1;	Length 371;
Best Local Similarity	97.8%	Pred. No. 2.1e-93;		
Matches 363;	Conservative	0;	Mismatches 8;	Indels 0;
				Gaps 0;

QY	192	ctggaaactcgttcctccgcacccagctcgtggcagcagctgagctctcctaagatcgtg	251
Db	1	CTGGAATGTGTTCCTCCGCAACCAAGTGTGGGCCAGGCATGTGAATGTTCTTAAAGAAATGTG	60
QY	252	gcttcgcgtcattcgtggagagatgcacagctgtcgtgcgtcgcgcgtcgcagaagttcacaagag	311
Db	61	GCTTCGGCTATGGGAGAGATGCACAGTGTGAGCTGGCGGCTGCACAGGTTCAAGAGG	120
QY	312	actcgtggttcacagaatgcacaagccctcgtctgcacctgcgcagctcgtcgaacccgttcaga	371
Db	121	ACTGGGGCTTTCAAAAGCAAGCCCTGTCTGTGCATCGCGCAGTGTGAACCGCTTTTCAGA	180
QY	372	aggcaaatctgtcagcccaagctgatatccatctcgtcggagctgtgttcacagatttata	431
Db	181	AGGCAAAATGTGTCCGCCACAGTATGCAATCTCCGGGAGTGTGTTCCAGATTTTATA	240
QY	432	ggaagacgaacctcgtcgcgtcttcaagacatcggatcgtcgtcttgcggagaccctctc	491
Db	241	GGAAGACGAACCTGTGTGGCTTTCAAAACATGAGATGTGTGCTTTGTGGAAACCTCTCTC	300
QY	492	ctccttaacgaacgcgcactcgtgcacgaagatcaaacctctcgtgaagatcgcgtcccaagcct	551
Db	301	CTCCTTAACGAAACCCACTGTGCCAGCAAGTCACACTCTGTAATATNCGTCCACGGGCT	360
QY	552	ccaagcccaagcgg	562
Db	361	CCAGCCCAACGG	371

RESULT	9	
ID	X23417	
AC	X23417 standard; DNA; 591 BP.	
DT	18-JUN-1999 (first entry)	
DE	Mouse mAPO4-gamma DNA.	
KW	Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4; developmental abnormality; gestational abnormality; prostate cancer; APO6; APO8; APO9; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease	
KW	cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;	
KW	apoptosis; mouse; APO4-gamma; ss.	
OS	Mus sp.	
FH	Key	Location/Qualifiers
FT	CDS	95..547
FT		/*lag= a
FT		/product= "mAPO4-gamma"
PN	W09911791-A2.	
PD	11-MAR-1999.	
PF	04-SEP-1998; U18393.	
PR	05-SEP-1997; US-924634.	
PA	(UNIW) UNIV WASHINGTON.	
PI	Chaudhary PM;	
DR	WPI: 99-205191/17.	
DR	P-PSDB: W93583.	
PT	New Tumor Necrosis Factor family receptor polypeptides and ligands -	
PT	useful for diagnosis and treatment of prostate cancer and	
PT	developmental or gestational abnormalities	
PS	disclosure; Fig 7E; 156pp; English.	
CC	This invention describes isolated Tumor Necrosis Factor (TNF) family	
CC	receptor polypeptides: APO4, APO6, APO8 and APO9 or their active	

CC fragment and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
CC their active fragments. APO4 is useful for diagnosing prostate cancer
CC by determining levels of APO4 in an individual. Prostate cancer can also
CC be treated using APO4 selective binding agents linked to a therapeutic
CC moiety. APO4 polypeptides are also useful for identifying selective
CC binding agents, useful in diagnosis/treatment of disease by binding of
CC agents to the polypeptide/active fragment which is extracellular, or
CC expressed on the cell surface. The binding is preferably performed *in*
CC vivo. APO4 polypeptides/active fragments are also useful for screening
CC for agonists and antagonists by binding and observing the change in APO4
CC activity. Effective pharmacological agents useful in diagnosis or
CC treatment of disease are also identified using APO4 polypeptides/active
CC fragments and APO4 signal transducer molecules that specifically interact
CC with a cytoplasmic domain of APO4 and detecting a change in level of APO4
CC activity. The method is performed *in vivo* or *in vitro*. APO polypeptides
CC are all useful as immunogens for preparing antibodies. APO4 is also
CC useful for diagnosis/treatment of developmental or gestational
CC abnormalities. APO8 was transfectsed to human breast carcinoma cell line
CC MCF-7, and induced apoptosis. 145 C; 175 G; 123 T;
50 Sequence 591 BP; 140 A;

Query Match	21.8%	Score 325;	DB 1;	Length 591;
Best Local Similarity	78.0%	Pred. No. 2.8e-83;		
Matches 391;	Conservative	0;	Mismatches 110;	Indels 0;
			Gaps	0

QY	38	caacaataaataaccccttggataaagaagatgctgtcttaaaatgctcaacacagacaagaagaaa	97
Db	68	CAGGAATTAACACGTTTGATGGAGAGCCATG6CACTCAAGGTCCTCACTCAACAGAGACG	127
QY	98	acgttttcaactctcttaagtattactactagctatgtctatgctacgttaaagtgtacttggaaatca	157
Db	128	GTGCTCTTCGCTGGCAATCTCTTCCTCACTCACTCGACCTGGCAGTAAAGTAAGTATGGGAAC	187
QY	158	ggagactgtatacagacaagaattcaaggatcgcgtgtcgaacactgtgtccctgcaaccag	217
Db	188	GGAAATTGGCAGCGCAGAGGAATTTAAAGATCGATCTGGAAACTGTCTCTTGCAAAACAG	247
QY	218	tgttggcccaaggcatgtgaagtgtgtctaaagaaatgtgcttggctatgtagggagatgcaag	277
Db	248	TGCGGACCTGGCAAGGAGATTGTCCAAAGAAATGTGGCTTCGGCTATATGGGGAGAGTGCACAG	307
QY	278	tgttggcgtgtccggtgcgcacaggttcaagaagagactggtggcttccagaatgcgaagccc	337
Db	308	TGTGTGCCCTTCACAGCCGCGCACCGGTTTAAGAGAGACTGGGGTTTCCAGAACTGTAAAGCA	367
QY	338	tgtcttgactgtcgcaatgtgtgaacccgcttccagaaggaacaaattgttcaagcccaacagtat	397
Db	368	TGTCCGACACTGTGGCGTGGTGAACCGGTTTCAGAGGGCCCAACTAGTCTCACACACAGATAT	427
QY	398	gcaactcgcgcggagactcgtctggacagagatttatatagagaagacgaactgtgcggtttcaa	457
Db	428	GCTGTCTGCGGGGACCTGCTCTGCGAGATTTTACCGGAAAGACCAAACTGGTGTGGTTTCAA	487
QY	458	gaacatgaagtgtgtgccttgbtgaagacccctcctctccttaagaaaccgcacgtgtgccagc	517
Db	488	GACATGTAGATGTGTGGCCTCGGGAGAGACCACTCCTCTCCCTACGAAACACACTGTGAATGA	547
QY	518	aagttcaaacctcgtgaagatc	538
Db	548	TGTGCCCAAGTGGCAGCAGAC	568

RESULT	10	*
ID	X24976	standard; cDNA; 599 BP.
AC	X24976	
DT	05-JUL-1999	(first entry)
DE	Mouse TRAI-N-R (short form)	cDNA.
KW	TRAI-N-R; receptor; mouse;	tumour necrosis factor receptor;
KW	agonist; antagonist; cancer;	immunological disease; therapy;
KW	cytostatic; ss.	
OS	Mus musculus.	

Key	Location/Qualifiers
FT CDS	104..556
FT	/*tag= a
PD	MO9913078-A1.
PD	18-MAR-1999.
PF	11-SEP-1998; UI9030.
PR	06-MAY-1998; US-084422.
PR	12-SEP-1997; US-058631.
PI	(BioV) BIOGEN INC.
PI	Hession C, Tschopp J;
DR	WPJ; 99-229238/19.
DR	P-PSDB: W98144.
PT	New cysteine-rich tumor necrosis factor receptor
PS	Claim 1, Page 26; 30pp; English.
CC	The present sequence encodes a novel murine cysteine-rich tumour
CC	necrosis factor receptor family member termed TRAIN-R (short form)
CC	(see W98144). This putative natural soluble form of murine TRAIN-R
CC	may inhibit signalling by the full-length TRAIN-R (see W98145).
CC	Murine TRAIN-R is expressed at high levels in brain and lung, and
CC	at lower levels in liver, skeletal muscle and kidney. Cell death
CC	can be induced by administering an agent capable of inhibiting the
CC	binding of TRAIN-R to its ligand. A claimed method of treating, or
CC	reducing, the advancement, severity or effects of an immunological
CC	disease in a mammal comprises administering a pharmaceutical
CC	composition which comprises a TRAIN-R blocking agent, e.g. soluble
CC	TRAIN-R. TRAIN-R can be fused to an immunoglobulin molecule to
CC	produce a fusion protein which may be targeted to various sites.
CC	It can be used in binding assays, and to identify antagonists and
CC	agonists. Anti-TRAIN receptor antibodies can be used to reduce the
CC	severity of an immune response or to treat cancer. TRAIN-R
CC	blocking agents can be used to reduce the severity or effects of an
CC	immunological disease (all claimed).
SQ	Sequence 599 BP; 149 A; 147 C; 180 G; 123 T;
Query Match	21.8%; Score 325; DB 1; Length 599;
Best Local Similarity	78.0%; Pred. No. 2.8e-83;
Matches 391; Conservative	0; Mismatches 110; Indels 0; Gaps 0;
0y	38 caacataaatcatttgataagaagaatgggttaaaagtctactagaacaagaana 97
Db	77 CAGGAATTAACACGTTTGCTGAGAGCCATGACATCAAGTCTTACTTACACAGAGC 136
0y	98 acgttttcaactctttagtattactaggctaattgctcatgtaagaatgacttgtaata 157
Db	137 GAGCTCTTCGCGCATCTCTCTCTACACACCTGGCATGTAAAGTAGTGGCAAC 196
0y	158 ggaagactgtagaacagaagaatlcagggatcggtctggaactgtgtccctgcaacag 217
Db	197 GGAGATTGCGACGACAGCAAGAAATTCAGATCATCTGAAACTGTGTCTTCGCAACAG 256
0y	218 tttgggcaggagatgagttgtcttaagaaatgtgcttgctatagggagaatgaaag 277
Db	257 TCGGGAACCTGGGATGGAGATTGTCCAAGGATGTGGCTTATGGCTATGGGAGATGTGACAG 316
0y	278 tgtgtgcgcgtgcgcgcgtgcacaggttccaaggagaaatggtggtctccagaatcgaagccc 337
Db	317 TGTGTGTCCTTCGACAGGCCGACCGGTTCAAGGAAGACTGGGGTTTCCAGAAGTGTAAAGCA 376
0y	338 tgtctggaactgcgcagttgtgtgaacgcgtcttcagaaggaacaattgttcaagccacagtgat 397
Db	377 TGTGCGGAACTGTGCGCTGTGTAACCGCTTTCAGAGGCGCAACTGCTCAACACCACTGAT 436
0y	398 gccactctgaggagactgcgtctgcagaattttatagaanaacgaagaattgtcgcttcaa 457
Db	437 GGTGTCTGGGGGACGCTCTGCCAGGATTTTACCGGAATAACCAAACTGTGTGGTTTCAA 496
0y	458 gacatggaagtgtgtgcctgttgagaacccctccctcccttaagaacgcgaactgtgcagc 517
Db	497 GACATGGAATGTGTGTGCTGCGGAGAGCCACACTCTCTCTCTACGAACACACACTGTAGTGA 556
0y	518 aaggtcaacctcgtgaagatc 538

D8	557	TGTGGCAAGTGGCAGACGACC	577
RESULT	11	.	
ID	X23416		
AC	X23416	standard; DNA; 1133 BP.	
DT	18-JUN-1999	(first entry)	
DE	Rat rAPO4-alpha factor.		
KW	Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;		
KM	developmental abnormality; gestational abnormality; prostate cancer;		
KW	APO6; APO8; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease;		
KM	cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;		
KW	apoptosis; rat; APO4-alpha; ss.		
OS	Rattus sp.		
FH	Key	Location/Qualifiers	
FT	CDS	1..330	
FT		/*tag= a	
FT		/product= "rAPO4-alpha"	
FN	W09911791.A2.		
PD	11-MAR-1999.		
PF	04-SEP-1998; U18393.		
PR	05-SEP-1997; US-924634.		
PA	(UNITV) UNIV WASHINGTON.		
PI	Chaudhary PM.		
DR	WPI: 99-205191/17.		
P-PSDB:	W93582.		
PT	New Tumor Necrosis Factor family receptor polypeptides and ligands -		
PT	useful for diagnosis and treatment of prostate cancer and		
PT	developmental or gestational abnormalities		
PS	Example IV; Fly 7D; 156pp; English.		
CC	This invention describes isolated Tumor Necrosis Factor (TNF) family		
CC	receptor polypeptides: APO4, APO6, APO8 and APO9 or their active		
CC	fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or		
CC	their active fragments. APO4 is useful for diagnosing prostate cancer		
CC	by determining levels of APO4 in an individual. Prostate cancer can also		
CC	be treated using APO4 selective binding agents linked to a therapeutic		
CC	moleity. APO4 polypeptides are also useful for identifying selective		
CC	binding agents, useful in diagnosis/treatment of disease by binding of		
CC	agents to the polypeptide/active fragment which is extracellular, or		
CC	expressed on the cell surface. The binding is preferably performed in		
CC	vivo. APO4 polypeptides/ active fragments are also useful for screening		
CC	for agonists and antagonists by binding and observing the changer in APO4		
CC	activity. Effective pharmacological agents useful in diagnosis or		
CC	treatment of disease are also identified using APO4 polypeptides/active		
CC	fragments and APO4 signal transducer molecules that specifically interact		
CC	with a cytoplasmic domain of APO4 and detecting a change in level of APO4		
CC	activity. The method is performed in vivo or in vitro. APO polypeptides		
CC	are all useful as immunogens for preparing antibodies. APO4 is also		
CC	useful for diagnosis/treatment of developmental or gestational		
CC	abnormalities. APO8 was transfected to human breast carcinoma cell line		
CC	MCF-7, and induced apoptosis.		
SQ	Sequence 1133 BP; 278 A; 275 C; 258 G; 296 T;		
Query Match	8.1%; Score 120.2; DB 1; Length 1133;		
Best Local Similarity	62.8%; Pred. No. 1.3e-24;		
Matches 204; Conservative	0; Mismatches 118; Indels 3; Gaps 1;		
OY	tggtcctctgatagcagaatcccatcggtggatgaacaacatccttttgyactcttatcct	1045	
DB	1 tggcctctgatgcagaaatcctctgggtgg--acagctctctgtagactcttatcct	57	
OY	gaattcacatgaggaagacattatctcttcacatccaagaattggaagctcaacgctcttg	1105	
DB	58 gaacctaccatgaggaaagatratcataattccctcaattccggaaaatgaagctcaacatcttg	117	
OY	gattcaaatagatgcagaagtcttggtgggctgttcacagctccagctcatctatcgaa	1165	
DB	118 gatttccaaatggtggtcagatatctggctggggacgctgccctccagattcttctggagatttt	177	
OY	aacttacgcgcgactactgattatctatataaacacacacacgcgtgtagatcagcatca	1225	

Db 178 CAAGAAATACAGACACCTAGATATGATGACGCGATAGCGTGTGGGAGCAACCCCTA 237
Oy 1226 actcagatgactaactatgagaagccagctagatcagagagatggtcgtcctcacc 1285
Db 238 GCTCAGGATGCTCAAGGAGCTCCAGCAGAGGCTGTGGAGCCAGTGAACCTGAAAT 297
Oy 1286 ccagccactcagcgtccctccagcag 1310
Db 298 CTAGCCACCTCCACAGCCTTCCAGG 322

RESULT 12

X24979
ID X24979 standard; cDNA; 791 BP.
AC X24979; (first entry)
DT 05-JUL-1999
DE Clone GJ156 encoding TRAIN-R secreted form C-terminus.
KW TRAIN-R; receptor; human; tumour necrosis factor receptor;
KW agonist; antagonist; cancer; immunological disease; therapy;
KW cyostatic; ss.
OS Homo sapiens.
FH Key
FT Location/Qualifiers
FT 1..350
FT intron
FT /*tag= a
FT 351..790
FT exon /*tag= b
FT 352..444
FT CDS /*tag= c
FT /*partial
FT /product= "TRAIN-R secreted form C-terminus"
FT 45..790
FT /*tag= d
FN WO9913078-A1.
PD 18-MAR-1999.
PE 11-SEP-1998; U19030.
PR 06-MAY-1998; US-084422.
PR 12-SEP-1997; US-058631.
PI (BIOJ) BIOGEN INC.
PI Hession G, Tschopp J;
DR WPI; 99-229238/19.
DR P-PSDB; W98147.
PT New cysteine-rich tumor necrosis factor receptor
PS Claim 1; Page 28; 30pp; English.
CC The present sequence includes an exon encoding the C-terminus (see
CC W98147) of a soluble form of a novel human cysteine-rich tumour
CC necrosis factor receptor family member termed TRAIN-R. It comprises
CC clone GJ156, obtained from a Clontech human adult lung cDNA library.
CC The encoded 30-amino acid C-terminal peptide is identical to amino
CC acids 121-149 of the composite TRAIN-R protein given in W98146 and
CC to amino acids 121-150 of the C-terminus of murine TRAIN-R short
CC form (secreted protein, see W98144). The soluble protein is
CC expected to inhibit signalling by the full-length TRAIN-R. Human
CC TRAIN-R is expressed at low levels in every tissue and cell line
CC tested thus far, with higher expression detected in heart, prostate,
CC ovary, testis, peripheral blood lymphocytes, thyroid and adrenal
CC gland. Cell death can be induced by administering an agent capable
CC of inhibiting the binding of TRAIN-R to its ligand. A clinical method
CC of treating, or reducing, the advancement, severity or effects of
CC an immunological disease in a mammal comprises administering a
CC pharmaceutical composition which comprises a TRAIN-R blocking agent,
CC e.g. soluble TRAIN-R. TRAIN-R can be used to an immunoglobulin to
CC produce a fusion protein which may be targeted to various sites.
CC It can be used in binding assays, and to identify antagonists and
CC agonists. Anti-TRAIN-R antibodies can be used to reduce the
CC severity of an immune response or to treat cancer. TRAIN-R
CC blocking agents can also be used to reduce the severity or effects
CC of an immunological disease (all claimed).
SQ Sequence 791 BP; 202 A; 189 C; 165 G; 235 T;

Query Match 6.1%; Score 90.4; DB 1; Length 791;
Best Local Similarity 89.8%; Pred. No. 3.6e-16;
Matches 97; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy 413 tgcgtccagagattttagaagaacgaacttgcgtcttcaagacatgagtggtg 472
Db 340 TTCCTCTTAAATTTTAAAGAAACGAACCTTCCGCTTCAAGACATGAGTGTGTG 399
Oy 473 cctgtgagagaccctccctcccttaccgaaccgacctgtgcagcaag 520
Db 400 CCTGTGTGAGACCTCTCTCTCTTACGACCACGACACTGTGTGTAGACG 447

RESULT 13

V11423
ID V11423 standard; cDNA; 181 BP.
AC V11423; (first entry)
DT 23-JUL-1998
DE Human secreted protein clone AX92_3 cDNA internal fragment.
KW Secreted protein; prevention; treatment; gene therapy; ds.
OS Homo sapiens.
PN WO9801554-A2.
PD 15-JAN-1998.
PE 07-JUL-1997; U11876.
PR 09-JUL-1996; US-677231.
PI (GENY) GENETICS INST INC.
PI Bowman M, Evans C, Jacobs K, Lavallie ER, McCoy JM,
PI Merberg D, Racie LA, Spaulding V, Treacy M;
DR WPI; 98-110230/10.
DR P-PSDB; W58844.
PT Secreted proteins and polynucleotides encoding them - useful to
PT prevent, treat and ameliorate medical conditions
PS Claim 13; Page 57; 93pp; English.
CC V11422-V11424 encode fragments of a novel secreted protein derived from
CC clone AX92_3 which was isolated from a human fetal brain cDNA library.
CC The protein can be used to prevent, treat or ameliorate a medical
CC condition, while the polynucleotides can be used for gene therapy.
SQ Sequence 181 BP; 43 A; 47 C; 34 G; 57 T;

Query Match 5.9%; Score 87.4; DB 1; Length 181;
Best Local Similarity 98.9%; Pred. No. 1.1e-15;
Matches 88; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 423 gattttagaagaacgaacttgcgtcttcaagacatgagtggtggtgag 482
Db 88 GATTTATAGGAACGAAACTTTCGGCTTCAAGACATGAGTGTGTGTGTGAG 147
Oy 483 accctccctcccttaccgaaccgacctgt 511
Db 148 ACCCTCTCTCTCTCTTACGACCACGACACTCT 176

RESULT 14

V86655
ID V86655 standard; cDNA; 201 BP.
AC V86655; (first entry)
DT 27-APR-1999
DE EST clone AX92.
KW Expressed sequence tag; secreted protein; haematopoiesis regulator;
KW tissue growth; activin; inhibin; tumour invasion suppressor; EST; human;
KW chemotaxis; chemokinesis; haemostasis; gene therapy; thrombolysis;
KW receptor; ligand; anti-inflammatory; tumour inhibitor; ds.
OS Homo sapiens.
PN WO9845435-A2.
PD 15-OCT-1998.
PE 10-APR-1998; U06954.
PR 10-APR-1997; US-835913.
PI (GENY) GENETICS INST INC.
PI Agostino MJ, Jacobs K, Lavallie ER, McCoy JM, Merberg D,
PI Racie LA, Spaulding V, Treacy M;
DR WPI; 99-070076/06.
PT New polynucleotides encoding human secreted proteins - derived from
PT e.g. human blood, kidney, foetal lung, placenta, testes, brain,
PT ovary, pituitary, retina and colon cDNA libraries
PS Claim 1; Page 306; 633pp; English.

CC This sequence represents an expressed sequence tag (EST), and is a
CC polynucleotide of the invention. The polynucleotides of the invention are
CC all secreted EST sequences isolated from a variety of human tissue
CC sources. The EST sequences and proteins encoded by them are predicted to
CC have useful biological activities which would make them suitable for
CC treating, preventing or ameliorating medical conditions in humans and
CC animals, although no supporting data is given. Suggested activities
CC include nutritional activity, immune stimulating or suppressing activity,
CC haematopoiesis regulating activity, tissue growth activity,
CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, cadherin/tumour invasion suppressor activity, tumour inhibition
CC activity. The EST sequences are also stated to be useful for gene
CC therapy.
SQ Sequence 201 BP; 52 A; 51 C; 38 G; 60 T;

Query Match 5.9%; Score 87.4; DB 1; Length 201;
Best Local Similarity 98.9%; Pred. No. 1.2e-15;
Matches 88; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 423 gattatagaagaacgaactgtcgccttcaagacatgagtggtgcttgag 482
|||
DB 93 GATTATAGGAACGAACTGTCTCGCTTCAAGACATGAGTGTCTGCTGTGAG 152
|||

QY 483 accctcctcctccttaagacgcactgt 511
|||
DB 153 ACCCTCCTCCTCCTTACGACCGCATCT 181
|||

RESULT 15
X23418
ID X23418 standard; DNA; 396 BP.
AC X23418;
DT 18-JUN-1999 (first entry)
DE Mouse MAP04-beta DNA.
KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;
KW development abnormality; gestational abnormality; prostate cancer;
KW APO6; APO8; APO9; TNRL-1; TNRL-3; diagnosis; treatment; therapy; disease;
KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
KW apoptosis; mouse; APO4-beta; ss.
OS Mus sp.
FH
FT Key Location/Qualifiers
FT CDS 1..289
FT /tag- a
FT /product- "MAP04-beta"

MO911791-A2.
PD 11-MAR-1999.
PE 04-SEP-1998; U18393.
PR 05-SEP-1997; US-924634.
PA (UNIW) UNIV WASHINGTON.
PI Chaudhary PM;
DR WPI: 99-205191/17.
DR P-PSDB; W93584.
PT New Tumour Necrosis Factor family receptor polypeptides and ligands -
PT useful for diagnosis and treatment of prostate cancer and
PT developmental or gestational abnormalities
PT Example IV; Fig 8; 156pp; English.

CC This invention describes isolated Tumor Necrosis Factor (TNF) family
CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active
CC fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
CC their active fragments. APO4 is useful for diagnosing prostate cancer
CC by determining levels of APO4 in an individual. Prostate cancer can also
CC be treated using APO4 selective binding agents linked to a therapeutic
CC moiety. APO4 polypeptides are also useful for identifying selective
CC binding agents, useful in diagnosis/treatment of disease by binding of
CC agents to the polypeptide/active fragment which is extracellular, or
CC expressed on the cell surface. The binding is preferably performed in
CC vivo. APO4 polypeptides/active fragments are also useful for screening
CC for agonists and antagonists by binding and observing the change in APO4
CC activity. Effective pharmacological agents useful in diagnosis or
CC treatment of disease are also identified using APO4 polypeptides/active
CC fragments and APO4 signal transducer molecules that specifically interact

CC with a cytoplasmic domain of APO4 and detecting a change in level of APO4
CC activity. The method is performed in vivo or in vitro. APO polypeptides
CC are all useful as immunogens for preparing antibodies. APO4 is also
CC useful for diagnosis/treatment of developmental or gestational
CC abnormalities. APO8 was transfected to human breast carcinoma cell line
CC MCF-7, and induced apoptosis.
SQ Sequence 396 BP; 107 A; 102 C; 108 G; 79 T;

Query Match 5.4%; Score 80.4; DB 1; Length 396;
Best Local Similarity 55.8%; Pred. No. 1.7e-13;
Matches 153; Conservative 0; Mismatches 121; Indels 0; Gaps 0;

QY 1037 tctatcctgaactcaactcagcagacatctcctcctcaatcgaacttgaagctca 1096
|||
DB 8 TCCGATCCTGAACCTCACTGAGAGATACCAATTCCTCAATCCGAAACGAAAGCGCA 67
|||

QY 1097 acgtccttgattcaaatagacagtcagattgtgtgtgtgtgtgtcagtcagtc 1156
|||
DB 68 GCATCTCTGTGATTCTCACTGCGGCGCAGAGATCTGCTGGACAGCTGCTTAGACTCTCT 127
|||

QY 1157 cattctgaactttagacagcagctcattatctatagatataacacacactgttagaa 1216
|||
DB 128 GGGAAATGTTTCAAGATCTACTGACTCACTAGACATGCTGACACTGTGACGTTGGAG 187
|||

QY 1217 tcaagcatcaactcagatgactactatgagaagccagctagagagtgagcgt 1276
|||
DB 188 CAGACGCTAGCTCAGATGCTCAAGAGACCTCAAGAGAGAGCTGGAAAGACAGGGA 247
|||

QY 1277 gtcatcaccagcagcactcagagctccctcag 1310
|||
DB 248 AACCTGATCTAGCCATGCCACAGCCTTCAGG 281
|||

Search completed: April 23, 2000, 02:02:33
Job time: 1272 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 23, 2000, 01:28:55 ; Search time 700.48 Seconds
(without alignments)
-6454.397 Million cell updates/sec

US-09-490-187-1

Title: 1489
Perfect score: 1 ggaactgcagctcccaagtc.....gtattttttaaacattt 1489
Sequence: 1 ggaactgcagctcccaagtc.....gtattttttaaacattt 1489

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 821193 segs, -1518192014 residues

Total number of hits satisfying chosen parameters: 1642386

Minimum DB seq length: 0

Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database :

GenEmbl: *
1: gb_ba1:*
2: gb_ba2:*
3: gb_om:*
4: gb_ov:*
5: gb_pat:*
6: gb_ph:*
7: gb_pl1:*
8: gb_pl2:*
9: gb_pl3:*
10: gb_pr2:*
11: gb_pr3:*
12: gb_ro:*
13: gb_sts:*
14: gb_sy:*
15: gb_un:*
16: gb_v1:*
17: em_fun:*
18: em_hum1:*
19: em_hum2:*
20: em_in:*
21: em_om:*
22: em_or:*
23: em_ov:*
24: em_pat:*
25: em_ph:*
26: em_pl:*
27: em_ro:*
28: em_sts:*
29: em_sy:*
30: em_un:*
31: em_v1:*
32: gb_htg1:*
33: gb_htg2:*
34: gb_in1:*
35: gb_in2:*
36: em_ba1:*
37: em_ba2:*
38: em_hum3:*
39: em_hum4:*
40: gb_pr4:*
41: gb_htg3:*
42: gb_htg4:*
43: gb_htg5:*
44: gb_htg6:*

45: gb_htg7:*
46: em_htg1:*
47: em_htg2:*
48: em_htg3:*
49: em_hum5:*
50: gb_pl3:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	41.2	2.8	26258	34	CELZK816	U41018 Caenorhabd
2	40.8	2.7	123416	33	AC004847	AC004847 Homo sapi
3	40.6	2.7	149	5	A08919	A08919 H.sapiens (
4	40.4	2.7	207699	42	AC012074	AC012074 Homo sapi
5	40.4	2.7	215566	42	AC012365	AC012365 Homo sapi
6	40.2	2.7	111944	32	HS0130E4	AL078582 Homo sapi
7	40.2	2.7	237316	42	AC011599	AC011599 Homo sapi
8	40	2.7	3417	7	LEGERPOT	X80908 L.esculentu
9	40	2.7	173767	10	AC002449	AC002449 Human PAC
10	39.8	2.7	2670	7	D88490	D88490 Candida alb
11	39.6	2.7	4673	34	PFASA	M84732 Plasmodium
12	39.6	2.7	299820	33	AC006803	AC006803 Caenorhab
13	39.6	2.7	299820	33	AC006871	AC006871 Caenorhab
14	39.4	2.6	1840	34	DD073686	U73686 Dictyostell
15	39.4	2.6	80331	40	AC004994	AC004994 Homo sapi
16	39.4	2.6	98864	11	HS460D19	AL031905 Human DNA
17	39.4	2.6	110000	32	CEY73F8_2	Continuation (3 of
18	39.4	2.6	216625	43	AC012671	AC012671 Homo sapi
19	39.4	2.6	322774	34	CEY73F8A	AL132862 Caenorhab
20	39.2	2.6	327720	8	CNS01BX6	AL118802 Botrytis
21	39.2	2.6	38532	1	SCS94	AL045628 Streptomy
22	39.2	2.6	184811	43	AC009399	AC009399 Homo sapi
23	39.2	2.6	321003	32	PFMAL4P3	AL035476 Plasmodiu
24	39	2.6	8586	43	AC015290	AC015290 Drosophil
25	38.8	2.6	2271	10	HSW800417	AL050106 Homo sapi
26	38.6	2.6	1582	5	A77033	A77033 Sequence 10
27	38.6	2.6	1582	5	A77035	A77035 Sequence 12
28	38.6	2.6	114467	10	AP000462	AP000462 Homo sapi
29	38.6	2.6	128537	33	AC007775	AC007775 Homo sapi
30	38.4	2.6	157825	10	CNS01DRT	AL117258 Human chr
31	38.4	2.6	196287	10	CNS0000B	AL049828 Human chr
32	38.4	2.6	200309	33	AC006910	AC006910 Caenorhab
33	38.4	2.6	207370	33	AC006798	AC006798 Caenorhab
34	38.2	2.6	163612	43	AC012213	AC012213 Homo sapi
35	38.2	2.6	178972	44	AC016369	AC016369 Homo sapi
36	38.2	2.6	182374	44	AC008114	AC008114 Homo sapi
37	38.2	2.6	204652	32	PFMAL13P6	AL049183 Plasmodiu
38	38	2.6	14433	35	AE001369	AE001369 Plasmodiu
39	38	2.6	58516	42	AC011982	AC011982 Homo sapi
40	38	2.6	173648	43	AC015861	AC015861 Homo sapi
41	38	2.6	196149	33	AC004709	AC004709 Plasmodiu
42	38	2.6	208807	41	AC004688	AC004688 Plasmodiu
43	38	2.6	259474	40	HDAC004605	AC004605 Homo sapi
44	37.8	2.5	31950	34	CEC38H2	Z35641 Caenorhabd1
45	37.8	2.5	52238	33	AC007972	AC007972 Homo sapi

ALIGNMENTS

RESULT 1
LOCUS CELZK816/c
DEFINITION Caenorhabditis elegans cosmid ZK816.
ACCESSION U41018
VERSION U41018.1 GI:1086666
KEYWORDS

CELZK815 26258 bp DNA
U41018
U41018.1 GI:1086666

INV 30-NOV-1995

REFERENCE 1 Eutheria: Primates: Catarrhini; Homiidae; Homo.
AUTHORS 1 (bases 1 to 123416)
TITLE Waterston, R.H.
JOURNAL The sequence of Homo sapiens clone
UNPUBLISHED
REFERENCE 2 (bases 1 to 123416)
AUTHORS Waterston, R.H.
TITLE Direct Submission
JOURNAL Submitted (12-JUN-1998) Genome Sequencing Center, Washington
University School of Medicine, 4444 Forest Park Parkway, St. Louis,
MO 63108, USA

COMMENT
* NOTE: This is a 'working draft' sequence. It currently
* consists of 10 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.

1 1580: contig of 1580 bp in length
* 1581 1598: gap of unknown length
* 1599 3512: contig of 1914 bp in length
* 3513 3530: gap of unknown length
* 3531 3531
* 6664: contig of 3134 bp in length
* 6665 6682: gap of unknown length
* 6683 11088: contig of 4406 bp in length
* 11089 11106: gap of unknown length
* 11107 20349: contig of 9243 bp in length
* 20350 20367: gap of unknown length
* 20368 33197: contig of 12830 bp in length
* 33198 33215: gap of unknown length
* 33216 43072: contig of 9857 bp in length
* 43073 43090: gap of unknown length
* 43091 65746: contig of 22656 bp in length
* 65747 65765: gap of unknown length
* 65765 85286: contig of 19504 bp in length
* 85286 85287: gap of unknown length
* 85287 123416: contig of 38130 bp in length.

FEATURES
source 1. 123416
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="DJ0647J21"

BASE COUNT 30903 a 29142 c 29866 g 33343 t 162 others

ORIGIN

Query Match 2.7%; Score 40.8; DB 33; Length 123416;
Best Local Similarity 59.5%; Pred. No. 14;
Matches 69; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 1365 acctgtccagcagatagattgggggaaccgagatgtttttttgcatctta 1424
|||||
Db 34675 ACCTGTTCAGAGGCGCGAGCAAGTCAAGAGAGTGTCTCTTTTAAATTTTA 34616
|||||

QY 1425 ataattctatagtgtgagatgttttaataaattccaagatctttta 1480
|||||
Db 34615 AAAAATTTTAAATATATATATTTTACTTAAATTTACGATTTATTTTA 34560
|||||

RESULT 3
LOCUS A08919 149 bp DNA PAT 02-SEP-1993
DEFINITION H.sapiens (haplotype 2A, allele MS32, isolate English, serial
number 30) minisatellite sequence.
ACCESSION A08919
VERSION A08919.1 GI:411841
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 149)

AUTHORS Jeffreys, A.J.
TITLE Extended nucleotide sequences
JOURNAL Patent: EP 0370719-A 74 30-MAY-1990;
IMPERIAL CHEMICAL INDUSTRIES PLC
FEATURES
source 1. 149
/organism="Homo sapiens"
/db_xref="taxon:9606"

BASE COUNT 100 a 0 c 0 g 49 t

ORIGIN

Query Match 2.7%; Score 40.6; DB 5; Length 149;
Best Local Similarity 66.7%; Pred. No. 6.9;
Matches 58; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1403 agttttttttgcatcttaattcttctatgttgtaagatgttttaataa 1462
|||||
Db 92 ATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATA 33
|||||

QY 1463 attcaagatctttttaaaactt 1489
|||||
Db 32 ATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATA 6
|||||

RESULT 4
LOCUS AC012074
DEFINITION Homo sapiens clone H90458N05, *** SEQUENCING IN PROGRESS ***; 40
unnumbered pieces.
ACCESSION AC012074
VERSION AC012074.1 GI:6067201
KEYWORDS HTGS_PHASE1.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 207699)
AUTHORS Waterston, R.H.
TITLE The sequence of Homo sapiens clone
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 207699)
AUTHORS Waterston, R.H.
TITLE Direct Submission
JOURNAL Submitted (19-OCT-1999) Genome Sequencing Center, Washington
University School of Medicine, 4444 Forest Park Parkway, St. Louis,
MO 63108, USA

COMMENT
* NOTE: This is a 'working draft' sequence. It currently
* consists of 40 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.

1 2641: contig of 2641 bp in length
* 2642 2660: gap of unknown length
* 2661 5448: contig of 2788 bp in length
* 5449 5467: gap of unknown length
* 5468 9447: contig of 3980 bp in length
* 9448 9466: gap of unknown length
* 9467 13258: contig of 3792 bp in length
* 13259 13277: gap of unknown length
* 13278 17777: contig of 4500 bp in length
* 17778 17796: gap of unknown length
* 17797 22203: contig of 4407 bp in length
* 22204 22222: gap of unknown length
* 22223 25932: contig of 3710 bp in length
* 25933 25951: gap of unknown length
* 25952 29791: contig of 3840 bp in length
* 29792 29810: gap of unknown length
* 29811 33884: contig of 4074 bp in length
* 33885 33903: gap of unknown length

QY	1395	CGTGAAGAGGCTTTCTTTTGGCCTCTTAATCTTATGTTAGATGCTT	1454
Db	127387	CGTGGCTATTATTATTATTATTAACTATAATCTTCGGAAATTGCTTAGAATATTATG	127446
QY	1455	taaaataattcaagatttttttaaaaa	1484
Db	127447	TAAAAATATATCTAATATTATTATTATTA	127476
RESULT	5		
AC012365/c			
LOCUS			
DEFINITION	AC012365 215566 bp DNA	HMG	25-OCT-1999
ACCESSION	Homo sapiens clone NH0459C22, *** SEQUENCING IN PROGRESS ***		37
VERSION	AC012365.1		
KEYWORDS	HTG: HTGS_PHASE1.		
SOURCE	human.		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;		
AUTHORS	Eutheria; Primates; Catarrhini; Homindae; Homo.		
REFERENCE	1 (bases 1 to 215566)		
AUTHORS	Waterston, R.H.		
TITLE	The sequence of Homo sapiens clone		
JOURNAL	Unpublished		
REFERENCE	2 (bases 1 to 215566)		
AUTHORS	Waterston, R.H.		
TITLE	Direct Submission		
JOURNAL	Submitted (25-OCT-1999) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA		
COMMENT	<p>NOTE: This is a 'working draft' sequence. It currently consists of 37 contigs. The true order of the pieces is not known and their order in this sequence record is arbitrary. Gaps between the contigs are represented as runs of N, but the exact sizes of the gaps are unknown. This record will be updated with the finished sequence as soon as it is available and the accession number will be preserved.</p>		
	1	6252: contig of 6252 bp in length	
	6253	6271: gap of unknown length	
	6272	13316: contig of 7045 bp in length	
	6317	13335: gap of unknown length	
	13336	21229: contig of 7894 bp in length	
	21230	21248: gap of unknown length	
	21249	27594: contig of 6346 bp in length	
	27595	27613: gap of unknown length	
	27614	35972: contig of 8359 bp in length	
	35973	35991: gap of unknown length	
	35992	45671: contig of 9680 bp in length	
	45672	45690: gap of unknown length	
	45691	58710: contig of 13020 bp in length	
	58711	58729: gap of unknown length	
	58730	71377: contig of 12648 bp in length	
	71378	71396: gap of unknown length	
	71397	90008: contig of 18612 bp in length	
	90009	90027: gap of unknown length	
	90028	121592: contig of 31565 bp in length	
	121593	121610: gap of unknown length	
	121611	124080: contig of 2470 bp in length	

Query Match	2.7%	Score 40.4;	DB 42;	Length 207699;
Best Local Similarity	65.6%	Pred. No. 19;		
Matches 59; Conservative	0;	Mismatches 31;	Indels 0;	Gaps 0

	AC012365	215566 bp	DNA	HFG	25-OCT-1999
*	Homo sapiens clone	NH0459C22,	*** SEQUENCING IN PROGRESS ***		37
*	uncloned pieces.				
*	AC012365				
*	AC012365.1	GI:6114946			
*	HTG; HFGS_PHASE1.				
*	human.				
*	Homo sapiens				
*	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;				
*	Eutheria; Primates; Catarrhini; Homnidae; Homo.				
*	1 (bases 1 to 215566)				
*	Waterston,R.H.				
*	The sequence of Homo sapiens clone				
*	Unpublished				
*	2 (bases 1 to 215566)				
*	Waterston,R.H.				
*	Direct Submission				
*	Submitted (25-OCT-1999) Genome Sequencing Center, Washington				
*	University School of Medicine, 4444 Forest Park Parkway, St. Louis,				
*	MO 63108, USA				
*	* NOTE: This is a 'working draft' sequence. It currently				
*	* consists of 37 contigs. The true order of the pieces				
*	* is not known and their order in this sequence record is				
*	* arbitrary. Gaps between the contigs are represented as				
*	* runs of N, but the exact sizes of the gaps are unknown.				
*	* This record will be updated with the finished sequence				
*	* as soon as it is available and the accession number will				
*	* be preserved.				
*	1	6252: contig of 6252 bp in length			
*	6253	6271: gap of unknown length			
*	6272	13316: contig of 7045 bp in length			
*	13317	13335: gap of unknown length			
*	13336	21229: contig of 7894 bp in length			
*	21230	21248: gap of unknown length			
*	21249	27594: contig of 6346 bp in length			
*	27595	27613: gap of unknown length			
*	27614	35972: contig of 8359 bp in length			
*	35973	35991: gap of unknown length			
*	35992	45671: contig of 9680 bp in length			
*	45672	45690: gap of unknown length			
*	45691	58710: contig of 13020 bp in length			
*	58711	58729: gap of unknown length			
*	58730	71377: contig of 12648 bp in length			
*	71378	71396: gap of unknown length			
*	71397	90008: contig of 18612 bp in length			
*	90009	90027: gap of unknown length			
*	90028	121592: contig of 31565 bp in length			
*	121593	121610: gap of unknown length			
*	121611	124080: contig of 2470 bp in length			
*	124081	124098: gap of unknown length			
*	124099	126360: contig of 2262 bp in length			
*	126361	126378: gap of unknown length			
*	126379	129231: contig of 2853 bp in length			
*	129232	129249: gap of unknown length			
*	129250	131412: contig of 2163 bp in length			
*	131413	131430: gap of unknown length			
*	134031	134035: contig of 2605 bp in length			
*	134036	134053: gap of unknown length			
*	134054	136191: contig of 2138 bp in length			
*	136192	136209: gap of unknown length			
*	136210	138604: contig of 2395 bp in length			

*	138605	138622:	gap of unknown length
*	138623	141375:	contig of 2753 bp in length
*	141376	141393:	gap of unknown length
*	141394	144063:	contig of 2670 bp in length
*	144064	144081:	gap of unknown length
*	144082	146269:	contig of 2188 bp in length
*	146370	146287:	gap of unknown length
*	146388	149382:	contig of 3095 bp in length
*	149383	149400:	gap of unknown length
*	149401	152120:	contig of 2720 bp in length
*	152121	152138:	gap of unknown length
*	152139	155611:	contig of 3473 bp in length
*	155612	155629:	gap of unknown length
*	155630	157629:	contig of 2000 bp in length
*	157630	157647:	gap of unknown length
*	157648	163928:	contig of 5281 bp in length
*	162829	165946:	gap of unknown length
*	162847	166662:	contig of 2716 bp in length
*	165643	166680:	gap of unknown length
*	165681	166902:	contig of 3222 bp in length
*	168903	168920:	gap of unknown length
*	168921	171775:	contig of 2855 bp in length
*	171776	171793:	gap of unknown length
*	171794	175623:	contig of 3832 bp in length
*	175626	175643:	gap of unknown length
*	175644	179540:	contig of 3897 bp in length
*	179541	179558:	gap of unknown length
*	179559	183777:	contig of 4219 bp in length
*	183778	183795:	gap of unknown length
*	183796	187401:	contig of 3606 bp in length
*	187402	187419:	gap of unknown length
*	187420	192407:	contig of 4988 bp in length
*	192408	192425:	gap of unknown length
*	192426	197395:	contig of 4970 bp in length
*	197396	197413:	gap of unknown length
*	197414	203803:	contig of 6390 bp in length
*	203804	203821:	gap of unknown length
*	203822	209450:	contig of 5629 bp in length
*	209451	209468:	gap of unknown length
*	209469	215566:	contig of 6098 bp in length

[illegible]

Query Match	2.7%;	Score 40.4;	DB 42;	Length 215566;
Best Local Similarity	65.6%;	Pred. No. 19;		
Matches 59; Conservative	0;	Mismatches 31;	Indels 0;	Gaps 0

OY 1395 cctgagtaagctcttttttttgcgactcttaataactctctatggttgtagagatcttc 1454
 Db 124819 CGTGGCTATTTTATTTATTTTAAACATATATCTTCGGAAATTTGCTTTGAATATATG 124760
 OY 1455 taataataattccaagatctttttttaaaa 1484
 Db 124759 TAAAAATATATGTAATAATATTTATTTTAA 124730

RESULT	6
HSDJ130E4/C	
LOCUS	
DEFINITION	HSDJ130E4 11944 bp DNA HTG 23-NOV-1999
ACCESSION	AL078582
VERSION	AL078582.7 GI:6018773
KEYWORDS	HTG; HTGS_PHASE1.
SOURCE	human.
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;

REFERENCE
AUTHORS
TITLE
JOURNAL

Eutheria; Primates; Carnivora; Hominoidea; Homo.
1 (bases 1 to 11944)
Parker, A.
Direct Submission
Submitted (12-NOV-1999) Wellcome Trust Genome Campus, Hinxton

COMMENT

On Oct 11, 1999 this sequence version replaced g1:6018475.

IMPORTANT: This sequence is unfinished and does not necessarily represent the correct sequence. Work on the sequence is in progress and the release of this data is based on the understanding that the sequence may change as work continues. The sequence may be contaminated with foreign sequence from E.coli, yeast, vector, phage etc. Order of segments is not known: 800 n's separate segments. Unfinished: dJ130E4 contig_ID: 00522 acc=AL078582 Length: 111944 bp.

* NOTE: This is a 'working draft' sequence.

* This record will be updated with the finished sequence as soon as it is available and the accession number will * be preserved.

```
FEATURES
SOURCE
    location=Qualifiers
    1..111944
    /organism="Homo sapiens"
    /db_xref="taxon:9606"
    /chromosome="6"
    /clone="RP1-130E4"
    /clone_1b="RPC1-1"
    /clone_1b="RPC1-1"
BASE COUNT    33294 a    23483 c    22954 g    32213 t
ORIGIN
```

Query Match	2.7%	Score 40.2	DB 32	Length 111944
Best Local Similarity	67.1%	Pred. No. 19		
Matches 57, Conservative	0	Mismatches 28	Indels 0	Gaps 0

Qy	1405	tttttttttttccacctttaaatcttctatagttagagatgttttaaaaat	1464
Db	40544	TTATATTATTTAAATATTTAATTTAATAATATAAATAAATTTATTTTAAATAAT	404855
Qy	1465	ttcaagtatctttttaaaaaactt	1489
Db	40484	ATTAAAGTATTATTTAAATACTATT	40460

LOCUS	AC011599	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS
LOCUS	AC011599	237316 bp DNA	AC011599	237316 bp	AC011599.2	GI:6087865	HTG	21-OCT-1999	
DEFINITION	Homo sapiens chromosome 3 seeders clone RPc11-606L6, ***								
ACCESSION	AC011599								
VERSION	AC011599.2								
KEYWORDS	HTG; HTGS_PHASE1.								
SOURCE	human								
ORGANISM	Homo sapiens								
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.								
AUTHORS	Muzny,D.M., Adams,C., Bailey,M., Barbara,J., Blankenburg,K.,								

Burkett, C., Burrows, J., Carter, M., Chacko, J., Chen, Z., Cox, C., David, R., Delgado, O., Deshazo, D., Ding, X., Domah-kashid, N., Dugan-Rocha, S., Durbin, K. J., Fernandez, C., Ferraguto, D., Forcuna-Tansey, J., Francis, P., Ganesh, R., Gorelli, J. H., Gorelli, L., Guevara, W., Harris, K., Hernandez, J., Hodgson, A., Hugues, M., Holloway, C., Hosak, H., Jackson, L. E., Jackson, L., Jia, X., Jones, M., Kelly, S., Kondewski, N., Kong, Y., Kovar, C., Leal, B., Li, Z., Lichtarge, O., Liu, J., Liu, W., Logan, O., Lu, J., Lucier, R., Martin, R., Martinez, C., McLeod, M. P., Mei, G., Morgan, M., Morris, S., Nash, S., Nelson, A., Nguyen, R., Nguyen, N., Nguyen, S., Oswald, G., Patish, B., Paxton, S., Payton, B., Perez, L., Pu, L. L., Quilis, M., Reiter, D., Rives, M., Samuel, S., Say, J., Scherer, S., Shah, E., Shen, H., Simon, M., Sparks, A., Stamps, S., Sungang, R., Tabor, P., Taylor, T., Vasquez, L., Vinson, R., Vo, Q., Wabdan, M., Wallington, S.,

TITLE Weinstock, G., Weinstock, I.R., Williamson, A., Worley, K., Wren, J.,
 JOURNAL Weinstorf, G., Yu, W., Zhou, X., Nelson, D. and Gibbs, R.
 REFERENCE Unpublished
 AUTHORS 2 (bases 1 to 237316)
 TITLE Direct Submission
 JOURNAL Submitted (08-OCT-1999) Human Genome Sequencing Center, Department
 of Molecular and Human Genetics, Baylor College of Medicine, One
 Baylor Plaza, Houston, TX 77030, USA
 On Oct 20, 1999 this sequence version replaced g1:6016622.
 * NOTE: This is a 'working draft' sequence. It currently
 * consists of 29 contigs. The true order of the pieces
 * is not known and their order in this sequence record is
 * arbitrary. Gaps between the contigs are represented as
 * runs of N, but the exact sizes of the gaps are unknown.
 * This record will be updated with the finished sequence
 * as soon as it is available and the accession number will
 * be preserved.

COMMENT

1 1094: contig of 1094 bp in length
 * 1095 1961: contig of 867 bp in length
 * 1962 3033: contig of 1072 bp in length
 * 3034 3849: contig of 816 bp in length
 * 3850 4810: contig of 961 bp in length
 * 4811 5605: contig of 795 bp in length
 * 5606 6734: contig of 1149 bp in length
 * 6735 7721: contig of 967 bp in length
 * 7722 8612: contig of 891 bp in length
 * 8613 9661: contig of 1049 bp in length
 * 9662 10580: contig of 919 bp in length
 * 10581 11501: contig of 921 bp in length
 * 11502 12914: contig of 1413 bp in length
 * 12915 13809: contig of 895 bp in length
 * 13810 14625: contig of 816 bp in length
 * 14626 15624: contig of 999 bp in length
 * 15625 16672: contig of 1048 bp in length
 * 16673 17704: contig of 1032 bp in length
 * 17705 19083: contig of 1379 bp in length
 * 19084 20081: contig of 998 bp in length
 * 20082 20958: contig of 877 bp in length
 * 20959 23350: contig of 2392 bp in length
 * 23351 26220: contig of 2870 bp in length
 * 26221 32050: contig of 5829 bp in length
 * 32051 46821: contig of 14772 bp in length
 * 46822 64420: contig of 17599 bp in length
 * 64421 91572: contig of 27159 bp in length
 * 91573 129163: contig of 37591 bp in length
 * 129164 237316: contig of 108153 bp in length.

FEATURES

source Location/Qualifiers
 1..237316
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="3 seeders"
 /clone="RPC111-606L6"
 BASE COUNT 54463 a 63949 c 63339 g 55490 t 75 others
 ORIGIN

Query Match 2.7%; Score 40.2; DB 42; Length 237316;
 Best Local Similarity 49.8%; Pred. No. 21;
 Matches 102; Conservative 0; Mismatches 103; Indels 0; Gaps 0;
 Oy 746 gaataatgcccacagagcctgtcagtcgagcgcgcgtactcagtcgacactgcggcg 805
 Db 58413 GCAGATTGCCACCCGCTCCACACGCCGCCGCGGGAAGTGGCCGGGAGTGG 58472
 Oy 806 gtgcgcttgcctccatcctgtctgtgagagcctgcagcccaaccgcggcgaacttt 865
 Db 58473 AGCGGTGACAGCATCCCGCTGTCTCGAGTCAGGCTGTGGGACAGCTGACAGCAG 58532
 Oy 866 gttgttggtggcgtcttgcagcagcgtcttgcagcagaagaacgcagccgcggcgag 925
 Db 58533 GCCCGGAGGGGACAGCGGCGGACGAGGCCGCCAGGCTCCAGAGCAGCGCGTGCAC 58592

Oy 926 atggtgccgacttcttcgagatcc 950
 Db 58593 AGCGTGTCCAGCTGCATCGGGGTCTC 58617

RESULT 8
 LEGFPOL 3417 bp DNA PLN 24-AUG-1995
 LOCUS L-esculentum gene for fruit ripening polygalacturonase.
 DEFINITION X80908
 ACCESSION X80908.1 GI:963065
 VERSION polygalacturonase.
 KEYWORDS tomato.
 SOURCE Lycopersicon esculentum
 ORGANISM Lycopersicon esculentum
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 euphyllophytes; Spermatophyta; Magnoliophyta; eudicotyledons;
 Asteridae; Solanales; Solanales; Solanales; Solanaceae; Solanum; Potatoe;
 Lycopersicon.

REFERENCE 1 (bases 1 to 3417)
 AUTHORS Nicholas, F.J., Smith, C.J., Schuch, W., Bird, C.R. and Grierson, D.
 TITLE High levels of ripening-specific reporter gene expression directed
 JOURNAL by tomato fruit polygalacturonase gene-flanking regions
 MEDLINE Plant Mol. Biol. 28 (3), 423-435 (1995)
 REFERENCE 2 (bases 1 to 3417)
 AUTHORS Nicholas, F.J.
 TITLE Direct Submission
 JOURNAL Submitted (11-AUG-1994) F.J. Nicholas, University of Nottingham,
 AFRC Research Group in Plant Gene Reg., Dept. of Physiology & Envir.
 Science, Sutton Bonington Campus, Loughborough Leics. LE12 5RD, UK

FEATURES

source Location/Qualifiers
 1..3417
 /organism="Lycopersicon esculentum"
 /cultivar="Alisa Craig"
 /db_xref="taxon:4081"
 /chromosome="10"
 /clone="GTOM23.73"
 1..3417
 /product="fruit ripening specific polygalacturonase"
 BASE COUNT 1307 a 438 c 424 g 1248 t
 ORIGIN

Query Match 2.7%; Score 40; DB 7; Length 3417;
 Best Local Similarity 65.9%; Pred. No. 14;
 Matches 58; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
 Oy 1400 atgagtttttttttcgacatttaataattcttatatgtgtagatgttttaaa 1459
 Db 3173 AAGATATTATTTTGGAGCACAACATTTATTTAGTACACGCTTAAAGTATTTTAAAA 3232
 Oy 1460 taatttcagatgtttttttaaaact 1487
 Db 3233 TAAATTAAGGTATTTTGAATAAAATT 3260

RESULT 9
 AC002449 173767 bp DNA PRI 20-AUG-1997
 LOCUS Human PAC clone D1404K21 from Xq23, complete sequence.
 DEFINITION AC002449
 ACCESSION AC002449.1 GI:2337886
 VERSION HTG.
 KEYWORDS human.
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Primates; Catarrhini; Hominini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 173767)
 AUTHORS Hinds, K., Tin-Mollam, A., Sutterer, C. and Fironick, B.
 TITLE The sequence of H. sapiens PAC clone D1404K21
 JOURNAL Unpublished (1997)
 REFERENCE 2 (bases 1 to 173767)

AUTHORS
JOURNAL

COMMENT

Waterston, R.
Direct Submission
Submitted (20-AUG-1997) Department of Genetics, Washington
University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
SUBMITTED BY:
Genome Sequencing Center
Department of Genetics
Washington University
St. Louis MO 63108, USA
http://genome.wustl.edu/gsc
mailto:saplens@watson.wustl.edu

NOTICE: This sequence may not represent the entire insert of this
clone. It may be shorter because we only sequence overlapping
clone sections once, or longer because we provide a small overlap
between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:
all regions were double stranded or sequenced with an alternate
chemistry; an attempt was made to resolve all sequencing problems,
such as compressions and repeats; all regions were covered by
sequence from more than one subclone; and the assembly was
confirmed by restriction digest.

MAPPING INFORMATION:

This sequence was generated from part of bacterial clone contigs of
human chromosome X, constructed by David Bentley's chromosome X
mapping group at the Sanger Centre, Wellcome Trust Genome Campus,
Hinxton, UK. Further information can be found at
http://www.sanger.ac.uk/HGP/ChrX

SOURCE INFORMATION:

This clone was derived from human PAC library RPCI-3 prepared by
Pieter de Jong and coworkers at Roswell Park Cancer Institute,
using the method described by Ioannou et al., Nature Genetics
6:84-9 (1994). The library is from one male donor. For further
details, see http://bacpac.med.buffalo.edu/. The clone is available
from Genome Systems, Inc. (http://www.genomesystems.com).
VECTOR: pCYPAC2

NEIGHBORING SEQUENCE INFORMATION:

The clone sequenced to the left is H_DJ290B04. The actual start of
this clone is at base position 1 of DJ404K21; actual end is at
137661 of DJ404K21. This clone is part of an unanchored island,
orientation is unknown.

This clone contains STS's SMD757 (NID:9405440) and SMD512
(NID:9995449).

FEATURES

source

Location/Qualifiers
1. 173767
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="X"
/clone="DJ404K21"
/clone_id="RPCI-3"
/map="Xq23"
3958. 3983
/rpt_family="L1"
7187. 7448
/rpt_family="MER"
7450. 7832
/rpt_family="ALU"
complement(7833. 7891)
/rpt_family="THR"
7893. 8184
/rpt_family="ALU"
complement(8198. 9670)
/rpt_family="THR"
9671. 10045
/rpt_family="ALU"
10047. 10226
/rpt_family="MER"
repeat_region
10461. 11065

/rpt_family="L1"
complement(11071. 11286)
/rpt_family="MER"
11291. 11433
/rpt_family="L1"
complement(11434. 11593)
/rpt_family="MER"
complement(11616. 11641)
/rpt_family="MER"
complement(14472. 14820)
/rpt_family="L1"
complement(14833. 15202)
/rpt_family="L1"
15777. 15808
/rpt_family="L1"
16030. 16436
/rpt_family="L1"
16525. 16719
/rpt_family="L1"
16860. 18448
/rpt_family="L1"
18450. 18738
/rpt_family="ALU"
18756. 22756
/rpt_family="L1"
complement(24561. 24819)
/rpt_family="ALU"
25322. 25360
/rpt_family="L1"
25871. 25936
/rpt_family="L1"
27205. 27559
/rpt_family="ALU"
27921. 28394
/rpt_family="L1"
29212. 29235
/rpt_family="L1"
complement(30468. 30557)
/rpt_family="L1"
30844. 31126
/note="match to EST R00201 (NID:9749937) ye71f11.r1"
31050. 31156
/note="match to EST R00201 (NID:9749937) ye71f11.r1"
31530. 32115
/rpt_family="L1"
complement(34006. 34295)
/rpt_family="ALU"
35839. 35865
/rpt_family="L1"
36463. 37291
/rpt_family="L1"
39129. 39159
/rpt_family="L1"
complement(39829. 40254)
/rpt_family="ALU"
40512. 4114
/rpt_family="L1"
41227. 41458
/rpt_family="L1"
complement(41461. 41750)
/rpt_family="ALU"
42582. 42630
/rpt_family="L1"
43534. 43661
/rpt_family="L1"
44290. 44440
/rpt_family="L1"
44494. 44678
/rpt_family="L1"
complement(45130. 45422)
/rpt_family="ALU"
complement(45972. 46009)
/rpt_family="THR"


```

/dn_xref="taxon:6239"
/clone="Y53G8X"
BASE COUNT      98291 a 51999 c 51839 g 96253 t 1438 others
ORIGIN
Query Match      2.7%; Score 39.6; DB 33; Length 299820;
Best Local Similarity 60.0%; Fred. No. 31;
Matches 66; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
OY 1380 taagatttcggggaaccgagatgagtttttttttttcgcatcttaataattctatg 1439
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 159048 TGATTTTGAAGTAACGACGAGCTTTTGAAGCTTTTCAGCGAAATTTTTCATTAAT 158989
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
OY 1440 ttgtagagatggtttaaataatcaagatctttttaaaaaactt 1489
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 158988 ATTCGAAATTTGTTTCAAAAAATTTAAATTTTAAACAAATTT 158939
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 14
DDU73686      1840 bp      DNA      INV      08-DEC-1997
LOCUS      Dictyostelium discoidium cytosolic glycoprotein FP21 (fpa2) gene,
DEFINITION      complete cds.
ACCESSION      U73686.1 GI:1658023
VERSION      U73686.1
KEYWORDS
SOURCE      Dictyostelium discoidium.
ORGANISM      Dictyostelium discoidium.
REFERENCE      1 (bases 1 to 1840)
AUTHORS      West,C.M., Kozarov,E. and Teng-umnuay,P.
TITLE      The cytosolic glycoprotein FP21 of Dictyostelium discoidium is
            encoded by two genes resulting in a polymorphism at a single amino
            acid position
JOURNAL      Gene 200 (1-2), 1-10 (1997)
MEDLINE      98038971
REFERENCE      2 (bases 1 to 1840)
AUTHORS      West,M.C., Kozarov,E. and Teng-umnuay,P.
TITLE      Direct Submission
JOURNAL      Submitted (08-OCT-1996) Anatomy & Cell Biology, University of
            Florida, 1600 SW Archer Rd., Gainesville, FL 32610-0235, USA
FEATURES
Source      1..1840
            /organism="Dictyostelium discoidium"
            /strain="Ax3"
            /db_xref="taxon:44689"
            /protein_id="AA086390.1"
            /gene="fpa2"
            /gene="fpa2"
            /gene="fpa2"
            /note="SKP1-like; similar to the product of the fpa1 gene"
            /codon_start=1
            /product="cytosolic glycoprotein FP21"
            /protein_id="AA086390.1"
            /db_xref="GI:1658024"
            /translation="MSLVKLESDSEKVEIEKEJACMSVTKNMIEDIGSDAPIPAP
            NVTSTLEKLVLDYCRHHNHQHPGQDGRKDEKRDIDIPYDRDCKVDKOPTIFELILA
            ANYLDIKPLDVTCKTVANMIRKTPREIRIKIFIKNDPEPEEQARKKEMEMEDG
            GN"
            intron      1158..1311
            /gene="fpa2"
BASE COUNT      742 a 166 c 170 g 762 t
ORIGIN
Query Match      2.6%; Score 39.4; DB 34; Length 1840;
Best Local Similarity 62.9%; Fred. No. 18;
Matches 61; Conservative 0; Mismatches 36; Indels 0; Gaps 0;
OY 1393 aaccggatgagtggttttttttcgcatcttaataattctatggtgagagatg 1452
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 870 AACCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 929

```

```

OY 1453 tttaataaattcaagatctttttttaaaaaactt 1489
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 930 TTTAAAAATAAATAATTTTAAAAAAAGCTT 966
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 15
AC004994/c      80331 bp      DNA      PRI      21-NOV-1998
LOCUS      Homo sapiens PAC clone DJ1194E15 from 7p15.3-p21, complete
DEFINITION      sequence.
ACCESSION      AC004994
VERSION      AC004994.1 GI:3900849
KEYWORDS      HTG.
SOURCE      human.
ORGANISM      Homo sapiens
REFERENCE      1 (bases 1 to 80331)
AUTHORS      Eutheria, Primates; Catarrhini; Homnidae; Homo.
TITLE      The sequence of Homo sapiens PAC clone DJ1194E15
JOURNAL      Unpublished (1998)
REFERENCE      2 (bases 1 to 80331)
AUTHORS      Waterston,R.H.
TITLE      Direct Submission
JOURNAL      Submitted (12-JUN-1998) Genome Sequencing Center, Washington
            University School of Medicine, 4444 Forest Park Parkway, St. Louis,
            MO 63108, USA
REFERENCE      3 (bases 1 to 80331)
AUTHORS      Waterston,R.
TITLE      Direct Submission
JOURNAL      Submitted (21-NOV-1998) Department of Genetics, Washington
            University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
            On Nov 21, 1998 this sequence version replaced gi:3377480.
SUBMITTED BY: WUGSC
            Genome Sequencing Center
            Department of Genetics
            Washington University
            St. Louis MO 63108, USA
            http://genome.wustl.edu/gsc
            mailto:sapiens@watson.wustl.edu

NOTICE: This sequence may not represent the entire insert of this
clone. It may be shorter because we only sequence overlapping
clone sections once, or longer because we provide a small overlap
between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:
all regions were double stranded or sequenced with an alternate
chemistry; an attempt was made to resolve all sequencing problems,
such as compressions and repeats; all regions were covered by
sequence from more than one subclone; and the assembly was
confirmed by restriction digest.

MAPPING INFORMATION:
The sequence of this clone was established as part of a mapping and
sequencing collaboration between the NHGRI Chromosome 7 Mapping
Project (Eric D. Green, Director), John D. McPherson in the
Department of Genetics (Washington University), and the Washington
University Genome Sequencing Center. For additional information
about the map position of this sequence, see
http://www.nhgri.nih.gov/DIR/GRB/CHR7, send
mailto:egreen@nhgri.nih.gov, or see http://genome.wustl.edu/gsc

SOURCE INFORMATION:
This clone was derived from human PAC library RCI-5, prepared by
Pieter de Jong and coworkers at the Roswell Park Cancer Institute
(http://bacpac.med.buffalo.edu) using the method described by
Ioannou et al., Nature Genetics 6:84-9 (1994). The library is from
one male donor.
The clone may be obtained either from Genome Systems, Inc.
(http://www.genomesystems.com) or Research Genetics, Inc.
(http://www.resgen.com); or from Pieter de Jong.

```


Db 77586 TTTTTCATTAAAGAAATGTTTCATAAAATGATGAGAAATAGATTTTTTTTTTT 77527

Qy 1477 tttaaaaa 1485

Db 77526 TTTAGACA 77518

Search completed: April 23, 2000, 02:20:29
Job time: 3094 sec

(IM)

Distribution rights by Oxford Molecular Ltd

protein database search, using Smith-Waterman algorithm

Tue Apr 18 14:00:52 2000; MasPar time 93.97 Seconds

generated

1 MALKVILLE EKTFTLLVLL.....

PAM 150

225878 seqs, 69334122 residues

Listing first 45 summaries

13:sp_vertebrate 14:sp_virus

Mean 46.756; Variance 76.185; scale 0.614

ved by analysis of the total score distribution.

SUMMARIES

4.8	418	4	000275	LYMPHOCYTE ASSOCIATED	7.58e-10
-----	-----	---	--------	-----------------------	----------

45	128	4.1	471	6	019131	TUMOR NECROSIS FACTOR-	7.37e-06
----	-----	-----	-----	---	--------	------------------------	----------

ALIGNMENTS

DT 01~NOV-1999 (T:EMBLrel. 12, Created)

DT 01-NOV-1999 (Tremblrel. 12, Last sequence update)
 DE 01-NOV-1999 (Tremblrel. 12, Last annotation update)
 DE TUMOUR NECROSIS FACTOR RECEPTOR PRECURSOR.
 GN A53R.
 OS Vaccinia virus.
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-LISTER;
 RA MEDLINE: 99226947.
 RA ALCAMI A., KHANNA A., PAUL N., SMITH J.L.;
 RT "Vaccinia virus strains lister. USSR and Evans express soluble and
 RT cell-surface tumour necrosis factor receptors."
 RL J. Gen. Virol. 80:949-959(1999).
 DR EMBL: Y17728; CAB41042.1; -.
 KM Signal: Receptor.
 FT SIGNAL 1 22 POTENTIAL.
 SQ SEQUENCE 186 AA; 20646 MW; 6D548A28 CRC32;

Query Match 6.5%; Score 201; DB 14; Length 186;
 Best Local Similarity 32.4%; Pred. No. 5,80e-20;
 Matches 36; Conservative 22; Mismatches 42; Indels 11; Gaps 10;

DB 34 NGACDGEYLDKRNQC--CNCPPG-EFAKVRGN-G-NDNTKCEKCPHTYTAIPNYSN 88
 QY 31 SDCRCQOEFRD-RSGNCVPCNCGPMELSKE-CGFGYEDACVACRLHREKEDMGFOK 88
 DB 89 GCHOCRCPT-GSPDKVCTGTONSCKS-CLPGWCATDSOTEDRCDCIP 137
 QY 89 -CKPCIDCAVVRNFOKANCATSATDAICGDCPLPGFYKTKLVGFOD-MECVP 137

RESULT 3
 ID 09YR87; PRELIMINARY; PRT; 186 AA.
 AC 09YR87;
 DT 01-MAY-1999 (Tremblrel. 10, Created)
 DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
 DT 01-MAY-1999 (Tremblrel. 10, Last annotation update)
 DE SOLUBLE TNF RECEPTOR CRMC.
 GN CRMC.
 OS Cowpox virus (CPV).
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-BRIGHTON REDGENE;
 RA SMITH C.A., GOODMAN R.G., PICKUP D.J.;
 RT "Cowpox virus Encodes a second soluble TNF receptor (Crmc) Distinct
 RT from Crmb."
 RL Submitted (Apr-1996) to the EMBL/GenBank/DBJ databases.
 DR EMBL: U55052; AADI0325.1; -.
 KM Receptor.
 SQ SEQUENCE 186 AA; 20372 MW; 2A90DC98 CRC32;

Query Match 6.0%; Score 187; DB 14; Length 186;
 Best Local Similarity 30.0%; Pred. No. 4.32e-17;
 Matches 33; Conservative 28; Mismatches 40; Indels 9; Gaps 9;

DB 34 NSGCDGEYLDKRNQC--CNCPPG-EFAKIRS-G-SDNTKCEKCPHTYTVPNYSNG 89
 QY 31 SDCRCQOEFRD-RSGNCVPCNCGPMELSKE-CGFGYEDACVACRLHREKEDMGFOK 88
 DB 90 CHOCRCPT-GSPDKVCTGTONSCKS-CLPGWCATDSOTEDRCDCIP 137
 QY 89 CKPCIDCAVVRNFOKANCATSATDAICGDCPLPGFYKTKLVGFOD-MECVP 137

RESULT 4
 ID 09XS28; PRELIMINARY; PRT; 283 AA.
 AC 09XS28;
 DT 01-NOV-1999 (Tremblrel. 12, Created)
 DT 01-NOV-1999 (Tremblrel. 12, Last sequence update)

DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
 DE HVEAS.
 GN HVEAS.
 OS Cercopithecus aethiops (Green monkey) (Griwet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Primates; Catarrhini; Cercopithecidae; Cercopithecinae;
 OC Chlorocebus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE-KIDNEY;
 RA MEDLINE: 99296730.
 RA FOSTER T.P., CHOUJENKO V.N., KOUTSOLAS K.G.;
 RT "Functional characterization of the HveA homolog specified by African
 RT green monkey kidney cells with a herpes simplex virus expressing the
 RT green fluorescence protein."
 RL Virology 258:365-374(1999).
 DR EMBL: AF147720; AAD37381.1; -.
 DR PROSITE: PS00652; TNFR_NGFR_1; 1
 SQ SEQUENCE 283 AA; 30199 MW; 9B499EAB CRC32;

Query Match 5.2%; Score 161; DB 6; Length 283;
 Best Local Similarity 27.4%; Pred. No. 6.13e-12;
 Matches 31; Conservative 27; Mismatches 46; Indels 9; Gaps 8;

DB 20 ILTLVLYTFEGSSCYAPALPSCKEDYV-GSEC--CPKCGPFHYRQACG-E-QIGTV 74
 QY 13 FETLLVILGYISCVY-TCESGDCRQOEFRDRSGNCVPCNCGPMELSKECGFGYEDADQ 71
 DB 75 CEPSPGYIAHFNGLSKICQCMCDPAMGLRTSRNSTANACG-CSPGHF 126
 QY 72 CVACHLHFREDW-GFOKCRFLDCAVVRNFOKA-NCATSATDAICGDCPLPGFY 122

RESULT 5
 ID 057108; PRELIMINARY; PRT; 348 AA.
 AC 057108;
 DT 01-JUN-1998 (Tremblrel. 06, Created)
 DT 01-JUN-1998 (Tremblrel. 06, Last sequence update)
 DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
 DE TUMOR NECROSIS FACTOR RECEPTOR II HOMOLOG.
 GN CRMB.
 OS Monkeypox virus.
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-ZAIRE-1970 (CONGO-8);
 RA LOHAREY V.N., PARSONS J.M., ESPOSITO J.J.;
 RL Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.
 DR EMBL: U88142; AAB94367.1; -.
 DR HSSP: P25942; ICDF.
 DR PROSITE: PS00652; TNFR_NGFR_1; 2.
 DR PFAM: PF00020; TNFR_C6; 2.
 SQ SEQUENCE 348 AA; 38212 MW; 28F1C77C CRC32;

Query Match 4.9%; Score 152; DB 14; Length 348;
 Best Local Similarity 30.9%; Pred. No. 3.19e-10;
 Matches 29; Conservative 20; Mismatches 36; Indels 9; Gaps 8;

DB 29 NGCKDNEYRSN-IG--CLSCPPGYASRLCD-S-KTNQCPTGSGDFTSHNNHLOAC 83
 QY 31 SDCRCQOEFRDRSGNCVPCNCGPMELSKECGFGYEDACVACRLHREKEDMG-FOKC 89
 DB 84 LSCNGRDS-NQVETSCNTNHRIC-EGSPGY 115
 QY 90 KPCID-CAVVRNFOKANCATSATDAICGDCPLPGFY 122

RESULT 6
 ID 057103; PRELIMINARY; PRT; 348 AA.
 AC 057103;
 DT 01-JUN-1998 (Tremblrel. 06, Created)
 DT 01-JUN-1998 (Tremblrel. 06, Last sequence update)


```

OC Orthopoxvirus.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-NIGERIA-1971 (71-0082);
RA LOPAREV V.N., PARSONS J.M., ESPOSITO J.J.;
RL Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL: U87844; AAB94361.1; -.
DR HSSP: P25942; ICDF.
DR PROSITE: PS00652; TNFR_NGFR_1; 2.
DR PRAM: PF00020; TNFR_C6; 2.
SQ SEQUENCE 349 AA; 38239 MW; F8871DD2 CRC32;

Query Match 4.9%; Score 152; DB 14; Length 349;
Best Local Similarity 30.9%; Pred. No. 3.19e-10;
Matches 29; Conservative 20; Mismatches 36; Indels 9; Gaps 8;

Db 29 NGKCKNEYSRN-IC--CLSCPPTYASRLCD-S-KTNTQCTPCGSDPTFSHNNHLOAC 83
QY 31 SGDCRQGEFDRSGNCVPCNCGPMELSKEGFGYGEDACVACRLHRKEDWG-FQKC 89
DB 84 LSCNGRCDs-NOVETRSCTTHNRIC-ECSPGY 115
QY 90 KPCLD-CAVYNRFOKANCATSATDAICGDCLPFGY 122

RESULT 11
ID 057291 PRELIMINARY; PRT; 349 AA.
AC 057291;
DT 01-JUN-1998 (Tremblrel. 06, Created)
DT 01-JUN-1998 (Tremblrel. 06, Last sequence update)
DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
DE TUMOR NECROSIS FACTOR RECEPTOR II HOMOLOG.
GN CMAB.
OS Monkeypox virus.
OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
OC Orthopoxvirus.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-VARIOUS STRAINS;
RA LOPAREV V.N., PARSONS J.M., ESPOSITO J.J.;
RL Submitted (JAN-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL: U88144; AAB94369.1; -.
DR EMBL: U87842; AAB94359.1; -.
DR EMBL: U87994; AAB94365.1; -.
DR EMBL: U87995; AAB94366.1; -.
DR EMBL: U88143; AAB94368.1; -.
DR HSSP: P25942; ICDF.
DR PROSITE: PS00652; TNFR_NGFR_1; 2.
DR PRAM: PF00020; TNFR_C6; 2.
SQ SEQUENCE 349 AA; 38295 MW; 7313FCF9 CRC32;

Query Match 4.9%; Score 152; DB 14; Length 349;
Best Local Similarity 30.9%; Pred. No. 3.19e-10;
Matches 29; Conservative 20; Mismatches 36; Indels 9; Gaps 8;

Db 29 NGKCKNEYSRN-IC--CLSCPPTYASRLCD-S-KTNTQCTPCGSDPTFSHNNHLOAC 83
QY 31 SGDCRQGEFDRSGNCVPCNCGPMELSKEGFGYGEDACVACRLHRKEDWG-FQKC 89
DB 84 LSCNGRCDs-NOVETRSCTTHNRIC-ECSPGY 115
QY 90 KPCLD-CAVYNRFOKANCATSATDAICGDCLPFGY 122

RESULT 12
ID 057099 PRELIMINARY; PRT; 349 AA.
AC 057099;
DT 01-JUN-1998 (Tremblrel. 06, Created)
DT 01-JUN-1998 (Tremblrel. 06, Last sequence update)
DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
DE TUMOR NECROSIS FACTOR RECEPTOR II HOMOLOG.
GN CMAB.
OS Monkeypox virus.

```

```

OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
OC Orthopoxvirus.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-SIERA LEONE-1970 (70-0266);
RA LOPAREV V.N., PARSONS J.M., ESPOSITO J.J.;
RL Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL: U87843; AAB94360.1; -.
DR HSSP: P25942; ICDF.
DR PROSITE: PS00652; TNFR_NGFR_1; 2.
DR PRAM: PF00020; TNFR_C6; 2.
SQ SEQUENCE 349 AA; 38321 MW; 5315315C CRC32;

Query Match 4.9%; Score 152; DB 14; Length 349;
Best Local Similarity 30.9%; Pred. No. 3.19e-10;
Matches 29; Conservative 20; Mismatches 36; Indels 9; Gaps 8;

Db 29 NGKCKNEYSRN-IC--CLSCPPTYASRLCD-S-KTNTQCTPCGSDPTFSHNNHLOAC 83
QY 31 SGDCRQGEFDRSGNCVPCNCGPMELSKEGFGYGEDACVACRLHRKEDWG-FQKC 89
DB 84 LSCNGRCDs-NOVETRSCTTHNRIC-ECSPGY 115
QY 90 KPCLD-CAVYNRFOKANCATSATDAICGDCLPFGY 122

RESULT 13
ID 000276 PRELIMINARY; PRT; 253 AA.
AC 000276;
DT 01-JUL-1997 (Tremblrel. 04, Created)
DT 01-JUL-1997 (Tremblrel. 04, Last sequence update)
DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
DE LYMPHOCYTE ASSOCIATED RECEPTOR OF DEATH 2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
OC Eutheria; Primates; Catarrhini; Homiidae; Homo.
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE; 97272273.
RA SCREATION G.R., XU X.N., OLSEN A.L., COMPER A.E., TAN R.,
RA MCMICHAEL A.J., BELL J.I.;
RL "IABD: a new lymphoid-specific death domain containing receptor
RT regulated by alternative pre-mRNA splicing."
RT Proc. Natl. Acad. Sci. U.S.A. 94:4615-4619(1997).
DR EMBL: U94503; AAC51308.1; -.
DR HSSP: P19438; ITNR.
DR PROSITE: PS00652; TNFR_NGFR_1; 2.
DR PRAM: PF00020; TNFR_C6; 2.
SQ SEQUENCE 253 AA; 26934 MW; A21C863E CRC32;

Query Match 4.8%; Score 150; DB 4; Length 253;
Best Local Similarity 52.9%; Pred. No. 7.58e-10;
Matches 18; Conservative 5; Mismatches 10; Indels 1; Gaps 1;

Db 138 COPCLDCGALHRRHRLCS-RDTPDGTCLPGFY 170
QY 89 CKPCLDCAVYNRFOKANCATSATDAICGDCLPFGY 122

RESULT 14
ID 014866 PRELIMINARY; PRT; 277 AA.
AC 014866;
DT 01-JAN-1998 (Tremblrel. 05, Created)
DT 01-JAN-1998 (Tremblrel. 05, Last sequence update)
DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
DE SOLUBLE DEATH RECEPTOR 3 BETA.
GN DR3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
OC Eutheria; Primates; Catarrhini; Homiidae; Homo.
RN [1]
RP SEQUENCE FROM N.A.
RA WARZCHA K., RIBEIRO P., RENARD N., CHARLOT C., COIFFER B.,

```


KW Receptor; T-cell; Antigen; Glycoprotein; Transmembrane; Repeat;
 FT Signal. 1 19
 FT SIGNAL. 20 272
 FT CHAIN 20 211
 FT DOMAIN 20 211
 FT TRANSSEM 212 236
 FT DOMAIN 237 272
 FT DOMAIN 26 165
 FT REPEAT 26 61
 FT REPEAT 62 103
 FT REPEAT 104 124
 FT REPEAT 125 165
 FT CARBOHYD 144 144
 FT CONFLICT 15 15
 SQ SEQUENCE 272 AA; 30153 MW; 67D1B978 CRC32;
 Query Match 5.5%; Score 170; DB 1; Length 272;
 Best Local Similarity 27.3%; Pred. No. 1,946-14;
 Matches 48; Conservative 36; Mismatches 78; Indels 14; Gaps 11;
 Db 9 TALLILA-LTLGVYARLNVKHTYPS-GHKC--CREQPGHGVSRCD--HTRDTLCHP 62
 15 TLVLTLGLYLSCKVYCESGDCRQOEFRDRSGNCVPCNCGPMELSKEGCGYGEDAQCAVA 74
 QY
 Db 63 CEEGYNAVNVDPCKOCQOCNHRSGSELKONCPTEOTVC--RCRPGTQRPQD--SGYRLG 120
 75 CRLHREKEDMGFKCKPCLDCAVNVRFQ--KANCSTSDALCGDLPGFYRTKTLVGFQD 132
 QY
 Db 121 VDCVPCPPEHSPGNQACKPWTNCTLSGKQTRHAPSDDLAV--CED-RSLTLATL 174
 133 MECVPC--GDPPPEPRPCASKNVLYKIASSTASSPRDRLAALVICSALATVLLALL 186
 QY
 RESULT 2
 ID OK40_RAT STANDARD; PRT: 271 AA.
 AC P15725;
 DT 01-APR-1990 (Rel. 14, Created)
 DT 01-APR-1990 (Rel. 14, Last sequence update)
 DT 01-OCT-1996 (Rel. 34, Last annotation update)
 DE OK40L RECEPTOR PRECURSOR (OK40 ANTIGEN) (MRC OK40).
 GN TXGP1 OR OK40.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE-T-CELL;
 RX MEDLINE: 90214614.
 RA MALLERT S., FOSSUM S., BARCLAY A.N.;
 RT "Characterization of the MRC OK40 antigen of activated CD4 positive T lymphocytes -- a molecule related to nerve growth factor receptor.";
 RL EMOB J. 9:1063-1068(1990).
 CC -1- FUNCTION: RECEPTOR FOR THE OK40L/GP34 CYTOKINE.
 CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
 CC -1- TISSUE SPECIFICITY: ACTIVATED T-CELLS.
 CC -1- SIMILARITY: CONTAINS A LA-NGR/TNFR-TYPE CYSTEINE-RICH REGION.
 CC
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See [http://www.isb-sib.ch/announce/](http://www.isb-sib.ch/announce/or send an email to license@isb-sib.ch) or send an email to license@isb-sib.ch).
 CC
 CC EMBL: X17037, CA34897.1, -
 DR PIR: S08036, S08036.
 DR PIR: S12783, S12783.
 DR HSSP: P25942, ICDF.
 DR PROSITE: PS00652, TNFR_NGFR.1; 3.
 DR PROSITE: PS50050, TNFR_NGFR.2; 2.
 DR PFAM: PF00020, TNFR_C6; 3.
 KW Receptor; T-cell; Antigen; Glycoprotein; Transmembrane; Repeat;

KW Signal. 1 19
 FT SIGNAL. 20 271
 FT CHAIN 20 210
 FT DOMAIN 20 210
 FT TRANSSEM 211 235
 FT DOMAIN 236 271
 FT DOMAIN 25 164
 FT REPEAT 25 60
 FT REPEAT 61 102
 FT REPEAT 103 123
 FT REPEAT 124 164
 FT CARBOHYD 143 143
 SQ SEQUENCE 271 AA; 29895 MW; 6540ED2 CRC32;
 Query Match 4.8%; Score 149; DB 1; Length 271;
 Best Local Similarity 29.1%; Pred. No. 2,866-10;
 Matches 39; Conservative 27; Mismatches 57; Indels 11; Gaps 8;
 Db 9 TAFILLG-LSLGYVKL--NCVKDTYPS-GHKC--CREQPGHGVSRCD--HTRDTVCHP 61
 15 TLVLTLGLYLSCKVYCESGDCRQOEFRDRSGNCVPCNCGPMELSKEGCGYGEDAQCAVA 74
 QY
 Db 62 CEEGYNAVNVDPCKOCQOCNHRSGSELKONCPTEOTVC--RCRPGTQRPQD--SGYRLG 120
 75 CRLHREKEDMGFKCKPCLDCAVNVRFQ--KANCSTSDALCGDLPGFYRTKTLVGFQD 132
 QY
 Db 121 DCVPC--PPEHSP 132
 134 ECVPCGDPPEPPEP 147
 QY
 RESULT 3
 ID WSL1_HUMAN STANDARD; PRT: 417 AA.
 AC Q93038; Q93036; Q93037; Q92983; P78515; Q99831; Q99722; P78507;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 15-DEC-1999 (Rel. 39, Last annotation update)
 DE WSL-1 PROTEIN PRECURSOR (APOPTOSIS-MEDIATING RECEPTOR DR3) (APOPTOSIS-MEDIATING RECEPTOR TRAMP) (DEATH DOMAIN RECEPTOR 3) (WSL PROTEIN) (APOPTOSIS INDUCING RECEPTOR AIR) (APO-3) (LYMPHOCYTE ASSOCIATED DE RECEPTOR OF DEATH) (LARD).
 GN TNFRSF12 OR WSL1 OR WSL OR APO3 OR DR3 OR DR3.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Primates; Catarrhini; Homiidae; Homo.
 RN [1]
 RP SEQUENCE FROM N.A., ALTERNATIVE SPLICING, AND MTOGENESIS.
 RC TISSUE-LYMPHOID;
 RX MEDLINE: 9708617.
 RA KITSON J., RAVEN T., JIANG Y.-P., GOEDDEL D.V., GILES K.M., PUN K.-T., GRINHAM C.J., BROWN R., FARROW S.N.;
 RT "A death-domain-containing receptor that mediates apoptosis.";
 RL Nature 384:372-375(1996).
 CC [2]
 CC SEQUENCE FROM N.A.
 CC TISSUE-UMBILICAL VEIN ENDOTHELIAL CELLS;
 RX MEDLINE: 97081063.
 RA CHINNAIYAN A.M., O'ROURKE K., YU G.-L., LYONS R.H., GANG M., DIAN D.R., XING L., GENTZ R., NI J., DIXIT V.M.;
 RT "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95.";
 RL Science 274:990-992(1996).
 CC [3]
 CC SEQUENCE FROM N.A.
 CC DEGLI-ESPOSTI M.A., DIN W.S., COSMAN D., SMITH C.A., GOODMAN R.G.;
 RL Submitted (JAN-1997) to the EMBL/Genbank/DBD databases.
 RN [4]
 RP SEQUENCE FROM N.A.
 RC TISSUE-HEART;
 RA MARSTERS S.A., SHERIDAN J.P., DONAHUE C.J., PITTI R.M., GRAY C.L., GODDARD A.D., BAUER K.D., ASHKENAZI A.;
 RT "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa-B.";

DB 44 CPQKXVSHQNSICCTKCHKGTLYHNDCLDPGLDTCRECDNGTFTASNHLLQCLSC 102
AC P2518:
DT 01-MAY-1992 (Rel. 22, Created)
DI 01-MAY-1992 (Rel. 22, Last sequence update)
DE 15-JUL-1999 (Rel. 38, Last annotation update)
DN TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR (P60) (TNF-R1) (P55).
OS MUS MUSCULUS (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia;
RN Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
RP MEDLINE: 9118785.
RA LERIS M., TARTAGLIA L.A., LEE A., BENNETT G.L., RICE G.C.,
WONG G.H., CHEN E.Y., GOEDEL D.V.;
RT "Cloning and expression of cDNAs for two distinct murine tumor
necrosis factor receptors demonstrate one receptor is species
specific";
RL Proc. Natl. Acad. Sci. U.S.A. 88:2830-2834(1991).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE: 91246168.
RA GOODWIN R.G., ANDERSON D., JERRY R., DAVIS T., BRANNAN C.I.,
RA COPLAND N.G., JENKINS N.A., SMITH C.A.;
RT "Molecular cloning and expression of the type 1 and type 2 murine
receptors for tumor necrosis factor";
RL Mol. Cell. Biol. 11:3020-3026(1991).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE: 91285014.
RA BARRETT K., TAYLOR-FISHWICK D.A., COPE A.P., KISSONERCHIS A.M.,
GRAV P.W., FELDMAN M., FOXWELL B.M.J.;
RT "Cloning, expression and cross-linking analysis of the murine p55
tumor necrosis factor receptor";
RL Eur. J. Immunol. 21:1649-1656(1991).
RN [4]
RP SEQUENCE FROM N.A.
RC TISSUE-SPLEEN.
RX MEDLINE: 92039815.
RA ROTHE J.G., BROCKHAUS M., GENTZ R., LESSLAUER W.;
RT "Molecular cloning and expression of the mouse Tnf receptor type b.";
RL Immunogenetics 34:338-340(1991).
RN [5]
RP SEQUENCE FROM N.A.
RX MEDLINE: 94245292.
RA BEBO B.F., LINTHICUM D.S.;
RT "Nucleotide sequence of the TNF type I receptor from a mouse
endotheloma cell line";
RL Immunogenetics 39:450-451(1994).
RN [6]
RP SEQUENCE FROM N.A.
RX MEDLINE: 93156721.
RA ROTHE J., BLUTHMANN H., GENTZ R., LESSLAUER W., STEINMETZ M.;
RT "Genomic organization and promoter function of the murine tumor
necrosis factor receptor beta gene";
RL Mol. Immunol. 30:165-175(1993).
CC -1- FUNCTION: RECEPTOR FOR TNF-ALPHA. THE ADAPTOR MOLECULE FADD
RECRUITS CASPASE-8 TO THE ACTIVATED RECEPTOR. THE RESULTING
AGGREGATE CALLED THE DEATH-INDUCING SIGNALING COMPLEX (DISC)
PERFORMS CASPASE-8 PROTEOLYTIC ACTIVATION WHICH INITIATES THE
SUBSEQUENT CASCADE OF CASPASES (ASPARTATE-SPECIFIC CYSTEINE
PROTEASES) MEDIATING APOPTOSIS (BY SIMILARITY).

CC -1- SUBUNIT: TNF BINDING TO THE EXTRACELLULAR DOMAIN OF TNFR1 LEADS TO
HOMOTRIMERIZATION. ONCE AGGREGATED THE RECEPTORS DEATH DOMAINS
PROVIDE A NOVEL MOLECULAR INTERFACE THAT INTERACTS SPECIFICALLY
WITH THE DEATH DOMAIN OF TRADD. VARIOUS TRADD-INTERACTING
PROTEINS SUCH AS TRAFs, RIP AND POSSIBLY FADD, ARE RECRUITED TO
TNFR1 COMPLEX BY THEIR ASSOCIATION WITH TRADD. THIS COMPLEX
ACTIVATES AT LEAST TWO DISTINCT SIGNALING CASCADES, APOPTOSIS AND
NF-KAPPA B SIGNALING (BY SIMILARITY).
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL Outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (see <http://www.isb.ch/announce/>
or send an email to license@isb.slb.ch).
CC -----
DR EMBL: M60468; AAA39751.1; -;
DR EMBL: M59377; AAA40464.1; -;
DR EMBL: X59238; CAA41922.1; -;
DR EMBL: X57796; CAA40936.1; -;
DR EMBL: L26349; AAA59361.1; -;
DR EMBL: M76656; AAA40465.1; -;
DR EMBL: M88067; AAA40465.1; JOINED.
DR EMBL: M76655; AAA40465.1; JOINED.
DR PIR: A38634; GOMST1.
DR PIR: S16677; S16677.
DR PIR: S19021; S19021.
DR HSSP: P19438; 1EXT.
DR MGD: MGI:1314884; TNFRSF1A.
DR PROSITE: PS00652; TNFR_NGFR_1; 3.
DR PROSITE: PS50050; TNFR_NGFR_2; 3.
DR PROSITE: PS50017; DEATH_DOMAIN; 1.
DR PIRAM: PF00020; TNFR_C6; 4.
DR PIRAM: PF00531; death; 1.
KW Receptor; Transmembrane; Glycoprotein; Repeat; Signal; Apoptosis.
FT SIGNAL 1 21
FT CHAIN 22 454
FT DOMAIN 22 212
FT TRANSMEM 23 235
FT DOMAIN 236 454
FT DOMAIN 43 196
FT REPEAT 83 82
FT REPEAT 83 125
FT REPEAT 126 166
FT REPEAT 167 196
FT DOMAIN 339 349
FT DOMAIN 356 441
FT DISULFID 59 58
FT DISULFID 62 81
FT DISULFID 84 99
FT DISULFID 102 117
FT DISULFID 105 125
FT DISULFID 127 143
FT DISULFID 146 158
FT DISULFID 149 166
FT DISULFID 168 179
FT DISULFID 182 191
FT DISULFID 185 195
FT CARBOHYD 54 54
FT CARBOHYD 151 151
FT CARBOHYD 202 202
FT CONFLICT 394 394
SQ SEQUENCE 454 AA; 50129 MW; 486EEC09 CRC32;
Query Match 4 6%; Score 142; DB 1; Length 454;
Best Local Similarity 26.9%; Pred. No. 6,22e-09;
Matches 29; Conservativity 16; Mismatches 58; Indels 5; Gaps 5;

DB 44 CPQKXVSHQNSICCTKCHKGTLYVSDCPSP-GDVTVCRECEKGTFTASQNYLHLLQCLSC 102

QY 34 CROKEMSOVEISPCQADRDYVG-CRKNOFORILSETHOCVDCSPC 149
DB 103
QY 93 LCCA-VVNRFRKANKSATSALIGDCLPG-FYRKTKLVGFQDEMCVPC 138

RESULT 7
ID TNRI_HUMAN STANDARD; PRT; 455 AA.
AC P19438;
DT 01-FEB-1991 (Rel. 17, last sequence update)
DT 01-FEB-1991 (Rel. 38, last annotation update)
DE 15-JUL-1999 (Rel. 38, last annotation update)
DE TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR (TUMOR NECROSIS FACTOR
GN BINDING PROTEIN 1) (TNFRI) (P60) (TNF-R1) (P55) (CD120A).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
OC Eutheria; Primates; Catarrhini; Homiidae; Homo.
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-PLACENTA;
RX MEDLINE: 90235285.
RA SCHALL T.J., LEWIS M., KOLLER K.J., LEE A., RICE G.C., WONG G.H.W.,
RA GETINAGI T., GRANGER G.A., LENTZ R., RAAB H., KOHR W.J., GOEDDEL D.V.,
RT "Molecular cloning and expression of a receptor for human tumor
RT necrosis factor".
RL Cell 61:361-370(1990).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE: 90235284.
RA LOETSCHER H., PAN Y.-C.E., LAHM H.-W., GENTZ R., BROCKHAUS M.,
RA TABOCHI H., LESSLAUER W.,
RT "Molecular cloning and expression of the human 55 kd tumor necrosis
RT factor receptor".
RL Cell 61:351-359(1990).
RN [3]
RP SEQUENCE FROM N.A., AND SEQUENCE OF 41-53; 110-124 AND 199-201.
RX MEDLINE: 91006021.
RA NOPAR Y., KEMPER O., BRAKEBUSH C., ENGELMANN H., ZWANG R.,
RA ADEKKA D., HOLTSMANN H., WALLACH D.,
RT "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA
RT for the type I TNF-R, cloned using amino acid sequence data of its
RT soluble form, encodes both the cell surface and a soluble form of the
RT receptor".
RL EMO J. 9:3269-3278(1990).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE: 91090841.
RA HIMMLER A., MAURER-FOGY I., KROENKE M., SCHEURICH P., FITZENMAIER K.,
RA LANTZ M., OLSSON I., HAUPTMANN R., STRATOWA C., ADOLF G.R.,
RT "Molecular cloning and expression of human and rat tumor necrosis
RT factor receptor chain (p60) and its soluble derivative, tumor
RT necrosis factor-binding protein".
RL DNA Cell Biol. 9:705-715(1990).
RN [5]
RP SEQUENCE FROM N.A.
RC TISSUE-PLACENTA;
RX MEDLINE: 91017509.
RA GRAY P.W., BARRETT K., CHANTRY D., TURNER M., FELDMAN M.,
RT "Cloning of human tumor necrosis factor (TNF) receptor cDNA and
RT expression of recombinant soluble TNF-binding protein".
RL Proc. Natl. Acad. Sci. U.S.A. 87:7380-7384(1990).
RN [6]
RP SEQUENCE FROM N.A.
RX MEDLINE: 92250049.
RA FUCHS P., STREHL S., DMORZAK M., HIMMLER A., AMBROS P.F.,
RT "Structure of the human TNF receptor 1 (p60) gene (TNFRI) and
RT localization to chromosome 12p13".
RL Genomics 13:219-224(1992).
RN [7]
RP SEQUENCE OF 41-45.

RX MEDLINE: 90110215.
RA ENGELMANN H., NOVICK D., WALLACH D.,
RT "Two tumor necrosis factor-binding proteins purified from human
RT urine. Evidence for immunological cross-reactivity with cell surface
RT tumor necrosis factor receptors".
RL J. Biol. Chem. 265:1531-1536(1990).
RN [8]
RP X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 30-211.
RX MEDLINE: 93258809.
RA BANNER D.W., D'ARCY A., JAMES W., GENTZ R., SCHOENFELD H.-J.,
RA BROGER C., LOETSCHER H., LESSLAUER W.,
RT "Crystal structure of the soluble human 55 kd TNF receptor-human TNF
RT beta complex: implications for TNF receptor activation".
RL Cell 73:431-445(1993).
RN [9]
RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 41-202.
RX MEDLINE: 97094982.
RA NAIMSMITH J.H., DEVINE T.Q., KHONO H., SPRANG S.R.,
RT "Structures of the extracellular domain of the type I tumor necrosis
RT factor receptor".
RL Structure 4:1251-1262(1996).
CC -!- FUNCTION: RECEPTOR FOR TNF-ALPHA. THE ADAPTOR MOLECULE FADD
CC RECRUITS CASPASE-8 TO THE ACTIVATED RECEPTOR. THE RESULTING
CC AGGREGATE CALLED THE DEATH-INDUCING SIGNALING COMPLEX (DISC)
CC PERFORMS CASPASE-8 PROTEOLYTIC ACTIVATION WHICH INITIATES THE
CC SUBSEQUENT CASCADE OF CASPASES (ASPARATE-SPECIFIC CYSTEINE
CC PROTEASES) MEDIATING APOPTOSIS. CONTRIBUTES TO THE INDUCTION OF
CC NONCYTOTOXIC TNF EFFECTS INCLUDING ANTI-VIRAL STATE AND ACTIVATION
CC OF THE ACID SPHINGOMYELINASE.
CC -!- SUBUNIT: TNF BINDING TO THE EXTRACELLULAR DOMAIN OF TNFRI LEADS TO
CC HOMOTRIMERIZATION. ONCE AGGREGATED THE RECEPTORS DEATH DOMAINS
CC PROVIDE A NOVEL MOLECULAR INTERFACE THAT INTERACTS SPECIFICALLY
CC WITH THE DEATH DOMAIN OF TRADD. VARIOUS TRADD-INTERACTING
CC PROTEINS SUCH AS TRAFs, RIP AND POSSIBLY TRADD, ARE RECRUITED TO
CC TNFRI COMPLEX BY THEIR ASSOCIATION WITH TRADD. THIS COMPLEX
CC ACTIVATES AT LEAST TWO DISTINCT SIGNALING CASCADES, APOPTOSIS AND
CC NF-KAPPA B SIGNALING.
CC -!- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -!- DOMAIN: THE DOMAIN THAT INDUCES A-SWASE IS PROBABLY IDENTICAL TO
CC THE DEATH DOMAIN. THE N-SWASE ACTIVATION DOMAIN (NSD) IS BOTH
CC NECESSARY AND SUFFICIENT FOR ACTIVATION OF N-SWASE.
CC -!- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
CC -!- DATABASE: NAME=PROV, NOTE=CD guide CD120a entry;
CC WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cd120a.htm".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: X55133; CA939021.1; -
DR EMBL: M33294; AAA03210.1; -
DR EMBL: M58286; AAA36753.1; -
DR EMBL: M63121; AAA36754.1; -
DR EMBL: M75866; AAA61201.1; -
DR EMBL: M75864; AAA61201.1; -
DR EMBL: M75865; AAA61201.1; JOINED.
DR EMBL: M60275; AAA36756.1; -
DR EMBL: A21522; CAA01558.1; -
DR PIR: A34899; GQHUT1.
DR PIR: A35010; A35010.
DR PIR: S12057; S12057.
DR PIR: A38208; A38208.
DR PDB: 1TNR; 31-JUL-94.
DR PDB: 1NCF; 07-DEC-95.
DR PDB: 1EXT; 11-JAN-97.
DR MIM: 191190; -
DR PROSITE: PS00652; TNFR_NGFR_1; 3.
DR PROSITE: PS50050; TNFR_NGFR_2; 3.
DR PROSITE: PS50017; DEATH_DOMAIN; 1.

OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Primates; Catarrhini; Hominidae; Homo.
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE: 91309137.
 RA ITOH N., YONEHARA S., ISHII A., YONEHARA M., MIZUSHIMA S.I.,
 RA SAMESHIMA M., HASE A., SETO Y., NAGAYA S.;
 RT "The polypeptide encoded by the cDNA for human cell surface antigen
 RT Fas can mediate apoptosis";
 RL Cell 66:233-243(1991).
 RN [2]
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 226-240: 269-291 AND 321-335.
 RX MEDLINE: 92268122.
 RA OEHM A., BEHRMANN I., FALK W., PAWLITA M., MAIER G., KLAS C.,
 RA LI-WEBER M., RICHARDS S., DHEIN J., TRAUTH B.C., PONSINGEL H.,
 RA KRAMER P.H.;
 RT "Purification and molecular cloning of the APO-1 cell surface
 RT antigen, a member of the tumor necrosis factor/nerve growth factor
 RT receptor superfamily. Sequence identity with the Fas antigen.";
 RL J. Biol. Chem. 267:10709-10715(1992).
 RN [3]
 RP STRUCTURE BY NMR OF 218-335.
 RX MEDLINE: 97122332.
 RA HUANG B., EBERSTADT M., OLEJNICZAK E.T., MEADOWS R.P., RESIK S.W.;
 RT "NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.";
 RL Nature 384:638-641(1996).
 CC -1- FUNCTION: RECEPTOR FOR A CYTOKINE LIGAND KNOWN AS FASL. THE
 CC ADAPTOR MOLECULE FADD RECRUITS CASPASE-8 TO THE ACTIVATED
 CC RECEPTOR. THE RESULTING AGGREGATE CALLED THE DEATH-INDUCING
 CC SIGNALING COMPLEX (DISC) PERFORMS CASPASE-8 PROTEOLYTIC
 CC ACTIVATION. ACTIVE CASPASE-8 INITIATES THE SUBSEQUENT CASCADE OF
 CC CASPASES (ASPARATE-SPECIFIC CYSTEINE PROTEASES) MEDIATING
 CC APOPTOSIS. FAS-MEDIATED APOPTOSIS MAY HAVE A ROLE IN THE
 CC INDUCTION OF PERIPHERAL TOLERANCE, IN THE ANTIGEN-STIMULATED
 CC SUICIDE OF MATURE T-CELLS, OR BOTH.
 CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
 CC -1- DOMAIN: CONTAINS A DEATH DOMAIN INVOLVED IN THE BINDING OF FADD,
 CC AND MAYBE TO OTHER CYTOSOLIC ADAPTOR PROTEINS.
 CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
 CC -1- DATABASE: NAME=PROW; NOTE=CD guide CD95 entry;
 CC WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cd95.htm".
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: M67454; AAA63174.1; -;
 DR EMBL: X63717; CA45250.1; -;
 DR PIR: A40036; A40036.
 DR PIR: S24543; S24543.
 DR PDB: 1DDF; 12-NOV-97.
 DR MIM: 134637; -;
 DR PROSITE: PS00652; TNFR_NGFR_1; 2.
 DR PROSITE: PS50050; TNFR_NGFR_2; 2.
 DR PROSITE: PS50017; DEATH_DOMAIN; 1.
 DR PFM: PF00020; TNFR_C6; 2.
 DR PFM: PF00531; Death; 1.
 KW Apoptosis; Receptor; Glycoprotein; Transmembrane; Repeat; Signal;
 KW 3D-structure.
 FT SIGNAL 1 16 POTENTIAL.
 FT CHAIN 17 335 FASL RECEPTOR.
 FT DOMAIN 17 173 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 174 190 POTENTIAL.
 FT DOMAIN 191 335 CYTOPLASMIC (POTENTIAL).
 FT DOMAIN 47 166 3 X TNFR-CYS.
 FT REPEAT 47 83 TNFR-CYS 1.
 FT REPEAT 84 127 TNFR-CYS 2.
 FT REPEAT 128 166 TNFR-CYS 3.

FT DOMAIN 230 314 DEATH DOMAIN.
 FT CARBOHYD 118 118 POTENTIAL.
 FT CARBOHYD 136 136 POTENTIAL.
 SQ SEQUENCE 335 AA; 37732 MW; 3BF8F973 CRC32;
 Query Match 4.3%; Score 133; DB 1; Length 335;
 Best Local Similarity 26.9%; Pred. No. 2,94e-07;
 Matches 21; Cconservative 21; Mismatches 30; Indels 6; Gaps 6;
 Db 59 CHKCPGPERARACTYV-N-GDEPCVPCQEGKETDKAHSSKRCRRLCDGEGHVEI 117
 QY 49 CNG-CGPMELSKRCGFGYGDACVACRLHR-FKEDMGFO-KCKPDLCAVYVNRFO-KA 104
 QY 105 NCSATSPALICDGLPGFY 122
 Db 118 NCTRTQNTKC-RCKPNEF 134
 QY 105 NCSATSPALICDGLPGFY 122
 RESULT 10
 ID VT2_MYXVL STANDARD; PRT; 326 AA.
 AC P29825;
 DT 01-APR-1993 (Rel. 25, Created)
 DT 01-APR-1993 (Rel. 25, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE TUMOR NECROSIS FACTOR SOLUBLE RECEPTOR PRECURSOR (PROTEIN T2).
 GN T2.
 OS Myxoma virus (strain Lausanne).
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirineae;
 OC Leporipoxvirus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE: 91335768.
 RA UYFON C., MACEN J.L., SCHREIBER M., MCPADDEN G.;
 RT "Myxoma virus expresses a secreted protein with homology to the tumor
 RT necrosis factor receptor gene family that contributes to viral
 RT virulence";
 RL Virology 184:370-382(1991).
 CC -1- FUNCTION: BINDS TO TNF-ALPHA AND BETA. PROBABLY PREVENTS TNF TO
 CC REACH CELLULAR TARGET AND THEREBY DEAMPENING THE POTENTIAL
 CC ANTIVIRAL EFFECTS OF THE CYTOKINE.
 CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: M95181; AAA46632.1; -;
 DR EMBL: A23729; CA01688.1; -;
 DR PIR: A40566; GCVZML.
 DR HSP: P19438; TNFR.
 DR PROSITE: PS00652; TNFR_NGFR_1; 2.
 DR PROSITE: PS50050; TNFR_NGFR_2; 2.
 DR PFM: PF00020; TNFR_C6; 2.
 KW Receptor; Glycoprotein; Repeat; Signal.
 FT SIGNAL 1 16 POTENTIAL.
 FT CHAIN 17 326 TUMOR NECROSIS FACTOR SOLUBLE RECEPTOR.
 FT DOMAIN 27 186 4 X TNFR-CYS.
 FT REPEAT 27 62 TNFR-CYS 1.
 FT REPEAT 63 104 TNFR-CYS 2.
 FT REPEAT 105 147 TNFR-CYS 3.
 FT REPEAT 148 186 TNFR-CYS 4.
 FT CARBOHYD 66 66 POTENTIAL.
 FT CARBOHYD 181 181 POTENTIAL.
 FT CARBOHYD 205 205 POTENTIAL.
 FT CARBOHYD 238 238 POTENTIAL.
 SQ SEQUENCE 326 AA; 35208 MW; 2F059A61 CRC32;
 Query Match 4.2%; Score 130; DB 1; Length 326;
 Best Local Similarity 29.5%; Pred. No. 1.03e-06;

[illegible]

```

DR PROSITE; PS00652; TNFR_NGFR.1; 3.
DR PROSITE; PS50050; TNFR_NGFR.2; 3.
DR PROSITE; PS50017; DEATH_DOMAIN; 1.
DR PFAM; PF00020; TNFR_C6; 4.
DR PFAM; PF00531; death; 1.
KW Receptor; Transmembrane; Glycoprotein; Repeat; Signal; Apoptosis.
FT SIGNAL 1 21
FT CHAIN 22 461
FT DOMAIN 22 211
FT TRANSSEM 212 234
FT DOMAIN 235 461
FT DOMAIN 43 196
FT REPEAT 43 82
FT REPEAT 83 125
FT REPEAT 126 166
FT REPEAT 167 196
FT DOMAIN 344 354
FT DOMAIN 363 448
FT DISULFID 44 58
FT DISULFID 59 72
FT DISULFID 62 81
FT DISULFID 84 99
FT DISULFID 102 117
FT DISULFID 105 125
FT DISULFID 127 143
FT DISULFID 146 158
FT DISULFID 149 166
FT DISULFID 168 179
FT DISULFID 182 191
FT DISULFID 185 195
FT CARBOHYD 54 54
FT CARBOHYD 151 151
FT CARBOHYD 201 201
SQ SEQUENCE 461 AA; 50969 MW; 82F68B08 CRC32;

Query Match 4.2%; Score 130; DB 1; Length 461;
Best Local Similarity 25.9%; Pred. No. 1.03e-06;
Matches 28; Conservative 16; Mismatches 59; Indels 5; Gaps 5;

Db 44 CPOGKYAHPKNNISICRKHGTYLVSDCPSP-GQETVCEVCDDKGTASQNHVRCISC 102
OY 34 CROGEFDRSGNCVPCNCGGFMELSGCGVEGDAGCAVCRHRRKEDMGF-QKCKPC 92
OY 93 LDCA-VVNRFOKANCATSIDICDCLPG-FYRKTKLVGFQDMCEVCPC 138

RESULT 13
ID FASA_MOUSE STANDARD; PRT; 327 AA.
AC P25446;
DT 01-MAY-1992 (Rel. 22, Created)
DT 01-MAY-1992 (Rel. 22, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE FASL RECEPTOR PRECURSOR (APOPTOSIS-MEDIATING SURFACE ANTIGEN FAS)
DE (APO-1 ANTIGEN) (CD95).
GN APT1 OR FAS.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
OC Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE; 92148151.
RA WATANABE-FUKUNAGA R., BRANNAN C.I., ITOH N., YONEHARA S.,
RA COPELAND N.G., JENKINS N.A., NAGATA S.;
RT "The CDNA structure, expression, and chromosomal assignment of the
mouse Fas antigen."
RL J. Immunol. 148:1274-1279(1992).
RN [2]
RP SEQUENCE OF 1-96 FROM N.A.
RX MEDLINE; 93189576.
RA ADACHI M., WATANABE-FUKUNAGA R., NAGATA S.;
RT "Aberrant transcription caused by the insertion of an early

```

```

RT transposable element in an intron of the Fas antigen gene of lpr
RT mice."
RL Proc. Natl. Acad. Sci. U.S.A. 90:1756-1760(1993).
RN [3]
RP VARIANT LPR.
RX MEDLINE; 92195401.
RA WATANABE-FUKUNAGA R., BRANNAN C.I., COPELAND N.G., JENKINS N.A.,
RA NAGATA S.;
RT "Lymphoproliferation disorder in mice explained by defects in Fas
antigen that mediates apoptosis."
RL Nature 356:314-317(1992).
CC -1- FUNCTION: RECEPTOR FOR A CYTOKINE LIGAND KNOWN AS FASL. THE
ADAPTOR MOLECULE FADD RECRUITS CASPASE-8 TO THE ACTIVATED
RECEPTOR. THE RESULTING AGGREGATE CALLED THE DEATH-INDUCING
SIGNALING COMPLEX (DISC) PERFORMS CASPASE-8 PROTEOLYTIC
ACTIVATION. ACTIVE CASPASE-8 INITIATES THE SUBSEQUENT CASCADE OF
CASPASES (ASPARTATE-SPECIFIC CYSTEINE PROTEASES) MEDIATING
APOPTOSIS. FAS-MEDIATED APOPTOSIS MAY HAVE A ROLE IN THE
INDUCTION OF PERIPHERAL TOLERANCE, IN THE ANTIGEN-STIMULATED
SUICIDE OF MATURE T-CELLS, OR BOTH (BY SIMILARITY).
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -1- TISSUE SPECIFICITY: DETECTED IN VARIOUS TISSUES INCLUDING THYMUS,
LIVER, LUNG, HEART, AND ADULT OVARY.
CC -1- DOMAIN: CONTAINS A DEATH DOMAIN INVOLVED IN THE BINDING OF FADD,
AND MAYBE TO OTHER CYTOSOLIC ADAPTOR PROTEINS.
CC -1- DISEASE: DEFECTS IN FAS ARE THE CAUSE OF A LYMPHOPROLIFERATION
DISORDER (LPR) RESPONSIBLE FOR LYMPHADENOPATHY AND AUTOANTIBODY
PRODUCTION.
CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sdb.ch/announce/
CC or send an email to license@sdb.ch).
-----
DR EMBL; M83649; AAA37593.1; -.
DR EMBL; S56490; AAB25700.1; -.
DR EMBL; S56485; AAB25700.1; JOINED.
DR EMBL; S56486; AAB25700.1; JOINED.
DR PIR; A46484; A46484.
DR HSSP; P25445; 1DDF.
DR MGI; MGI:95484; FAS.
DR PROSITE; PS00652; TNFR_NGFR.1; 2.
DR PROSITE; PS50050; TNFR_NGFR.2; 2.
DR PROSITE; PS50017; DEATH_DOMAIN; 1.
DR PFAM; PF00020; TNFR_C6; 3.
DR PFAM; PF00531; death; 1.
KW Apoptosis; Receptor; Glycoprotein; Transmembrane; Repeat; Signal;
KW Disease mutation.
FT SIGNAL 1 21
FT CHAIN 22 327
FT DOMAIN 22 169
FT TRANSSEM 170 186
FT DOMAIN 187 327
FT DOMAIN 43 162
FT REPEAT 43 79
FT REPEAT 80 123
FT REPEAT 124 162
FT REPEAT 222 306
FT CARBOHYD 43 43
FT CARBOHYD 114 114
FT VARIANT 246 246 I -> N (IN LPR).
SQ SEQUENCE 327 AA; 37418 MW; 22D6DC39 CRC32;

Query Match 4.1%; Score 127; DB 1; Length 327;
Best Local Similarity 26.0%; Pred. No. 3.58e-06;
Matches 20; Conservative 16; Mismatches 34; Indels 5; Gaps 5;

Db 56 CQPCQPKKRVKEDCKNN-GGPTCAPCTEGKRYMDKNHYADCCRCCTLCDEEHGLEVTN 114

```

US-09-490-187-2.rsp

OS Mus musculus (mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 [1]
 RN
 RP SEQUENCE FROM N.A.

[illegible]

FT DISULFID 86 102 BY SIMILARITY.
FT DISULFID 104 113 BY SIMILARITY.
FT DISULFID 116 128 BY SIMILARITY.
FT DISULFID 139 150 BY SIMILARITY.
FT DISULFID 141 155 BY SIMILARITY.
FT DISULFID 157 166 BY SIMILARITY.
FT DISULFID 169 184 BY SIMILARITY.
FT DISULFID 463 471 BY SIMILARITY.
FT DISULFID 465 482 BY SIMILARITY.
FT DISULFID 485 494 BY SIMILARITY.
FT DISULFID 497 515 BY SIMILARITY.
FT DISULFID 518 532 BY SIMILARITY.
FT DISULFID 520 539 BY SIMILARITY.
FT DISULFID 542 551 BY SIMILARITY.
FT DISULFID 554 571 BY SIMILARITY.
FT DISULFID 611 611 INTERCHAIN (PROBABLE).
FT DISULFID 614 614 INTERCHAIN (PROBABLE).
FT DISULFID 1183 1183 INTERCHAIN (WITH CHAIN BETA-3)
(PROBABLE).
FT CARBOHYD 342 342 POTENTIAL.
FT CARBOHYD 363 363 POTENTIAL.
FT CARBOHYD 527 527 POTENTIAL.
FT CARBOHYD 942 942 POTENTIAL.
FT CARBOHYD 1033 1033 POTENTIAL.
SQ SEQUENCE 1192 AA; 130287 MW; 76A7C102 CRC32;

Query Match 4.18; Score 126; DB 1; Length 1192;
Best Local Similarity 32.18; Pred. No. 5.39e-06;
Matches 35; Conservative 18; Mismatches 43; Indels 13; Gaps 11;

DB 386 LGYKQFOQ-ECASG-YKDSARLGAFCAYPCN-CQEGACDPDTGDCYSGDENPDIE 442
||| : | | | : : | | | | | | : | : : | :
QY 19 LGYLS--CKVTESGDCRQEFRR-DRSGCYPCNOC-GPGM-ELSK-ECGFYGE-DAQ 71
DB 443 CADCPICGFYNDPHDPRCKPC-PCH--NGFSCVMPETEVEVNCNCPG 488
| | : : : | | | | | : : : | : | |
QY 72 CVACRLHREKEDWGFQCKRCPCLDCAYVNRQKNCATSATSDAIGDCLPG 120

Search completed: Tue Apr 18 14:00:34 2000
Job time : 43 secs.